{"schema_version":1,"research_line":"existing-drug repurposing screen in cancer cell lines (v1b)","status":"pre-registered hypothesis ranking from public cell-line viability; no clinical efficacy, safety, achievable human exposure or patient benefit claim","freeze":{"plan_v1_commit":"bc4ed8c","amendment_v1a_commit":"78c4032","amendment_v1b_commit":"4070bc2","inputs_commit":"93103b7","inventory_commit":"75c860a","before_scoring":true,"plan_sha256":"02d52dcb0066ec3d5cedaec0974f85ebac341a3f733709ace7e9fa063ed0c9ea","inputs_sha256":"13f7956fe1cc75c6f830d56574a4674d8fcdec83a7fdfa5037bb918d4df807a6","report_sha256":"96e75f9d8a7d9997027145c62ee95f96397fb3812db51352f677d09c54f831e5"},"sources":{"discovery_and_confirmation":"PRISM Repurposing 19Q4 Dataset, Broad Institute, figshare doi:10.6084/m9.figshare.9393293.v4, CC BY 4.0; Corsello et al. 2020 Nature Cancer 1:235-248","independent_assay":"CTRP v2 expanded dataset (CTRPv2.0_2015_ctd2_ExpandedDataset), Broad Institute, NCI CTD2 Network, Index of NCI Studies CTD2_066","ctd2_acknowledgement":"The results published here are in whole or part based upon data generated by the Cancer Target Discovery and Development (CTD2) Network (https://ocg.cancer.gov/programs/ctd2/data-portal) established by the National Cancer Institute's Office of Cancer Genomics.","modification":"MAEN computed compound-level aggregates; no source rows are redistributed"},"rules":{"kill_rule":"primary log2 fold change strictly below log2(0.3), i.e. under 30% viability relative to vehicle","min_primary_lines":100,"selective_min_killed_lines":5,"selective_max_killed_fraction":0.5,"separation":"P(hit AUC < non-hit AUC) + 0.5 P(tie); hits and non-hits fixed by the primary screen; lower AUC is more sensitive","min_hit_lines":3,"min_nonhit_lines":20,"confirm_min_separation":0.75,"independent_min_separation":0.7,"interval_lower_bound_above":0.5,"bootstrap":{"repetitions":500,"seed":20267001,"interval":[2.5,97.5],"percentile_method":"numpy linear","unit":"cell lines resampled with replacement within hit and non-hit groups","seed_derivation":"first 16 SHA256 hex digits of seed:stage:compound"},"permutation":{"seed":20267002,"draws_per_compound":1,"unit":"stage AUC values shuffled across the shared hit and non-hit lines","rule":"identical separation threshold and bootstrap lower-bound rule; one draw, no retries"},"positive_controls":{"names":["dabrafenib","vemurafenib","lapatinib","disulfiram","tepoxalin"],"expectation":"primary class selective and secondary status confirmed","interpretation":"reported individually; thresholds are never retuned after a control result"},"amendment":"v1a, before any response value was read: MTS010 preference and skipping cell-info rows without a DepMap ID (control barcodes), both from the provider README; download MD5 checked when the provider publishes it; thresholds unchanged","amendment_v1b":"after the v1a inventory stopped on row labels, before any response statistic: cell-info rows without a DepMap ID include 10 failed-STR lines whose labels also appear as response rows; following the original failed-STR exclusion, those rows are dropped and counted in every stage; thresholds unchanged"},"cells":{"primary_matrix":568,"included":568,"str_excluded":0},"summary":{"compounds_screened":4532,"primary_classes":{"inactive":3620,"selective":710,"broad":202},"selective_tiers":{"independently_replicated":50,"confirmed_independent_pending":232,"confirmed_independent_conflict":29,"primary_only":72,"not_confirmed":327},"launched_non_oncology_tiers":{"independently_replicated":4,"confirmed_independent_pending":50,"confirmed_independent_conflict":4,"primary_only":19,"not_confirmed":109},"estimable":{"secondary":638,"independent":105},"observed_passes":{"secondary":311,"independent":54},"permutation_passes":{"secondary":8,"independent":1},"positive_controls":{"dabrafenib":{"status":"meets_expectation","compound":"BRD-K09951645","primary_class":"selective","secondary_status":"confirmed","independent_status":"replicated","tier":"independently_replicated","matches_in_library":1},"vemurafenib":{"status":"meets_expectation","compound":"BRD-K56343971","primary_class":"selective","secondary_status":"confirmed","independent_status":"replicated","tier":"independently_replicated","matches_in_library":1},"lapatinib":{"status":"meets_expectation","compound":"BRD-K19687926","primary_class":"selective","secondary_status":"confirmed","independent_status":"replicated","tier":"independently_replicated","matches_in_library":1},"disulfiram":{"status":"does_not_meet_expectation","compound":"BRD-K32744045","primary_class":"selective","secondary_status":"not_confirmed","independent_status":"not_available","tier":"not_confirmed","matches_in_library":1},"tepoxalin":{"status":"does_not_meet_expectation","compound":"BRD-K89714990","primary_class":"selective","secondary_status":"not_confirmed","independent_status":"not_available","tier":"not_confirmed","matches_in_library":1}}},"interpretation":{"updated_utc_date":"2026-10-07","scope":"Post-result wording correction; frozen rules, summary and candidate values are unchanged.","primary_hit":"A relative viable-cell abundance proxy below 30% of vehicle control; growth arrest and cell death are not distinguished. Legacy kill/lines_killed field names are retained for provenance, not as proof of cell death.","confirmation_and_replication":"Relative AUC separation of primary hit and non-hit lines; neither repeated absolute inhibition below 30% nor cell death is a pass requirement.","table_47":"Post-hoc display group: phase Launched, secondary confirmed, and disease_area containing neither oncology nor malignancy in the historical Repurposing Hub metadata. The 47 include veterinary compounds and compounds with oncology uses; current human approval, jurisdiction, formulation and route have not been verified.","lineage":"primary_tissue describes tissue of origin; skin alone does not establish melanoma histology or BRAF mutation status.","structure":"Structural and response similarity can suggest an association; identifying a causal active fragment requires additional evidence and inactive analogues. No structure analysis was performed in this screen."},"limitations":["cultured cancer cell lines only; no human efficacy, safety, exposure or normal-cell toxicity","the pre-registered oncology flag only matches \"oncology\", so hematologic-malignancy drugs are counted as non-oncology in summary.launched_non_oncology_tiers","some selective hits may reflect nonspecific membrane toxicity or sample identity/purity issues; compound identity was not re-verified","CTRP shares many cell lines and the Broad Institute with PRISM; it is a different assay, not a different laboratory","relative viable-cell abundance and relative AUC separation do not establish cell death or normal-cell selectivity","one fixed shuffle per compound is a descriptive control; individual permutation p-values, false discovery rates and candidate true-positive probabilities were not estimated","bootstrap intervals resample cell lines within hit and non-hit groups; related cell-line origins are not clustered and their dependence is not represented","2.5 uM is the nominal primary concentration; recorded selected doses vary, including 1.04 to 5.0 uM among the 710 selective candidates","Launched and disease-area annotations come from historical metadata and do not verify present human non-oncology approval"],"candidates":[{"compound":"BRD-K81528515","name":"nilotinib","moa":"Abl kinase inhibitor, Bcr-Abl kinase inhibitor","target":"ABL1, KIT","disease_area":"hematologic malignancy","indication":"chronic myeloid leukemia (CML)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":539,"lines_killed":5,"killed_fraction":0.00928,"class":"selective"},"secondary":{"status":"confirmed","separation":0.98986,"interval":[0.98031,0.99761],"hit_lines":4,"nonhit_lines":419,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.35028,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"replicated","separation":0.97296,"interval":[0.92657,1.0],"hit_lines":4,"nonhit_lines":453},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":11,"tested_annotated":539,"enrichment":9.8,"p_one_sided_uncorrected":0.09831}},{"compound":"BRD-K56343971","name":"vemurafenib","moa":"RAF inhibitor","target":"BRAF, RAF1","disease_area":"oncology","indication":"melanoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":17,"killed_fraction":0.03014,"class":"selective"},"secondary":{"status":"confirmed","separation":0.98561,"interval":[0.97136,0.99537],"hit_lines":17,"nonhit_lines":413,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":0.32092,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"replicated","separation":0.89244,"interval":[0.79982,0.95603],"hit_lines":13,"nonhit_lines":467},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":14,"hits_annotated":17,"lineage_tested":43,"tested_annotated":564,"enrichment":10.80164,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K23984367","name":"sorafenib","moa":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","target":"BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET","disease_area":"oncology","indication":"renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"confirmed","separation":0.98419,"interval":[0.96977,0.99628],"hit_lines":5,"nonhit_lines":430,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.61183,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"replicated","separation":0.99145,"interval":[0.97904,1.0],"hit_lines":5,"nonhit_lines":468},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":11,"tested_annotated":556,"enrichment":10.10909,"p_one_sided_uncorrected":0.09541}},{"compound":"BRD-K39974922","name":"lenvatinib","moa":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"FLT4, KDR","disease_area":"oncology","indication":"thyroid cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":7,"killed_fraction":0.01277,"class":"selective"},"secondary":{"status":"confirmed","separation":0.98344,"interval":[0.96806,0.99586],"hit_lines":7,"nonhit_lines":414,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.37974,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"replicated","separation":0.97277,"interval":[0.94492,0.99511],"hit_lines":7,"nonhit_lines":467},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":7,"lineage_tested":11,"tested_annotated":548,"enrichment":21.35065,"p_one_sided_uncorrected":0.0002}},{"compound":"BRD-K74514084","name":"pazopanib","moa":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3","disease_area":"oncology","indication":"renal cell carcinoma (RCC), soft tissue sarcoma (STS)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":5,"killed_fraction":0.00912,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93811,"interval":[0.81365,1.0],"hit_lines":4,"nonhit_lines":412,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.1643,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"replicated","separation":0.94861,"interval":[0.84776,1.0],"hit_lines":5,"nonhit_lines":469},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":11,"tested_annotated":548,"enrichment":19.92727,"p_one_sided_uncorrected":0.00355}},{"compound":"BRD-K16730910","name":"regorafenib","moa":"FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","target":"ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK","disease_area":"oncology","indication":"colorectal cancer, gastrointestinal stromal tumors (GIST)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":9,"killed_fraction":0.01601,"class":"selective"},"secondary":{"status":"confirmed","separation":0.9345,"interval":[0.88065,0.97548],"hit_lines":9,"nonhit_lines":419,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":0.53828,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"replicated","separation":0.9144,"interval":[0.86116,0.9626],"hit_lines":9,"nonhit_lines":466},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":12,"tested_annotated":562,"enrichment":15.61111,"p_one_sided_uncorrected":0.00058}},{"compound":"BRD-K70301465","name":"ibrutinib","moa":"Bruton's tyrosine kinase (BTK) inhibitor","target":"BLK, BMX, BTK","disease_area":"hematologic malignancy","indication":"chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":47,"killed_fraction":0.08453,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93276,"interval":[0.90644,0.95532],"hit_lines":40,"nonhit_lines":390,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":34,"median_ic50_uM":0.39939,"hit_lines_ic50_at_most_1uM":26}},"independent":{"status":"replicated","separation":0.83871,"interval":[0.72527,0.92859],"hit_lines":25,"nonhit_lines":310},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":8,"hits_annotated":47,"lineage_tested":27,"tested_annotated":556,"enrichment":3.50512,"p_one_sided_uncorrected":0.00093}},{"compound":"BRD-K02113016","name":"olaparib","moa":"PARP inhibitor","target":"PARP1, PARP2","disease_area":"oncology","indication":"ovarian cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":557,"lines_killed":8,"killed_fraction":0.01436,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92874,"interval":[0.87062,0.97371],"hit_lines":8,"nonhit_lines":428,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.90067,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"replicated","separation":0.94108,"interval":[0.88282,0.99179],"hit_lines":8,"nonhit_lines":471},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":23,"tested_annotated":557,"enrichment":6.05435,"p_one_sided_uncorrected":0.03928}},{"compound":"BRD-K09951645","name":"dabrafenib","moa":"RAF inhibitor","target":"BRAF, LIMK1, NEK11, RAF1, SIK1","disease_area":"oncology","indication":"melanoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":25,"killed_fraction":0.04621,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92216,"interval":[0.85119,0.97313],"hit_lines":24,"nonhit_lines":383,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":0.00971,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"replicated","separation":0.94918,"interval":[0.90607,0.98198],"hit_lines":14,"nonhit_lines":208},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":15,"hits_annotated":25,"lineage_tested":39,"tested_annotated":541,"enrichment":8.32308,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K64052750","name":"gefitinib","moa":"EGFR inhibitor","target":"EGFR","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":32,"killed_fraction":0.05776,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91169,"interval":[0.87245,0.94963],"hit_lines":24,"nonhit_lines":385,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":0.35504,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"replicated","separation":0.78389,"interval":[0.69434,0.86388],"hit_lines":29,"nonhit_lines":449},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":4,"hits_annotated":32,"lineage_tested":24,"tested_annotated":554,"enrichment":2.88542,"p_one_sided_uncorrected":0.043}},{"compound":"BRD-K12343256","name":"trametinib","moa":"MEK inhibitor","target":"MAP2K1, MAP2K2","disease_area":"oncology","indication":"melanoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":109,"killed_fraction":0.19464,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89986,"interval":[0.86525,0.93061],"hit_lines":93,"nonhit_lines":351,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":84,"median_ic50_uM":0.03482,"hit_lines_ic50_at_most_1uM":82}},"independent":{"status":"replicated","separation":0.85997,"interval":[0.80591,0.906],"hit_lines":48,"nonhit_lines":185},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":22,"hits_annotated":109,"lineage_tested":43,"tested_annotated":560,"enrichment":2.62855,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K42828737","name":"sunitinib","moa":"FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","target":"CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET","disease_area":"oncology","indication":"gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":13,"killed_fraction":0.02338,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87932,"interval":[0.73321,0.98455],"hit_lines":11,"nonhit_lines":429,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":0.96053,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"replicated","separation":0.84989,"interval":[0.71859,0.95601],"hit_lines":12,"nonhit_lines":463},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":13,"lineage_tested":12,"tested_annotated":556,"enrichment":7.12821,"p_one_sided_uncorrected":0.02921}},{"compound":"BRD-K22134346","name":"simvastatin","moa":"HMGCR inhibitor","target":"HMGCR, ITGB2","disease_area":"endocrinology, cardiology, neurology/psychiatry","indication":"hypercholesterolemia, coronary heart disease, myocardial infarction, stroke, hyperlipidemia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":39,"killed_fraction":0.07209,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87931,"interval":[0.81777,0.93245],"hit_lines":30,"nonhit_lines":406,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":30,"median_ic50_uM":2.28585,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"replicated","separation":0.7127,"interval":[0.62391,0.78977],"hit_lines":29,"nonhit_lines":407},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":6,"hits_annotated":39,"lineage_tested":23,"tested_annotated":541,"enrichment":3.61873,"p_one_sided_uncorrected":0.00385}},{"compound":"BRD-K51544265","name":"cabozantinib","moa":"RET tyrosine kinase inhibitor, VEGFR inhibitor","target":"KDR, MET","disease_area":"oncology","indication":"medullary thyroid cancer (MTC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":546,"lines_killed":10,"killed_fraction":0.01832,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86871,"interval":[0.67367,0.98225],"hit_lines":9,"nonhit_lines":435,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":0.37019,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"replicated","separation":0.84393,"interval":[0.68546,0.96347],"hit_lines":9,"nonhit_lines":451},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":20,"tested_annotated":546,"enrichment":5.46,"p_one_sided_uncorrected":0.04812}},{"compound":"BRD-K77625799","name":"vandetanib","moa":"EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor","target":"EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA","disease_area":"oncology","indication":"medullary thyroid cancer (MTC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":31,"killed_fraction":0.05496,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83008,"interval":[0.74626,0.9005],"hit_lines":25,"nonhit_lines":383,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":1.39192,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"replicated","separation":0.75594,"interval":[0.64411,0.85749],"hit_lines":29,"nonhit_lines":444},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":5,"hits_annotated":31,"lineage_tested":24,"tested_annotated":564,"enrichment":3.79032,"p_one_sided_uncorrected":0.00728}},{"compound":"BRD-K70401845","name":"erlotinib","moa":"EGFR inhibitor","target":"EGFR, NR1I2","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC), pancreatic cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":26,"killed_fraction":0.04626,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82941,"interval":[0.72457,0.93029],"hit_lines":22,"nonhit_lines":409,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.44696,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"replicated","separation":0.79261,"interval":[0.67978,0.88109],"hit_lines":23,"nonhit_lines":461},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":7,"hits_annotated":26,"lineage_tested":24,"tested_annotated":562,"enrichment":6.30449,"p_one_sided_uncorrected":4e-05}},{"compound":"BRD-K66175015","name":"afatinib","moa":"EGFR inhibitor","target":"EGFR, ERBB2, ERBB4","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":32,"killed_fraction":0.05839,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8288,"interval":[0.70595,0.92278],"hit_lines":28,"nonhit_lines":414,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":0.05905,"hit_lines_ic50_at_most_1uM":23}},"independent":{"status":"replicated","separation":0.82593,"interval":[0.7385,0.90864],"hit_lines":27,"nonhit_lines":413},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":5,"hits_annotated":32,"lineage_tested":24,"tested_annotated":548,"enrichment":3.56771,"p_one_sided_uncorrected":0.00946}},{"compound":"BRD-K19687926","name":"lapatinib","moa":"EGFR inhibitor","target":"EGFR, ERBB2","disease_area":"oncology","indication":"breast cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":22,"killed_fraction":0.03929,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82401,"interval":[0.7082,0.91204],"hit_lines":21,"nonhit_lines":424,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":1.46249,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"replicated","separation":0.73508,"interval":[0.61433,0.85177],"hit_lines":18,"nonhit_lines":443},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":5,"hits_annotated":22,"lineage_tested":24,"tested_annotated":560,"enrichment":5.30303,"p_one_sided_uncorrected":0.00151}},{"compound":"BRD-K49075727","name":"nintedanib","moa":"FGFR inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"FGFR1, FGFR2, FGFR3, FGFR4, FLT1, FLT4, KDR, PDGFRA, PDGFRB","disease_area":"pulmonary","indication":"idiopathic pulmonary fibrosis (IPF)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":15,"killed_fraction":0.02708,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81674,"interval":[0.63346,0.94757],"hit_lines":12,"nonhit_lines":437,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":0.77589,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"replicated","separation":0.86205,"interval":[0.77025,0.93415],"hit_lines":13,"nonhit_lines":455},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":15,"lineage_tested":12,"tested_annotated":554,"enrichment":12.31111,"p_one_sided_uncorrected":0.00015}},{"compound":"BRD-K93918653","name":"quizartinib","moa":"FLT3 inhibitor","target":"CSF1R, FLT3, KIT, PDGFRA, PDGFRB, RET","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":14,"killed_fraction":0.02496,"class":"selective"},"secondary":{"status":"confirmed","separation":0.9158,"interval":[0.78766,0.99382],"hit_lines":10,"nonhit_lines":443,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":0.56693,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"replicated","separation":0.79532,"interval":[0.60552,0.93926],"hit_lines":12,"nonhit_lines":467},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":14,"lineage_tested":12,"tested_annotated":561,"enrichment":6.67857,"p_one_sided_uncorrected":0.03311}},{"compound":"BRD-K92991072","name":"PAC-1","moa":"caspase activator","target":"CASP3","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":8,"killed_fraction":0.01479,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91413,"interval":[0.88114,0.94145],"hit_lines":6,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":2.83897,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"replicated","separation":0.81492,"interval":[0.7009,0.9189],"hit_lines":6,"nonhit_lines":430},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":4,"hits_annotated":8,"lineage_tested":33,"tested_annotated":541,"enrichment":8.19697,"p_one_sided_uncorrected":0.00068}},{"compound":"BRD-K54997624","name":"alpelisib","moa":"PI3K inhibitor","target":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":12,"killed_fraction":0.02128,"class":"selective"},"secondary":{"status":"confirmed","separation":0.9058,"interval":[0.85241,0.95036],"hit_lines":8,"nonhit_lines":418,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":1.01731,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"replicated","separation":0.79172,"interval":[0.62718,0.93531],"hit_lines":7,"nonhit_lines":333},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":21,"tested_annotated":564,"enrichment":4.47619,"p_one_sided_uncorrected":0.06962}},{"compound":"BRD-K17610631","name":"indisulam","moa":"CDK inhibitor","target":"CA1, CA12, CA14, CA2, CA6, CA7, CA9","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.42119,"lines_tested":541,"lines_killed":57,"killed_fraction":0.10536,"class":"selective"},"secondary":{"status":"confirmed","separation":0.90207,"interval":[0.86425,0.9391],"hit_lines":49,"nonhit_lines":382,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":44,"median_ic50_uM":0.29379,"hit_lines_ic50_at_most_1uM":40}},"independent":{"status":"replicated","separation":0.75558,"interval":[0.67488,0.82936],"hit_lines":42,"nonhit_lines":397},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":7,"hits_annotated":57,"lineage_tested":33,"tested_annotated":541,"enrichment":2.01329,"p_one_sided_uncorrected":0.04734}},{"compound":"BRD-K57080016","name":"selumetinib","moa":"MEK inhibitor","target":"MAP2K1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":69,"killed_fraction":0.12234,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89954,"interval":[0.8452,0.94526],"hit_lines":56,"nonhit_lines":358,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":49,"median_ic50_uM":0.27041,"hit_lines_ic50_at_most_1uM":40}},"independent":{"status":"replicated","separation":0.82273,"interval":[0.76809,0.87036],"hit_lines":61,"nonhit_lines":421},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":23,"hits_annotated":69,"lineage_tested":43,"tested_annotated":564,"enrichment":4.37209,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K20285085","name":"R406","moa":"SYK inhibitor","target":"RET, SYK","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":21,"killed_fraction":0.03882,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89948,"interval":[0.79337,0.97074],"hit_lines":17,"nonhit_lines":426,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":0.32747,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"replicated","separation":0.7111,"interval":[0.58011,0.82396],"hit_lines":18,"nonhit_lines":437},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":21,"lineage_tested":12,"tested_annotated":541,"enrichment":8.5873,"p_one_sided_uncorrected":0.00068}},{"compound":"BRD-K26603252","name":"PD-153035","moa":"EGFR inhibitor","target":"EGFR, KDR","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":23,"killed_fraction":0.04197,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89471,"interval":[0.83978,0.93928],"hit_lines":21,"nonhit_lines":417,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":20,"median_ic50_uM":0.99239,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"replicated","separation":0.8779,"interval":[0.81149,0.93974],"hit_lines":14,"nonhit_lines":320},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":4,"hits_annotated":23,"lineage_tested":24,"tested_annotated":548,"enrichment":3.97101,"p_one_sided_uncorrected":0.01434}},{"compound":"BRD-K86930074","name":"cediranib","moa":"KIT inhibitor, VEGFR inhibitor","target":"CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":15,"killed_fraction":0.02737,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89254,"interval":[0.79485,0.95321],"hit_lines":14,"nonhit_lines":454,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":0.64074,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"replicated","separation":0.98413,"interval":[0.96621,0.99693],"hit_lines":9,"nonhit_lines":217},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":15,"lineage_tested":11,"tested_annotated":548,"enrichment":13.28485,"p_one_sided_uncorrected":0.00011}},{"compound":"BRD-K62965247","name":"tipifarnib","moa":"farnesyltransferase inhibitor","target":"FNTA, FNTB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":15,"killed_fraction":0.02683,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88822,"interval":[0.79533,0.96665],"hit_lines":12,"nonhit_lines":454,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":0.04496,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"replicated","separation":0.87112,"interval":[0.74415,0.96546],"hit_lines":6,"nonhit_lines":258},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":15,"lineage_tested":20,"tested_annotated":559,"enrichment":3.72667,"p_one_sided_uncorrected":0.09663}},{"compound":"BRD-K08109215","name":"I-BET-762","moa":"bromodomain inhibitor","target":"BRD2, BRD3, BRD4","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":13,"killed_fraction":0.02403,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8716,"interval":[0.77998,0.93338],"hit_lines":11,"nonhit_lines":388,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.49405,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"replicated","separation":0.8185,"interval":[0.72536,0.90546],"hit_lines":9,"nonhit_lines":457},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":13,"lineage_tested":8,"tested_annotated":541,"enrichment":5.20192,"p_one_sided_uncorrected":0.17788}},{"compound":"BRD-K19540840","name":"saracatinib","moa":"src inhibitor","target":"ABL1, LCK, SRC, YES1","disease_area":"NA","indication":"NA","phase":"Phase 2/Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":39,"killed_fraction":0.06915,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86578,"interval":[0.81594,0.91576],"hit_lines":31,"nonhit_lines":417,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":0.71081,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"replicated","separation":0.81183,"interval":[0.73152,0.88701],"hit_lines":35,"nonhit_lines":454},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":6,"hits_annotated":39,"lineage_tested":24,"tested_annotated":564,"enrichment":3.61538,"p_one_sided_uncorrected":0.00394}},{"compound":"BRD-K68065987","name":"MK-2206","moa":"AKT inhibitor","target":"AKT1, AKT2, AKT3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":17,"killed_fraction":0.03063,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86143,"interval":[0.78456,0.92129],"hit_lines":15,"nonhit_lines":446,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.37664,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"replicated","separation":0.8135,"interval":[0.70128,0.90727],"hit_lines":15,"nonhit_lines":442},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":17,"lineage_tested":20,"tested_annotated":555,"enrichment":4.89706,"p_one_sided_uncorrected":0.01973}},{"compound":"BRD-K85606544","name":"neratinib","moa":"EGFR inhibitor","target":"EGFR, ERBB2, KDR","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":48,"killed_fraction":0.08872,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84858,"interval":[0.78821,0.903],"hit_lines":38,"nonhit_lines":370,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":26,"median_ic50_uM":0.61444,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"replicated","separation":0.77417,"interval":[0.6944,0.85287],"hit_lines":43,"nonhit_lines":422},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":10,"hits_annotated":48,"lineage_tested":26,"tested_annotated":541,"enrichment":4.33494,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K50168500","name":"canertinib","moa":"EGFR inhibitor","target":"AKT1, EGFR, ERBB2, ERBB4","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":16,"killed_fraction":0.02862,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84792,"interval":[0.70874,0.95466],"hit_lines":14,"nonhit_lines":422,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":0.15386,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"replicated","separation":0.76044,"interval":[0.61892,0.88371],"hit_lines":16,"nonhit_lines":458},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":3,"hits_annotated":16,"lineage_tested":27,"tested_annotated":559,"enrichment":3.88194,"p_one_sided_uncorrected":0.03697}},{"compound":"BRD-K75295174","name":"alisertib","moa":"Aurora kinase inhibitor","target":"AURKA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":549,"lines_killed":67,"killed_fraction":0.12204,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84089,"interval":[0.78639,0.89774],"hit_lines":56,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":56,"median_ic50_uM":0.12842,"hit_lines_ic50_at_most_1uM":53}},"independent":{"status":"replicated","separation":0.74742,"interval":[0.67453,0.81657],"hit_lines":56,"nonhit_lines":416},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":7,"hits_annotated":67,"lineage_tested":22,"tested_annotated":549,"enrichment":2.60719,"p_one_sided_uncorrected":0.01124}},{"compound":"BRD-K52911425","name":"GDC-0941","moa":"PI3K inhibitor","target":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":14,"killed_fraction":0.02482,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80879,"interval":[0.64258,0.93427],"hit_lines":11,"nonhit_lines":455,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":0.43582,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"replicated","separation":0.71007,"interval":[0.52702,0.88521],"hit_lines":12,"nonhit_lines":479},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":14,"lineage_tested":23,"tested_annotated":564,"enrichment":5.25466,"p_one_sided_uncorrected":0.0161}},{"compound":"BRD-K87124298","name":"OSI-027","moa":"mTOR inhibitor","target":"MTOR","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":36,"killed_fraction":0.06429,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76524,"interval":[0.68065,0.84542],"hit_lines":30,"nonhit_lines":443,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":30,"median_ic50_uM":0.5209,"hit_lines_ic50_at_most_1uM":26}},"independent":{"status":"replicated","separation":0.70392,"interval":[0.60288,0.7941],"hit_lines":31,"nonhit_lines":457},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":4,"hits_annotated":36,"lineage_tested":20,"tested_annotated":560,"enrichment":3.11111,"p_one_sided_uncorrected":0.03325}},{"compound":"BRD-K87737963","name":"cyt387","moa":"NA","target":"JAK1, JAK2, JAK3","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":7,"killed_fraction":0.0125,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75387,"interval":[0.55452,0.9061],"hit_lines":6,"nonhit_lines":409,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.69035,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"replicated","separation":0.71447,"interval":[0.5666,0.85198],"hit_lines":5,"nonhit_lines":456},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":23,"tested_annotated":560,"enrichment":3.47826,"p_one_sided_uncorrected":0.25561}},{"compound":"BRD-K72420232","name":"WZ-4002","moa":"EGFR inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"confirmed","separation":0.99849,"interval":[0.99395,1.0],"hit_lines":3,"nonhit_lines":441,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":0.32428,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"replicated","separation":0.9759,"interval":[0.94127,1.0],"hit_lines":4,"nonhit_lines":332},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":3,"hits_annotated":5,"lineage_tested":100,"tested_annotated":556,"enrichment":3.336,"p_one_sided_uncorrected":0.04286}},{"compound":"BRD-A57798112","name":"PD-318088","moa":"MEK inhibitor","target":"MAP2K1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":65,"killed_fraction":0.11628,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94385,"interval":[0.91682,0.96431],"hit_lines":57,"nonhit_lines":404,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":57,"median_ic50_uM":0.20033,"hit_lines_ic50_at_most_1uM":57}},"independent":{"status":"replicated","separation":0.82024,"interval":[0.76008,0.86604],"hit_lines":61,"nonhit_lines":430},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":20,"hits_annotated":65,"lineage_tested":43,"tested_annotated":559,"enrichment":4.0,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K36363294","name":"I-BET151","moa":"bromodomain inhibitor","target":"BRD2, BRD3, BRD4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":18,"killed_fraction":0.03327,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92815,"interval":[0.87064,0.9665],"hit_lines":16,"nonhit_lines":401,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":2.16007,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"replicated","separation":0.73062,"interval":[0.63745,0.81455],"hit_lines":16,"nonhit_lines":450},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":18,"lineage_tested":12,"tested_annotated":541,"enrichment":5.00926,"p_one_sided_uncorrected":0.05667}},{"compound":"BRD-K00317371","name":"RITA","moa":"MDM inhibitor","target":"MDM2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.4,"lines_tested":530,"lines_killed":221,"killed_fraction":0.41698,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91878,"interval":[0.89053,0.94208],"hit_lines":179,"nonhit_lines":245,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":178,"median_ic50_uM":0.22886,"hit_lines_ic50_at_most_1uM":149}},"independent":{"status":"replicated","separation":0.7878,"interval":[0.73828,0.83132],"hit_lines":180,"nonhit_lines":267},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":21,"hits_annotated":221,"lineage_tested":33,"tested_annotated":530,"enrichment":1.52612,"p_one_sided_uncorrected":0.00734}},{"compound":"BRD-A25004090","name":"erastin","moa":"ion channel antagonist","target":"VDAC2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":50,"killed_fraction":0.08929,"class":"selective"},"secondary":{"status":"confirmed","separation":0.90027,"interval":[0.85771,0.93514],"hit_lines":36,"nonhit_lines":349,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":36,"median_ic50_uM":1.30516,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"replicated","separation":0.75003,"interval":[0.661,0.82445],"hit_lines":44,"nonhit_lines":438},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":14,"hits_annotated":50,"lineage_tested":101,"tested_annotated":560,"enrichment":1.55248,"p_one_sided_uncorrected":0.04691}},{"compound":"BRD-K16478699","name":"PLX-4720","moa":"RAF inhibitor","target":"BRAF, KDR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":15,"killed_fraction":0.02698,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89317,"interval":[0.76616,0.9785],"hit_lines":14,"nonhit_lines":450,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":0.87476,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"replicated","separation":0.95312,"interval":[0.92124,0.98132],"hit_lines":12,"nonhit_lines":464},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":11,"hits_annotated":15,"lineage_tested":43,"tested_annotated":556,"enrichment":9.48217,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-A12230535","name":"nutlin-3","moa":"MDM inhibitor","target":"MDM2, TP53","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":19,"killed_fraction":0.03512,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88961,"interval":[0.8014,0.95151],"hit_lines":16,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":1.99884,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"replicated","separation":0.79333,"interval":[0.69291,0.88182],"hit_lines":15,"nonhit_lines":440},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":19,"lineage_tested":22,"tested_annotated":541,"enrichment":3.88278,"p_one_sided_uncorrected":0.03706}},{"compound":"BRD-K67578145","name":"GDC-0879","moa":"RAF inhibitor","target":"BRAF","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":23,"killed_fraction":0.04137,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8797,"interval":[0.76534,0.97025],"hit_lines":18,"nonhit_lines":381,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.72351,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"replicated","separation":0.75934,"interval":[0.59009,0.88618],"hit_lines":19,"nonhit_lines":455},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":13,"hits_annotated":23,"lineage_tested":43,"tested_annotated":556,"enrichment":7.30839,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K12040459","name":"AT7867","moa":"AKT inhibitor","target":"AKT2, GSK3B, PKIA, PRKACA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":11,"killed_fraction":0.01968,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87359,"interval":[0.77326,0.95786],"hit_lines":5,"nonhit_lines":337,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":0.67658,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"replicated","separation":0.86286,"interval":[0.69164,0.97667],"hit_lines":10,"nonhit_lines":451},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":23,"tested_annotated":559,"enrichment":4.41897,"p_one_sided_uncorrected":0.07108}},{"compound":"BRD-K81728688","name":"WZ8040","moa":"EGFR inhibitor","target":"EGFR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":11,"killed_fraction":0.01978,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85227,"interval":[0.65675,0.96602],"hit_lines":9,"nonhit_lines":443,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":0.78355,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"replicated","separation":0.81464,"interval":[0.62226,0.96368],"hit_lines":9,"nonhit_lines":422},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":24,"tested_annotated":556,"enrichment":6.31818,"p_one_sided_uncorrected":0.00931}},{"compound":"BRD-K67566344","name":"ku-0063794","moa":"mTOR inhibitor","target":"MTOR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":26,"killed_fraction":0.04676,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82011,"interval":[0.71943,0.90301],"hit_lines":22,"nonhit_lines":448,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":0.87082,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"replicated","separation":0.70129,"interval":[0.59476,0.79423],"hit_lines":22,"nonhit_lines":454},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":4,"hits_annotated":26,"lineage_tested":20,"tested_annotated":556,"enrichment":4.27692,"p_one_sided_uncorrected":0.01095}},{"compound":"BRD-K04923131","name":"GSK-3-inhibitor-IX","moa":"glycogen synthase kinase inhibitor, lipoxygenase inhibitor","target":"GSK3A, GSK3B","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":13,"killed_fraction":0.02347,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78795,"interval":[0.61523,0.89231],"hit_lines":11,"nonhit_lines":436,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":2.25696,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"replicated","separation":0.7956,"interval":[0.68622,0.8819],"hit_lines":12,"nonhit_lines":455},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":2,"hits_annotated":13,"lineage_tested":19,"tested_annotated":554,"enrichment":4.48583,"p_one_sided_uncorrected":0.06942}},{"compound":"BRD-K61323504","name":"SB-225002","moa":"CC chemokine receptor antagonist","target":"CXCR2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"independently_replicated","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":156,"killed_fraction":0.28159,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76308,"interval":[0.71295,0.80594],"hit_lines":115,"nonhit_lines":285,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":114,"median_ic50_uM":2.02058,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"replicated","separation":0.70628,"interval":[0.65898,0.75476],"hit_lines":131,"nonhit_lines":355},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":19,"hits_annotated":156,"lineage_tested":41,"tested_annotated":554,"enrichment":1.64572,"p_one_sided_uncorrected":0.00766}},{"compound":"BRD-A92537424","name":"danazol","moa":"estrogen receptor antagonist, progesterone receptor agonist","target":"AR, CCL2, ESR1, GNRHR, GNRHR2, PGR","disease_area":"obstetrics/gynecology, cardiology","indication":"endometriosis, angioedema","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":8,"killed_fraction":0.01418,"class":"selective"},"secondary":{"status":"confirmed","separation":0.9934,"interval":[0.98446,0.99922],"hit_lines":6,"nonhit_lines":429,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.65101,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":3,"hits_annotated":8,"lineage_tested":43,"tested_annotated":564,"enrichment":4.9186,"p_one_sided_uncorrected":0.01768}},{"compound":"BRD-K62200014","name":"anagrelide","moa":"phosphodiesterase inhibitor","target":"PDE3A","disease_area":"hematology, hematologic malignancy","indication":"thrombocythemia, myeloproliferative neoplasms","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":14,"killed_fraction":0.02532,"class":"selective"},"secondary":{"status":"confirmed","separation":0.96133,"interval":[0.92314,0.99433],"hit_lines":10,"nonhit_lines":406,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":0.01354,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":6,"hits_annotated":14,"lineage_tested":43,"tested_annotated":553,"enrichment":5.51163,"p_one_sided_uncorrected":0.00029}},{"compound":"BRD-K69726342","name":"atorvastatin","moa":"HMGCR inhibitor","target":"AHR, DPP4, HMGCR","disease_area":"neurology/psychiatry, cardiology","indication":"stroke, heart attack","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":46,"killed_fraction":0.08185,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94399,"interval":[0.91402,0.97308],"hit_lines":37,"nonhit_lines":400,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":37,"median_ic50_uM":1.21606,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":6,"hits_annotated":46,"lineage_tested":23,"tested_annotated":562,"enrichment":3.18715,"p_one_sided_uncorrected":0.00752}},{"compound":"BRD-K13514097","name":"everolimus","moa":"mTOR inhibitor","target":"MTOR","disease_area":"oncology, neurology/psychiatry, genetics, urology","indication":"breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":18,"killed_fraction":0.0322,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93184,"interval":[0.86315,0.98099],"hit_lines":15,"nonhit_lines":401,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.0093,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":5,"hits_annotated":18,"lineage_tested":24,"tested_annotated":559,"enrichment":6.46991,"p_one_sided_uncorrected":0.00056}},{"compound":"BRD-K54634444","name":"artesunate","moa":"DNA synthesis inhibitor","target":"NA","disease_area":"infectious disease","indication":"malaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":7,"killed_fraction":0.01246,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92222,"interval":[0.80439,0.98889],"hit_lines":5,"nonhit_lines":432,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":2.16485,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":3,"tested_annotated":562,"enrichment":26.7619,"p_one_sided_uncorrected":0.03697}},{"compound":"BRD-A50064262","name":"flumethasone-pivalate","moa":"glucocorticoid receptor agonist","target":"NR3C1, SERPINA6","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":8,"killed_fraction":0.01431,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91618,"interval":[0.8419,0.96937],"hit_lines":5,"nonhit_lines":408,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":3.85201,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":36,"tested_annotated":559,"enrichment":3.88194,"p_one_sided_uncorrected":0.08838}},{"compound":"BRD-K42898655","name":"temsirolimus","moa":"mTOR inhibitor","target":"MTOR","disease_area":"oncology","indication":"renal cell carcinoma (RCC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":17,"killed_fraction":0.03014,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89488,"interval":[0.82029,0.96406],"hit_lines":17,"nonhit_lines":418,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":0.00096,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":4,"hits_annotated":17,"lineage_tested":20,"tested_annotated":564,"enrichment":6.63529,"p_one_sided_uncorrected":0.00204}},{"compound":"BRD-K40496271","name":"eltrombopag","moa":"thrombopoietin receptor agonist","target":"MPL","disease_area":"hematology, infectious disease","indication":"anemia, hepatitis C, thrombocytopenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.34,"lines_tested":530,"lines_killed":13,"killed_fraction":0.02453,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89452,"interval":[0.84126,0.94014],"hit_lines":10,"nonhit_lines":420,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":1.59414,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":40,"tested_annotated":530,"enrichment":3.05769,"p_one_sided_uncorrected":0.06708}},{"compound":"BRD-K99964838","name":"bosutinib","moa":"Abl kinase inhibitor, Bcr-Abl kinase inhibitor, src inhibitor","target":"ABL1, BCR, CAMK1D, CAMK2G, CDK2, FRK, FYN, HCK, LYN, MAP2K1, MAP2K2, MAP3K2, MAP4K5, SRC, STK10, STK24, STK4, TNK2, TXK","disease_area":"hematologic malignancy","indication":"chronic myeloid leukemia (CML)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":13,"killed_fraction":0.02313,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89436,"interval":[0.80617,0.95977],"hit_lines":13,"nonhit_lines":434,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":1.3098,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":19,"tested_annotated":562,"enrichment":6.82591,"p_one_sided_uncorrected":0.00758}},{"compound":"BRD-K52256627","name":"chlorhexidine","moa":"membrane integrity inhibitor","target":"NA","disease_area":"dermatology, infectious disease, dental","indication":"cosmetic, skin infections, gingivitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":20,"killed_fraction":0.03578,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89102,"interval":[0.82833,0.93956],"hit_lines":16,"nonhit_lines":394,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":2.07366,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":3,"hits_annotated":20,"lineage_tested":21,"tested_annotated":559,"enrichment":3.99286,"p_one_sided_uncorrected":0.03451}},{"compound":"BRD-K49350383","name":"thioguanine","moa":"purine antagonist","target":"IMPDH1, IMPDH2","disease_area":"hematologic malignancy","indication":"acute myeloid leukemia (AML)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":77,"killed_fraction":0.13899,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88471,"interval":[0.83742,0.92011],"hit_lines":56,"nonhit_lines":364,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":30,"median_ic50_uM":2.87067,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":10,"hits_annotated":77,"lineage_tested":22,"tested_annotated":554,"enrichment":3.27037,"p_one_sided_uncorrected":0.00025}},{"compound":"BRD-K88429204","name":"pyrimethamine","moa":"dihydrofolate reductase inhibitor","target":"DHFR, SLC47A1","disease_area":"infectious disease","indication":"malaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":16,"killed_fraction":0.02852,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88113,"interval":[0.84325,0.9159],"hit_lines":15,"nonhit_lines":447,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":1.84142,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":2,"hits_annotated":16,"lineage_tested":19,"tested_annotated":561,"enrichment":3.69079,"p_one_sided_uncorrected":0.09832}},{"compound":"BRD-K66788707","name":"fludarabine","moa":"ribonucleotide reductase inhibitor","target":"ADA, RRM1, RRM2","disease_area":"hematologic malignancy","indication":"chronic lymphocytic leukemia (CLL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":7,"killed_fraction":0.01259,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87488,"interval":[0.70279,0.97187],"hit_lines":5,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.33927,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":23,"tested_annotated":556,"enrichment":6.90683,"p_one_sided_uncorrected":0.03031}},{"compound":"BRD-K92073408","name":"norethindrone","moa":"progesterone receptor agonist","target":"PGR","disease_area":"obstetrics/gynecology","indication":"endometriosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":5,"killed_fraction":0.0089,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87418,"interval":[0.82392,0.91017],"hit_lines":3,"nonhit_lines":408,"screen_id":"MTS005","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":5.99412,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":43,"tested_annotated":562,"enrichment":5.22791,"p_one_sided_uncorrected":0.04934}},{"compound":"BRD-K87827419","name":"melphalan","moa":"DNA alkylating agent, DNA inhibitor","target":"NA","disease_area":"hematologic malignancy","indication":"multiple myeloma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":74,"killed_fraction":0.13504,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8739,"interval":[0.81973,0.92223],"hit_lines":57,"nonhit_lines":399,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":56,"median_ic50_uM":1.67878,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":9,"hits_annotated":74,"lineage_tested":23,"tested_annotated":548,"enrichment":2.89777,"p_one_sided_uncorrected":0.00157}},{"compound":"BRD-K90374350","name":"chlorquinaldol","moa":"other antibiotic","target":"NA","disease_area":"infectious disease","indication":"fungal infection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":10,"killed_fraction":0.01825,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8713,"interval":[0.77665,0.94933],"hit_lines":8,"nonhit_lines":439,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":2.22544,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":10,"lineage_tested":9,"tested_annotated":548,"enrichment":6.08889,"p_one_sided_uncorrected":0.15379}},{"compound":"BRD-K75958547","name":"pitavastatin","moa":"HMGCR inhibitor","target":"HMGCR","disease_area":"endocrinology","indication":"hyperlipidemia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":184,"killed_fraction":0.3274,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86333,"interval":[0.82252,0.90313],"hit_lines":129,"nonhit_lines":203,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":125,"median_ic50_uM":0.648,"hit_lines_ic50_at_most_1uM":89}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":23,"hits_annotated":184,"lineage_tested":41,"tested_annotated":562,"enrichment":1.71341,"p_one_sided_uncorrected":0.00117}},{"compound":"BRD-K09602097","name":"forskolin","moa":"adenylyl cyclase activator","target":"ADCY2, ADCY5, GNAS","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86218,"interval":[0.75401,0.95238],"hit_lines":5,"nonhit_lines":357,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":0.93597,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":33,"tested_annotated":541,"enrichment":4.68398,"p_one_sided_uncorrected":0.06252}},{"compound":"BRD-K35240538","name":"methylprednisolone","moa":"glucocorticoid receptor agonist","target":"NR3C1","disease_area":"endocrinology, rheumatology, dermatology, infectious disease, allergy, hematology, neurology/psychiatry, gastroenterology","indication":"hypercalcemia, thyroiditis, ankylosing spondylitis, bursitis, osteoarthritis, psoriatic arthritis, seborrheic dermatitis, mycosis, allergic rhinitis, psoriasis, anemia, multiple sclerosis, ulcerative colitis, enteritis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":10,"killed_fraction":0.01852,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85662,"interval":[0.67714,0.98049],"hit_lines":8,"nonhit_lines":374,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":0.61387,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":1,"hits_annotated":10,"lineage_tested":11,"tested_annotated":540,"enrichment":4.90909,"p_one_sided_uncorrected":0.18744}},{"compound":"BRD-K42805893","name":"osimertinib","moa":"EGFR inhibitor","target":"EGFR","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":32,"killed_fraction":0.05674,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8539,"interval":[0.78917,0.90893],"hit_lines":26,"nonhit_lines":407,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":21,"median_ic50_uM":0.69223,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":5,"hits_annotated":32,"lineage_tested":24,"tested_annotated":564,"enrichment":3.67188,"p_one_sided_uncorrected":0.00838}},{"compound":"BRD-K03243820","name":"trifluridine","moa":"DNA directed DNA polymerase inhibitor, thymidylate synthase inhibitor","target":"TYMS","disease_area":"infectious disease","indication":"virus herpes simplex (HSV)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":51,"killed_fraction":0.09307,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85216,"interval":[0.79366,0.90142],"hit_lines":44,"nonhit_lines":416,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":44,"median_ic50_uM":0.1491,"hit_lines_ic50_at_most_1uM":43}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":6,"hits_annotated":51,"lineage_tested":33,"tested_annotated":548,"enrichment":1.95365,"p_one_sided_uncorrected":0.07487}},{"compound":"BRD-K99792991","name":"hexachlorophene","moa":"potassium channel activator","target":"GLUD1, SDHD","disease_area":"infectious disease","indication":"gram-positive bacterial infections","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":22,"killed_fraction":0.03922,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84895,"interval":[0.77361,0.91224],"hit_lines":20,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":1.87359,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":6,"hits_annotated":22,"lineage_tested":43,"tested_annotated":561,"enrichment":3.55814,"p_one_sided_uncorrected":0.0042}},{"compound":"BRD-K91601245","name":"mercaptopurine","moa":"immunosuppressant, protein synthesis inhibitor, purine antagonist","target":"HPRT1, IMPDH1, IMPDH2, PPAT","disease_area":"hematologic malignancy","indication":"acute lymphoblastic leukemia (ALL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":33,"killed_fraction":0.06022,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84423,"interval":[0.75589,0.91316],"hit_lines":26,"nonhit_lines":420,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":21,"median_ic50_uM":1.89502,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":5,"hits_annotated":33,"lineage_tested":23,"tested_annotated":548,"enrichment":3.61001,"p_one_sided_uncorrected":0.00895}},{"compound":"BRD-K38003476","name":"clocortolone-pivalate","moa":"steroid","target":"NR3C1, PLA2G1B","disease_area":"dermatology","indication":"corticosteroid-responsive dermatoses","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84267,"interval":[0.72947,0.95156],"hit_lines":4,"nonhit_lines":232,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":0.84203,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":8,"tested_annotated":564,"enrichment":14.1,"p_one_sided_uncorrected":0.06918}},{"compound":"BRD-K54955827","name":"niraparib","moa":"PARP inhibitor","target":"PARP1","disease_area":"oncology","indication":"primary peritoneal cancer (PPC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49998,"lines_tested":541,"lines_killed":14,"killed_fraction":0.02588,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84264,"interval":[0.6769,0.96955],"hit_lines":10,"nonhit_lines":421,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":0.61342,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":4,"hits_annotated":14,"lineage_tested":19,"tested_annotated":541,"enrichment":8.13534,"p_one_sided_uncorrected":0.00088}},{"compound":"BRD-K03390685","name":"cobimetinib","moa":"MEK inhibitor","target":"NA","disease_area":"oncology","indication":"melanoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":154,"killed_fraction":0.27698,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8395,"interval":[0.80312,0.87587],"hit_lines":128,"nonhit_lines":303,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":111,"median_ic50_uM":0.32649,"hit_lines_ic50_at_most_1uM":91}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":17,"hits_annotated":154,"lineage_tested":27,"tested_annotated":556,"enrichment":2.27321,"p_one_sided_uncorrected":9e-05}},{"compound":"BRD-K63750851","name":"mycophenolic-acid","moa":"dehydrogenase inhibitor, inositol monophosphatase inhibitor","target":"IMPDH1, IMPDH2","disease_area":"transplant","indication":"organ rejection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":41,"killed_fraction":0.07295,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83921,"interval":[0.73824,0.91175],"hit_lines":24,"nonhit_lines":312,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":24,"median_ic50_uM":0.61773,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":6,"hits_annotated":41,"lineage_tested":37,"tested_annotated":562,"enrichment":2.22281,"p_one_sided_uncorrected":0.04376}},{"compound":"BRD-K31698212","name":"icotinib","moa":"EGFR inhibitor","target":"EGFR","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":563,"lines_killed":12,"killed_fraction":0.02131,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83456,"interval":[0.6894,0.95161],"hit_lines":10,"nonhit_lines":408,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.3981,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":27,"tested_annotated":563,"enrichment":3.47531,"p_one_sided_uncorrected":0.1087}},{"compound":"BRD-K15567136","name":"papaverine","moa":"phosphodiesterase inhibitor","target":"PDE10A, PDE4B, PDE5A","disease_area":"cardiology, hematology, gastroenterology","indication":"myocardial infarction, angina pectoris, pulmonary embolism (PE), colitis, vascular spasm","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":5,"killed_fraction":0.0089,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82767,"interval":[0.74272,0.91236],"hit_lines":4,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":2.25048,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":100,"tested_annotated":562,"enrichment":2.248,"p_one_sided_uncorrected":0.21775}},{"compound":"BRD-K33622447","name":"abemaciclib","moa":"CDK inhibitor","target":"CDK4, CDK6","disease_area":"oncology","indication":"breast cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":21,"killed_fraction":0.0375,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82425,"interval":[0.72851,0.90155],"hit_lines":18,"nonhit_lines":428,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.83946,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":3,"hits_annotated":21,"lineage_tested":19,"tested_annotated":560,"enrichment":4.21053,"p_one_sided_uncorrected":0.02992}},{"compound":"BRD-K76634210","name":"idoxuridine","moa":"DNA directed DNA polymerase inhibitor","target":"NA","disease_area":"infectious disease","indication":"virus herpes simplex (HSV)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":28,"killed_fraction":0.05176,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82022,"interval":[0.73256,0.89697],"hit_lines":24,"nonhit_lines":410,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":20,"median_ic50_uM":1.15379,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":5,"hits_annotated":28,"lineage_tested":39,"tested_annotated":541,"enrichment":2.47711,"p_one_sided_uncorrected":0.04293}},{"compound":"BRD-K10670311","name":"sulfasalazine","moa":"cyclooxygenase inhibitor","target":"ACAT1, ALOX5, CHUK, IKBKB, PLA2G1B, PPARG, PTGS1, PTGS2, SLC46A1, SLC7A11, TBXAS1","disease_area":"gastroenterology","indication":"ulcerative colitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81932,"interval":[0.6514,0.94104],"hit_lines":5,"nonhit_lines":383,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":26,"tested_annotated":541,"enrichment":5.94505,"p_one_sided_uncorrected":0.04022}},{"compound":"BRD-K59753975","name":"vindesine","moa":"tubulin polymerization inhibitor","target":"TUBB, TUBB1","disease_area":"oncology","indication":"breast cancer, non-small cell lung cancer (NSCLC), melanoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":83,"killed_fraction":0.15342,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81866,"interval":[0.76156,0.86561],"hit_lines":76,"nonhit_lines":381,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":76,"median_ic50_uM":0.0116,"hit_lines_ic50_at_most_1uM":76}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":4,"hits_annotated":83,"lineage_tested":9,"tested_annotated":541,"enrichment":2.89692,"p_one_sided_uncorrected":0.03527}},{"compound":"BRD-K78960041","name":"oxaliplatin","moa":"DNA inhibitor","target":"NA","disease_area":"oncology","indication":"colorectal cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":138,"killed_fraction":0.26038,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81743,"interval":[0.77648,0.86052],"hit_lines":120,"nonhit_lines":305,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":113,"median_ic50_uM":0.8034,"hit_lines_ic50_at_most_1uM":64}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":10,"hits_annotated":138,"lineage_tested":19,"tested_annotated":530,"enrichment":2.02136,"p_one_sided_uncorrected":0.01067}},{"compound":"BRD-K88625236","name":"nonoxynol-9","moa":"membrane integrity inhibitor","target":"NA","disease_area":"endocrinology","indication":"contraceptive","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":37,"killed_fraction":0.06607,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81356,"interval":[0.72932,0.88719],"hit_lines":29,"nonhit_lines":435,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":1.02477,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":3,"hits_annotated":37,"lineage_tested":11,"tested_annotated":560,"enrichment":4.12776,"p_one_sided_uncorrected":0.03035}},{"compound":"BRD-K73753850","name":"hexaminolevulinate","moa":"NA","target":"NA","disease_area":"radiology","indication":"diagnostic agent","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49996,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81133,"interval":[0.57821,0.95773],"hit_lines":6,"nonhit_lines":447,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.64978,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":3,"tested_annotated":541,"enrichment":25.7619,"p_one_sided_uncorrected":0.03839}},{"compound":"BRD-K87700323","name":"cetylpyridinium","moa":"NA","target":"NA","disease_area":"dental","indication":"gingivitis, mouth inflammation","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":83,"killed_fraction":0.14848,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81036,"interval":[0.76545,0.85366],"hit_lines":74,"nonhit_lines":389,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":74,"median_ic50_uM":0.85986,"hit_lines_ic50_at_most_1uM":43}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":9,"hits_annotated":83,"lineage_tested":27,"tested_annotated":559,"enrichment":2.24498,"p_one_sided_uncorrected":0.01096}},{"compound":"BRD-K62213621","name":"dihydroartemisinin","moa":"antimalarial agent","target":"NA","disease_area":"infectious disease","indication":"malaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":11,"killed_fraction":0.01978,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80598,"interval":[0.65839,0.91172],"hit_lines":10,"nonhit_lines":418,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":2.3382,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":11,"lineage_tested":2,"tested_annotated":556,"enrichment":25.27273,"p_one_sided_uncorrected":0.03921}},{"compound":"BRD-K13183738","name":"pentamidine","moa":"anti-pneumocystis agent","target":"TRDMT1","disease_area":"infectious disease","indication":"pneumonia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":62,"killed_fraction":0.11091,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80539,"interval":[0.75077,0.86673],"hit_lines":45,"nonhit_lines":363,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":42,"median_ic50_uM":1.08035,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":9,"hits_annotated":62,"lineage_tested":43,"tested_annotated":559,"enrichment":1.8871,"p_one_sided_uncorrected":0.03712}},{"compound":"BRD-K60443845","name":"chlormidazole","moa":"fungal lanosterol demethylase inhibitor","target":"NA","disease_area":"infectious disease","indication":"fungal infection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":20,"killed_fraction":0.03697,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80477,"interval":[0.70942,0.87822],"hit_lines":18,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":1.83354,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":20,"lineage_tested":12,"tested_annotated":541,"enrichment":9.01667,"p_one_sided_uncorrected":0.00056}},{"compound":"BRD-K06519765","name":"vinblastine","moa":"microtubule inhibitor, tubulin polymerization inhibitor","target":"JUN, TUBA1A, TUBB, TUBD1, TUBE1, TUBG1","disease_area":"hematologic malignancy, infectious disease, oncology","indication":"Hodgkin's lymphoma, true histiocytic lymphoma (THL), mycosis, small lymphocytic lymphoma (SLL), testicular carcinoma, Kaposi sarcoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":110,"killed_fraction":0.20333,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80166,"interval":[0.75499,0.8434],"hit_lines":97,"nonhit_lines":360,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":97,"median_ic50_uM":0.00846,"hit_lines_ic50_at_most_1uM":97}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":6,"hits_annotated":110,"lineage_tested":10,"tested_annotated":541,"enrichment":2.95091,"p_one_sided_uncorrected":0.00643}},{"compound":"BRD-K54262262","name":"monobenzone","moa":"melanin inhibitor","target":"TYR","disease_area":"dermatology","indication":"skin depigmentation","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":6,"killed_fraction":0.01085,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80164,"interval":[0.69471,0.93719],"hit_lines":3,"nonhit_lines":326,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":3.88451,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":7,"tested_annotated":553,"enrichment":26.33333,"p_one_sided_uncorrected":0.00201}},{"compound":"BRD-K89121095","name":"tedizolid-phosphate","moa":"protein synthesis inhibitor","target":"NA","disease_area":"infectious disease","indication":"skin infections","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":21,"killed_fraction":0.03882,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80133,"interval":[0.71655,0.87038],"hit_lines":19,"nonhit_lines":435,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":0.90446,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":3,"hits_annotated":21,"lineage_tested":23,"tested_annotated":541,"enrichment":3.36025,"p_one_sided_uncorrected":0.05408}},{"compound":"BRD-K97472745","name":"gestrinone","moa":"progesterone receptor antagonist","target":"AR, ESR1, PGR","disease_area":"obstetrics/gynecology","indication":"endometriosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":11,"killed_fraction":0.0195,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79681,"interval":[0.59027,0.98215],"hit_lines":7,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.02614,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":4,"hits_annotated":11,"lineage_tested":43,"tested_annotated":564,"enrichment":4.76956,"p_one_sided_uncorrected":0.00654}},{"compound":"BRD-K58262659","name":"doxifluridine","moa":"thymidylate synthase inhibitor","target":"TYMS","disease_area":"oncology","indication":"colorectal cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":8,"killed_fraction":0.01479,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79333,"interval":[0.6903,0.87384],"hit_lines":7,"nonhit_lines":394,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":3.13607,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":26,"tested_annotated":541,"enrichment":5.20192,"p_one_sided_uncorrected":0.05205}},{"compound":"BRD-K82928892","name":"doxercalciferol","moa":"vitamin D receptor agonist","target":"VDR","disease_area":"nephrology, endocrinology","indication":"chronic kidney disease (CKD), hyperparathyroidism","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.46,"lines_tested":530,"lines_killed":16,"killed_fraction":0.03019,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78833,"interval":[0.68813,0.87938],"hit_lines":11,"nonhit_lines":338,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":1.72375,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":4,"hits_annotated":16,"lineage_tested":33,"tested_annotated":530,"enrichment":4.01515,"p_one_sided_uncorrected":0.01335}},{"compound":"BRD-K33813875","name":"valnemulin","moa":"bacterial 50S ribosomal subunit inhibitor","target":"NA","disease_area":"infectious disease, gastroenterology","indication":"dysentry, colitis, pneumonia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":6,"killed_fraction":0.01095,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78728,"interval":[0.60236,0.9343],"hit_lines":5,"nonhit_lines":456,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":0.71066,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":38,"tested_annotated":548,"enrichment":4.80702,"p_one_sided_uncorrected":0.05885}},{"compound":"BRD-K50677762","name":"oxiracetam","moa":"acetylcholine receptor agonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":235,"killed_fraction":0.42266,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78098,"interval":[0.73595,0.81885],"hit_lines":211,"nonhit_lines":258,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":198,"median_ic50_uM":2.08873,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":20,"hits_annotated":235,"lineage_tested":27,"tested_annotated":556,"enrichment":1.75256,"p_one_sided_uncorrected":0.00062}},{"compound":"BRD-K56981171","name":"brigatinib","moa":"ALK tyrosine kinase receptor inhibitor, EGFR inhibitor","target":"ALK, EGFR","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.50001,"lines_tested":540,"lines_killed":34,"killed_fraction":0.06296,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77962,"interval":[0.69302,0.85346],"hit_lines":29,"nonhit_lines":408,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":21,"median_ic50_uM":1.92478,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":5,"hits_annotated":34,"lineage_tested":24,"tested_annotated":540,"enrichment":3.30882,"p_one_sided_uncorrected":0.01307}},{"compound":"BRD-K08619574","name":"thioproperazine","moa":"dopamine receptor antagonist","target":"ADRA1A, ADRA1B, DRD1, DRD2, HTR1A, HTR2A","disease_area":"neurology/psychiatry","indication":"schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":14,"killed_fraction":0.02491,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77778,"interval":[0.64667,0.88667],"hit_lines":3,"nonhit_lines":150,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":14,"lineage_tested":41,"tested_annotated":562,"enrichment":2.93728,"p_one_sided_uncorrected":0.07467}},{"compound":"BRD-K59866480","name":"cyclovalone","moa":"breast cancer resistance protein inhibitor","target":"ABCG2","disease_area":"gastroenterology","indication":"bile stimulation","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.37966,"lines_tested":541,"lines_killed":53,"killed_fraction":0.09797,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77726,"interval":[0.69582,0.85688],"hit_lines":42,"nonhit_lines":411,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":42,"median_ic50_uM":2.43548,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":6,"hits_annotated":53,"lineage_tested":19,"tested_annotated":541,"enrichment":3.22344,"p_one_sided_uncorrected":0.00666}},{"compound":"BRD-K47832606","name":"floxuridine","moa":"DNA synthesis inhibitor","target":"TYMS","disease_area":"oncology","indication":"colorectal cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":184,"killed_fraction":0.33094,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77545,"interval":[0.72462,0.81673],"hit_lines":161,"nonhit_lines":295,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":158,"median_ic50_uM":0.05632,"hit_lines_ic50_at_most_1uM":158}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":4,"hits_annotated":184,"lineage_tested":4,"tested_annotated":556,"enrichment":3.02174,"p_one_sided_uncorrected":0.01173}},{"compound":"BRD-K07572174","name":"curcumin","moa":"cyclooxygenase inhibitor, histone acetyltransferase inhibitor, lipoxygenase inhibitor, NFkB pathway inhibitor","target":"APP, CA1, CA12, CA14, CA2, CA4, CA6, CA9, CYP3A4, DNMT3B, EP300, MMP13, MMP9, NOS2, PTGS1, PTGS2, XDH","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.48,"lines_tested":530,"lines_killed":68,"killed_fraction":0.1283,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77507,"interval":[0.71016,0.84055],"hit_lines":55,"nonhit_lines":372,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":55,"median_ic50_uM":1.79293,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":10,"hits_annotated":68,"lineage_tested":22,"tested_annotated":530,"enrichment":3.54278,"p_one_sided_uncorrected":0.00012}},{"compound":"BRD-K32821942","name":"azathioprine","moa":"dehydrogenase inhibitor","target":"HPRT1, IMPDH1, PPAT","disease_area":"transplant, rheumatology","indication":"renal homotransplantation, rheumatoid arthritis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":18,"killed_fraction":0.03203,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77395,"interval":[0.66861,0.87042],"hit_lines":14,"nonhit_lines":431,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":1.83408,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":4,"hits_annotated":18,"lineage_tested":35,"tested_annotated":562,"enrichment":3.56825,"p_one_sided_uncorrected":0.02067}},{"compound":"BRD-A09349126","name":"norethindrone-acetate","moa":"progesterone receptor agonist","target":"NA","disease_area":"endocrinology, orthopedics, obstetrics/gynecology","indication":"menopause, osteoporosis, vaginal atrophy","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":14,"killed_fraction":0.02593,"class":"selective"},"secondary":{"status":"confirmed","separation":0.7696,"interval":[0.5912,0.93983],"hit_lines":9,"nonhit_lines":367,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.23266,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":4,"hits_annotated":14,"lineage_tested":39,"tested_annotated":540,"enrichment":3.95604,"p_one_sided_uncorrected":0.01377}},{"compound":"BRD-K64120610","name":"vinflunine","moa":"microtubule inhibitor","target":"NA","disease_area":"oncology","indication":"bladder cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":132,"killed_fraction":0.24399,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76893,"interval":[0.71561,0.81098],"hit_lines":119,"nonhit_lines":340,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":117,"median_ic50_uM":0.08346,"hit_lines_ic50_at_most_1uM":117}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":15,"hits_annotated":132,"lineage_tested":43,"tested_annotated":541,"enrichment":1.4297,"p_one_sided_uncorrected":0.07238}},{"compound":"BRD-K00634421","name":"brivaracetam","moa":"voltage-gated sodium channel blocker","target":"SV2A","disease_area":"neurology/psychiatry","indication":"seizures","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.50004,"lines_tested":540,"lines_killed":91,"killed_fraction":0.16852,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76856,"interval":[0.71128,0.81493],"hit_lines":81,"nonhit_lines":367,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":81,"median_ic50_uM":0.51001,"hit_lines_ic50_at_most_1uM":70}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":11,"hits_annotated":91,"lineage_tested":27,"tested_annotated":540,"enrichment":2.41758,"p_one_sided_uncorrected":0.00218}},{"compound":"BRD-K09416995","name":"lovastatin","moa":"HMGCR inhibitor","target":"HDAC2, HMGCR, ITGAL, NR1I2","disease_area":"cardiology, endocrinology","indication":"coronary heart disease, myocardial infarction, hypercholesterolemia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":38,"killed_fraction":0.06798,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76853,"interval":[0.64882,0.87634],"hit_lines":15,"nonhit_lines":269,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":2.67266,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":10,"hits_annotated":38,"lineage_tested":42,"tested_annotated":559,"enrichment":3.50251,"p_one_sided_uncorrected":0.0002}},{"compound":"BRD-K93779381","name":"ingenol-mebutate","moa":"PKC activator","target":"PRKCA, PRKCB, PRKCD, PRKCE, PRKCG","disease_area":"dermatology","indication":"actinic keratosis (AK)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":56,"killed_fraction":0.09929,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76442,"interval":[0.69112,0.83273],"hit_lines":47,"nonhit_lines":401,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":0.06951,"hit_lines_ic50_at_most_1uM":22}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":56,"lineage_tested":12,"tested_annotated":564,"enrichment":2.51786,"p_one_sided_uncorrected":0.10698}},{"compound":"BRD-K08547377","name":"irinotecan","moa":"topoisomerase inhibitor","target":"TOP1, TOP1MT","disease_area":"oncology","indication":"colorectal cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":266,"killed_fraction":0.49168,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76196,"interval":[0.71731,0.80338],"hit_lines":223,"nonhit_lines":204,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":156,"median_ic50_uM":0.14652,"hit_lines_ic50_at_most_1uM":132}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":266,"lineage_tested":23,"tested_annotated":541,"enrichment":1.41484,"p_one_sided_uncorrected":0.03614}},{"compound":"BRD-A74914197","name":"pralatrexate","moa":"dihydrofolate reductase inhibitor","target":"DHFR, TYMS","disease_area":"hematologic malignancy","indication":"peripheral T-cell lymphoma (PTCL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":170,"killed_fraction":0.30686,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76196,"interval":[0.71469,0.81089],"hit_lines":139,"nonhit_lines":306,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":70,"median_ic50_uM":0.00648,"hit_lines_ic50_at_most_1uM":70}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":13,"hits_annotated":170,"lineage_tested":22,"tested_annotated":554,"enrichment":1.92567,"p_one_sided_uncorrected":0.00457}},{"compound":"BRD-K13112821","name":"artemisinin","moa":"DNA synthesis inhibitor","target":"CYP2B6","disease_area":"infectious disease","indication":"malaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75953,"interval":[0.53529,0.96477],"hit_lines":4,"nonhit_lines":446,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":1.81199,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":24,"tested_annotated":556,"enrichment":4.63333,"p_one_sided_uncorrected":0.19864}},{"compound":"BRD-K26634012","name":"tilmicosin","moa":"bacterial 50S ribosomal subunit inhibitor","target":"NA","disease_area":"pulmonary","indication":"bovine respiratory disease (BRD)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":7,"killed_fraction":0.01277,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75938,"interval":[0.58556,0.92941],"hit_lines":4,"nonhit_lines":400,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":8,"tested_annotated":548,"enrichment":9.78571,"p_one_sided_uncorrected":0.09834}},{"compound":"BRD-A25608658","name":"narasin","moa":"antiprotozoal agent","target":"NA","disease_area":"infectious disease","indication":"coccidiosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":279,"killed_fraction":0.49821,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75909,"interval":[0.70991,0.80173],"hit_lines":247,"nonhit_lines":216,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":230,"median_ic50_uM":0.81783,"hit_lines_ic50_at_most_1uM":135}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":16,"hits_annotated":279,"lineage_tested":21,"tested_annotated":560,"enrichment":1.52927,"p_one_sided_uncorrected":0.01143}},{"compound":"BRD-K96159438","name":"adefovir-dipivoxil","moa":"DNA polymerase inhibitor","target":"NA","disease_area":"infectious disease","indication":"hepatitis B","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":79,"killed_fraction":0.1426,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75281,"interval":[0.68424,0.81862],"hit_lines":52,"nonhit_lines":328,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":50,"median_ic50_uM":0.89137,"hit_lines_ic50_at_most_1uM":28}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":6,"hits_annotated":79,"lineage_tested":21,"tested_annotated":554,"enrichment":2.00362,"p_one_sided_uncorrected":0.06391}},{"compound":"BRD-K62627508","name":"idasanutlin","moa":"MDM inhibitor","target":"MDM2, TP53","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":103,"killed_fraction":0.18327,"class":"selective"},"secondary":{"status":"confirmed","separation":0.98555,"interval":[0.97656,0.9943],"hit_lines":84,"nonhit_lines":355,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":83,"median_ic50_uM":0.12966,"hit_lines_ic50_at_most_1uM":83}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":20,"hits_annotated":103,"lineage_tested":43,"tested_annotated":562,"enrichment":2.53782,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K72280606","name":"gilteritinib","moa":"FLT3 inhibitor","target":"FLT3","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49999,"lines_tested":541,"lines_killed":6,"killed_fraction":0.01109,"class":"selective"},"secondary":{"status":"confirmed","separation":0.96682,"interval":[0.92959,0.99336],"hit_lines":5,"nonhit_lines":422,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.75082,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":5,"tested_annotated":541,"enrichment":18.03333,"p_one_sided_uncorrected":0.05443}},{"compound":"BRD-K89085489","name":"fenretinide","moa":"apoptosis stimulant, retinoid receptor agonist","target":"RARA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49997,"lines_tested":541,"lines_killed":9,"killed_fraction":0.01664,"class":"selective"},"secondary":{"status":"confirmed","separation":0.96506,"interval":[0.94396,0.98424],"hit_lines":7,"nonhit_lines":417,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":2.51713,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":37,"tested_annotated":541,"enrichment":4.87387,"p_one_sided_uncorrected":0.01861}},{"compound":"BRD-K08248804","name":"LCL-161","moa":"XIAP inhibitor","target":"BIRC2, XIAP","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":40,"killed_fraction":0.07394,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95762,"interval":[0.92472,0.98269],"hit_lines":38,"nonhit_lines":380,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":38,"median_ic50_uM":0.19527,"hit_lines_ic50_at_most_1uM":35}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":40,"lineage_tested":39,"tested_annotated":541,"enrichment":2.77436,"p_one_sided_uncorrected":0.00489}},{"compound":"BRD-A56085258","name":"LGX818","moa":"RAF inhibitor","target":"BRAF","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":32,"killed_fraction":0.05694,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95619,"interval":[0.91912,0.98015],"hit_lines":29,"nonhit_lines":403,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":0.25563,"hit_lines_ic50_at_most_1uM":23}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":19,"hits_annotated":32,"lineage_tested":43,"tested_annotated":562,"enrichment":7.76017,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K64925568","name":"AMG-232","moa":"MDM inhibitor","target":"MDM2","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":129,"killed_fraction":0.23077,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95341,"interval":[0.92354,0.97901],"hit_lines":105,"nonhit_lines":333,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":101,"median_ic50_uM":0.8121,"hit_lines_ic50_at_most_1uM":69}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":23,"hits_annotated":129,"lineage_tested":43,"tested_annotated":559,"enrichment":2.31783,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K71221037","name":"birinapant","moa":"XIAP inhibitor","target":"BIRC2, XIAP","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":89,"killed_fraction":0.15836,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95286,"interval":[0.9335,0.97139],"hit_lines":78,"nonhit_lines":368,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":78,"median_ic50_uM":0.13124,"hit_lines_ic50_at_most_1uM":73}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":17,"hits_annotated":89,"lineage_tested":43,"tested_annotated":562,"enrichment":2.49647,"p_one_sided_uncorrected":8e-05}},{"compound":"BRD-K69001009","name":"golvatinib","moa":"VEGFR inhibitor","target":"KDR, MET","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":9,"killed_fraction":0.01619,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95192,"interval":[0.91088,0.98283],"hit_lines":7,"nonhit_lines":416,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":0.42134,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":9,"lineage_tested":12,"tested_annotated":556,"enrichment":10.2963,"p_one_sided_uncorrected":0.01415}},{"compound":"BRD-K70463136","name":"BAY-87-2243","moa":"hypoxia inducible factor inhibitor","target":"HIF1A","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":17,"killed_fraction":0.03025,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95156,"interval":[0.91675,0.97857],"hit_lines":12,"nonhit_lines":449,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":0.00767,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":17,"lineage_tested":3,"tested_annotated":562,"enrichment":11.01961,"p_one_sided_uncorrected":0.08818}},{"compound":"BRD-K25412176","name":"GSK2110183","moa":"AKT inhibitor","target":"AKT1, AKT2, AKT3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":26,"killed_fraction":0.04676,"class":"selective"},"secondary":{"status":"confirmed","separation":0.95026,"interval":[0.91577,0.97728],"hit_lines":25,"nonhit_lines":431,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":24,"median_ic50_uM":0.4498,"hit_lines_ic50_at_most_1uM":20}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":5,"hits_annotated":26,"lineage_tested":23,"tested_annotated":556,"enrichment":4.64883,"p_one_sided_uncorrected":0.00284}},{"compound":"BRD-K16180792","name":"bis(maltolato)oxovanadium(IV)","moa":"tyrosine phosphatase inhibitor","target":"PTPN1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":32,"killed_fraction":0.05915,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94651,"interval":[0.90082,0.98003],"hit_lines":28,"nonhit_lines":414,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":27,"median_ic50_uM":1.40959,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":14,"hits_annotated":32,"lineage_tested":43,"tested_annotated":541,"enrichment":5.50436,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K99604664","name":"tanaproget","moa":"progesterone receptor agonist","target":"PGR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":17,"killed_fraction":0.03014,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94438,"interval":[0.89235,0.98532],"hit_lines":12,"nonhit_lines":451,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":0.54453,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":5,"hits_annotated":17,"lineage_tested":43,"tested_annotated":564,"enrichment":3.85773,"p_one_sided_uncorrected":0.00634}},{"compound":"BRD-K43471985","name":"OTX015","moa":"bromodomain inhibitor","target":"BRD2, BRD3, BRD4","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":21,"killed_fraction":0.0375,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94078,"interval":[0.90725,0.96864],"hit_lines":18,"nonhit_lines":364,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":18,"median_ic50_uM":0.20524,"hit_lines_ic50_at_most_1uM":17}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":21,"lineage_tested":41,"tested_annotated":560,"enrichment":1.95122,"p_one_sided_uncorrected":0.1932}},{"compound":"BRD-K56751279","name":"Y-39983","moa":"rho associated kinase inhibitor","target":"ROCK1, ROCK2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":5,"killed_fraction":0.00893,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94031,"interval":[0.91008,0.96977],"hit_lines":3,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":2.35924,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":5,"lineage_tested":41,"tested_annotated":560,"enrichment":8.19512,"p_one_sided_uncorrected":0.0033}},{"compound":"BRD-K68938568","name":"GDC-0152","moa":"XIAP inhibitor","target":"BIRC2, BIRC3, BIRC7, XIAP","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":37,"killed_fraction":0.06584,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93725,"interval":[0.89462,0.97226],"hit_lines":36,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":35,"median_ic50_uM":0.2029,"hit_lines_ic50_at_most_1uM":31}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":37,"lineage_tested":43,"tested_annotated":562,"enrichment":2.8259,"p_one_sided_uncorrected":0.00438}},{"compound":"BRD-K80431395","name":"triciribine","moa":"AKT inhibitor","target":"AKT1, AKT2, AKT3","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49,"lines_tested":530,"lines_killed":18,"killed_fraction":0.03396,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93246,"interval":[0.88491,0.96542],"hit_lines":16,"nonhit_lines":422,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":0.15231,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":33,"tested_annotated":530,"enrichment":2.67677,"p_one_sided_uncorrected":0.09452}},{"compound":"BRD-K99023089","name":"AZD5363","moa":"AKT inhibitor","target":"AKT1, AKT2, AKT3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":43,"killed_fraction":0.07665,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92539,"interval":[0.88389,0.95849],"hit_lines":38,"nonhit_lines":419,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":37,"median_ic50_uM":1.02113,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":9,"hits_annotated":43,"lineage_tested":23,"tested_annotated":561,"enrichment":5.10516,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K40718343","name":"AEE788","moa":"EGFR inhibitor, VEGFR inhibitor","target":"EGFR, ERBB2, ERBB4, FGFR2, FGFR3, KDR","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":36,"killed_fraction":0.06383,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91865,"interval":[0.8785,0.95029],"hit_lines":29,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":1.25752,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":6,"hits_annotated":36,"lineage_tested":24,"tested_annotated":564,"enrichment":3.91667,"p_one_sided_uncorrected":0.00257}},{"compound":"BRD-K85751432","name":"refametinib","moa":"MEK inhibitor","target":"MAP2K1, MAP2K2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":30,"killed_fraction":0.05474,"class":"selective"},"secondary":{"status":"confirmed","separation":0.9171,"interval":[0.87279,0.95399],"hit_lines":20,"nonhit_lines":345,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":20,"median_ic50_uM":0.85379,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":12,"hits_annotated":30,"lineage_tested":43,"tested_annotated":548,"enrichment":5.09767,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K68552125","name":"12-O-tetradecanoylphorbol-13-acetate","moa":"PKC activator","target":"KCNT2, TRPV4","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.03,"lines_tested":562,"lines_killed":7,"killed_fraction":0.01246,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91462,"interval":[0.83491,0.97858],"hit_lines":6,"nonhit_lines":408,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.10165,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":4,"tested_annotated":562,"enrichment":20.07143,"p_one_sided_uncorrected":0.04903}},{"compound":"BRD-K03765900","name":"XL-647","moa":"EGFR inhibitor, VEGFR inhibitor","target":"EGFR, EPHB4, ERBB2, FLT4, KDR","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49999,"lines_tested":540,"lines_killed":43,"killed_fraction":0.07963,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91254,"interval":[0.86828,0.95071],"hit_lines":36,"nonhit_lines":377,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":33,"median_ic50_uM":0.18373,"hit_lines_ic50_at_most_1uM":32}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":15,"hits_annotated":43,"lineage_tested":27,"tested_annotated":540,"enrichment":6.97674,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K64538373","name":"Ro-4987655","moa":"MEK inhibitor","target":"MAP2K1","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":101,"killed_fraction":0.18068,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91125,"interval":[0.87432,0.9416],"hit_lines":87,"nonhit_lines":377,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":87,"median_ic50_uM":0.02561,"hit_lines_ic50_at_most_1uM":86}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":20,"hits_annotated":101,"lineage_tested":43,"tested_annotated":559,"enrichment":2.57426,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K79584249","name":"CGM097","moa":"MDM inhibitor","target":"MDM2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":98,"killed_fraction":0.17626,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91112,"interval":[0.87262,0.94397],"hit_lines":85,"nonhit_lines":337,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":70,"median_ic50_uM":0.95405,"hit_lines_ic50_at_most_1uM":43}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":18,"hits_annotated":98,"lineage_tested":43,"tested_annotated":556,"enrichment":2.37494,"p_one_sided_uncorrected":9e-05}},{"compound":"BRD-K44844162","name":"taselisib","moa":"PI3K inhibitor","target":"PIK3CA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":65,"killed_fraction":0.11733,"class":"selective"},"secondary":{"status":"confirmed","separation":0.90978,"interval":[0.86902,0.93985],"hit_lines":57,"nonhit_lines":407,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":57,"median_ic50_uM":0.41385,"hit_lines_ic50_at_most_1uM":53}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":14,"hits_annotated":65,"lineage_tested":27,"tested_annotated":554,"enrichment":4.41937,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K41599323","name":"lonafarnib","moa":"farnesyltransferase inhibitor","target":"FNTA, HRAS, KRAS, NRAS","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":17,"killed_fraction":0.03025,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89485,"interval":[0.84972,0.93645],"hit_lines":16,"nonhit_lines":444,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.50624,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":6,"hits_annotated":17,"lineage_tested":100,"tested_annotated":562,"enrichment":1.98353,"p_one_sided_uncorrected":0.06329}},{"compound":"BRD-K50010139","name":"poziotinib","moa":"EGFR inhibitor","target":"EGFR, ERBB2, ERBB4","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":63,"killed_fraction":0.11645,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89322,"interval":[0.85724,0.92623],"hit_lines":47,"nonhit_lines":375,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":32,"median_ic50_uM":0.03419,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":12,"hits_annotated":63,"lineage_tested":27,"tested_annotated":541,"enrichment":3.81658,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K70914287","name":"BIBX-1382","moa":"EGFR inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":9,"killed_fraction":0.01601,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89145,"interval":[0.74445,0.98482],"hit_lines":7,"nonhit_lines":433,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":0.44532,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":9,"lineage_tested":21,"tested_annotated":562,"enrichment":5.94709,"p_one_sided_uncorrected":0.04089}},{"compound":"BRD-K82244583","name":"MEK162","moa":"MEK inhibitor","target":"MAP2K1, MAP2K2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":52,"killed_fraction":0.09612,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8904,"interval":[0.84235,0.9271],"hit_lines":46,"nonhit_lines":383,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":46,"median_ic50_uM":0.10204,"hit_lines_ic50_at_most_1uM":45}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":12,"hits_annotated":52,"lineage_tested":39,"tested_annotated":541,"enrichment":3.20118,"p_one_sided_uncorrected":0.0001}},{"compound":"BRD-K98572433","name":"AZD8931","moa":"EGFR inhibitor","target":"EGFR, ERBB2, ERBB3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":47,"killed_fraction":0.08363,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88936,"interval":[0.84154,0.92827],"hit_lines":38,"nonhit_lines":382,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":27,"median_ic50_uM":0.12711,"hit_lines_ic50_at_most_1uM":25}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":6,"hits_annotated":47,"lineage_tested":24,"tested_annotated":562,"enrichment":2.98936,"p_one_sided_uncorrected":0.01047}},{"compound":"BRD-K62196610","name":"AVN-944","moa":"inosine monophosphate dehydrogenase inhibitor","target":"IMPDH1, IMPDH2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":45,"killed_fraction":0.08123,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88806,"interval":[0.83433,0.9328],"hit_lines":34,"nonhit_lines":407,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":0.56849,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":3,"hits_annotated":45,"lineage_tested":7,"tested_annotated":554,"enrichment":5.27619,"p_one_sided_uncorrected":0.01394}},{"compound":"BRD-K33610132","name":"rociletinib","moa":"EGFR inhibitor","target":"EGFR","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":26,"killed_fraction":0.04685,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88716,"interval":[0.83027,0.94419],"hit_lines":23,"nonhit_lines":393,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":1.69724,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":5,"hits_annotated":26,"lineage_tested":24,"tested_annotated":555,"enrichment":4.44712,"p_one_sided_uncorrected":0.0035}},{"compound":"BRD-K78055238","name":"LY2090314","moa":"glycogen synthase kinase inhibitor","target":"GSK3B","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":77,"killed_fraction":0.13899,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88616,"interval":[0.83164,0.92696],"hit_lines":61,"nonhit_lines":394,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":61,"median_ic50_uM":0.11445,"hit_lines_ic50_at_most_1uM":51}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":8,"hits_annotated":77,"lineage_tested":22,"tested_annotated":554,"enrichment":2.61629,"p_one_sided_uncorrected":0.00608}},{"compound":"BRD-K26838195","name":"AST-1306","moa":"EGFR inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":32,"killed_fraction":0.05674,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88025,"interval":[0.82865,0.92144],"hit_lines":16,"nonhit_lines":274,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":1.408,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":5,"hits_annotated":32,"lineage_tested":24,"tested_annotated":564,"enrichment":3.67188,"p_one_sided_uncorrected":0.00838}},{"compound":"BRD-K05104363","name":"PD-184352","moa":"MEK inhibitor","target":"MAP2K1, MAP3K1, MAP3K2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":58,"killed_fraction":0.10721,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88007,"interval":[0.82886,0.92616],"hit_lines":51,"nonhit_lines":386,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":46,"median_ic50_uM":1.15325,"hit_lines_ic50_at_most_1uM":22}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":16,"hits_annotated":58,"lineage_tested":39,"tested_annotated":541,"enrichment":3.8267,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K89014967","name":"AS-703026","moa":"MEK inhibitor","target":"MAP2K1, MAP2K2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":129,"killed_fraction":0.23077,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87939,"interval":[0.83812,0.91754],"hit_lines":109,"nonhit_lines":341,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":91,"median_ic50_uM":0.06601,"hit_lines_ic50_at_most_1uM":76}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":24,"hits_annotated":129,"lineage_tested":43,"tested_annotated":559,"enrichment":2.4186,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K31928526","name":"barasertib","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB","disease_area":"NA","indication":"NA","phase":"Phase 2/Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":85,"killed_fraction":0.15206,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87458,"interval":[0.82765,0.91412],"hit_lines":76,"nonhit_lines":359,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":50,"median_ic50_uM":0.49244,"hit_lines_ic50_at_most_1uM":40}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":7,"hits_annotated":85,"lineage_tested":23,"tested_annotated":559,"enrichment":2.00153,"p_one_sided_uncorrected":0.04572}},{"compound":"BRD-K23190681","name":"AV-412","moa":"protein tyrosine kinase inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":115,"killed_fraction":0.20683,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87228,"interval":[0.83544,0.90965],"hit_lines":98,"nonhit_lines":358,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":98,"median_ic50_uM":1.87336,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":17,"hits_annotated":115,"lineage_tested":27,"tested_annotated":556,"enrichment":3.04412,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K57169635","name":"dacomitinib","moa":"EGFR inhibitor","target":"EGFR, ERBB2, ERBB4","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":47,"killed_fraction":0.08333,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86977,"interval":[0.80897,0.91874],"hit_lines":33,"nonhit_lines":393,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":29,"median_ic50_uM":0.09044,"hit_lines_ic50_at_most_1uM":24}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":8,"hits_annotated":47,"lineage_tested":27,"tested_annotated":564,"enrichment":3.55556,"p_one_sided_uncorrected":0.00084}},{"compound":"BRD-K31309378","name":"lucitanib","moa":"FGFR inhibitor, VEGFR inhibitor","target":"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":27,"killed_fraction":0.04874,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86845,"interval":[0.78305,0.93935],"hit_lines":23,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":20,"median_ic50_uM":1.35955,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":5,"hits_annotated":27,"lineage_tested":12,"tested_annotated":554,"enrichment":8.54938,"p_one_sided_uncorrected":0.00012}},{"compound":"BRD-K75649340","name":"tioguanine","moa":"purine antagonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":82,"killed_fraction":0.14539,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86775,"interval":[0.82925,0.90442],"hit_lines":67,"nonhit_lines":388,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":65,"median_ic50_uM":1.05677,"hit_lines_ic50_at_most_1uM":29}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":5,"hits_annotated":82,"lineage_tested":11,"tested_annotated":564,"enrichment":3.12639,"p_one_sided_uncorrected":0.01304}},{"compound":"BRD-K80343549","name":"TAK-285","moa":"EGFR inhibitor","target":"ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":20,"killed_fraction":0.03697,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86624,"interval":[0.7955,0.92665],"hit_lines":14,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":1.10612,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":20,"lineage_tested":20,"tested_annotated":541,"enrichment":4.0575,"p_one_sided_uncorrected":0.03296}},{"compound":"BRD-K37687095","name":"AZD8330","moa":"MEK inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":183,"killed_fraction":0.32447,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86576,"interval":[0.83562,0.89607],"hit_lines":156,"nonhit_lines":310,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":156,"median_ic50_uM":0.01376,"hit_lines_ic50_at_most_1uM":155}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":26,"hits_annotated":183,"lineage_tested":43,"tested_annotated":564,"enrichment":1.86352,"p_one_sided_uncorrected":8e-05}},{"compound":"BRD-K71480163","name":"GDC-0068","moa":"AKT inhibitor","target":"AKT1, AKT2, AKT3, PRKG1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":26,"killed_fraction":0.04626,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86303,"interval":[0.76699,0.94699],"hit_lines":24,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":20,"median_ic50_uM":1.09093,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":5,"hits_annotated":26,"lineage_tested":23,"tested_annotated":562,"enrichment":4.699,"p_one_sided_uncorrected":0.00271}},{"compound":"BRD-K49865102","name":"PD-0325901","moa":"MEK inhibitor","target":"MAP2K1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":109,"killed_fraction":0.19711,"class":"selective"},"secondary":{"status":"confirmed","separation":0.86087,"interval":[0.82013,0.89948],"hit_lines":89,"nonhit_lines":371,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":88,"median_ic50_uM":0.06208,"hit_lines_ic50_at_most_1uM":87}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":16,"hits_annotated":109,"lineage_tested":43,"tested_annotated":553,"enrichment":1.88777,"p_one_sided_uncorrected":0.00415}},{"compound":"BRD-K19034817","name":"pacritinib","moa":"FLT3 inhibitor, JAK inhibitor","target":"FLT3, JAK1, JAK2, JAK3","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":23,"killed_fraction":0.04107,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85833,"interval":[0.78436,0.91574],"hit_lines":19,"nonhit_lines":438,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":1.77197,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":3,"hits_annotated":23,"lineage_tested":24,"tested_annotated":560,"enrichment":3.04348,"p_one_sided_uncorrected":0.06963}},{"compound":"BRD-K81016934","name":"INC-280","moa":"c-Met inhibitor","target":"MET","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":12,"killed_fraction":0.02218,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85714,"interval":[0.71728,0.99556],"hit_lines":7,"nonhit_lines":404,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.00199,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":12,"lineage_tested":20,"tested_annotated":541,"enrichment":6.7625,"p_one_sided_uncorrected":0.0077}},{"compound":"BRD-K58529924","name":"ONC201","moa":"AKT inhibitor, MAP kinase inhibitor","target":"TNFSF10","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.64858,"lines_tested":541,"lines_killed":9,"killed_fraction":0.01664,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85025,"interval":[0.74973,0.9407],"hit_lines":5,"nonhit_lines":406,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":2.51337,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":9,"lineage_tested":4,"tested_annotated":541,"enrichment":15.02778,"p_one_sided_uncorrected":0.06508}},{"compound":"BRD-K28965160","name":"BVD-523","moa":"MAP kinase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":63,"killed_fraction":0.11331,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85007,"interval":[0.79017,0.90141],"hit_lines":55,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":52,"median_ic50_uM":0.7298,"hit_lines_ic50_at_most_1uM":39}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":15,"hits_annotated":63,"lineage_tested":43,"tested_annotated":556,"enrichment":3.07863,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K11851476","name":"pardoprunox","moa":"serotonin receptor agonist, dopamine receptor agonist","target":"DRD2, DRD3, DRD4, HTR1A, HTR7","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49999,"lines_tested":541,"lines_killed":77,"killed_fraction":0.14233,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84915,"interval":[0.80797,0.89116],"hit_lines":68,"nonhit_lines":384,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":68,"median_ic50_uM":0.47526,"hit_lines_ic50_at_most_1uM":63}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":9,"hits_annotated":77,"lineage_tested":27,"tested_annotated":541,"enrichment":2.34199,"p_one_sided_uncorrected":0.00816}},{"compound":"BRD-K56405753","name":"MK-2461","moa":"FGFR inhibitor, VEGFR inhibitor","target":"FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, KDR, MERTK, MET, MST1R, NTRK1, NTRK2, PDGFRB","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":12,"killed_fraction":0.02128,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84625,"interval":[0.73368,0.9311],"hit_lines":12,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":1.43506,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":1,"hits_annotated":12,"lineage_tested":11,"tested_annotated":564,"enrichment":4.27273,"p_one_sided_uncorrected":0.21236}},{"compound":"BRD-K68747584","name":"PF-03814735","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":95,"killed_fraction":0.16904,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84345,"interval":[0.79213,0.88292],"hit_lines":79,"nonhit_lines":370,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":76,"median_ic50_uM":0.49877,"hit_lines_ic50_at_most_1uM":72}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":9,"hits_annotated":95,"lineage_tested":23,"tested_annotated":562,"enrichment":2.31487,"p_one_sided_uncorrected":0.00808}},{"compound":"BRD-K71512533","name":"SNS-314","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, AURKC","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":187,"killed_fraction":0.33633,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8405,"interval":[0.79939,0.87718],"hit_lines":152,"nonhit_lines":291,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":132,"median_ic50_uM":0.02593,"hit_lines_ic50_at_most_1uM":128}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":13,"hits_annotated":187,"lineage_tested":23,"tested_annotated":556,"enrichment":1.68054,"p_one_sided_uncorrected":0.01802}},{"compound":"BRD-K46386702","name":"ARRY-334543","moa":"EGFR inhibitor","target":"ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":5,"killed_fraction":0.00894,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83753,"interval":[0.55475,0.99771],"hit_lines":3,"nonhit_lines":437,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":0.32703,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":9,"tested_annotated":559,"enrichment":12.42222,"p_one_sided_uncorrected":0.07822}},{"compound":"BRD-K20722021","name":"CEP-32496","moa":"RAF inhibitor","target":"BRAF, RAF1","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":34,"killed_fraction":0.06285,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83691,"interval":[0.74599,0.91563],"hit_lines":24,"nonhit_lines":396,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":1.40866,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":10,"hits_annotated":34,"lineage_tested":39,"tested_annotated":541,"enrichment":4.07994,"p_one_sided_uncorrected":4e-05}},{"compound":"BRD-K95142244","name":"talazoparib","moa":"PARP inhibitor","target":"PARP2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":156,"killed_fraction":0.27758,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83315,"interval":[0.7869,0.87369],"hit_lines":130,"nonhit_lines":310,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":77,"median_ic50_uM":0.22255,"hit_lines_ic50_at_most_1uM":56}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":156,"lineage_tested":23,"tested_annotated":562,"enrichment":2.50613,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K29656036","name":"MK-8245","moa":"stearoyl-CoA desaturase inhibitor","target":"SCD","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":17,"killed_fraction":0.0303,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83224,"interval":[0.70508,0.94913],"hit_lines":16,"nonhit_lines":440,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.88614,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":3,"hits_annotated":17,"lineage_tested":21,"tested_annotated":561,"enrichment":4.71429,"p_one_sided_uncorrected":0.02194}},{"compound":"BRD-K42673188","name":"verubulin","moa":"tubulin polymerization inhibitor","target":"TUBB","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.36336,"lines_tested":541,"lines_killed":116,"killed_fraction":0.21442,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83186,"interval":[0.79307,0.86842],"hit_lines":107,"nonhit_lines":351,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":107,"median_ic50_uM":0.00347,"hit_lines_ic50_at_most_1uM":107}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":9,"hits_annotated":116,"lineage_tested":20,"tested_annotated":541,"enrichment":2.09871,"p_one_sided_uncorrected":0.01406}},{"compound":"BRD-K26667523","name":"TAK-733","moa":"MEK inhibitor","target":"MAP2K1","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":163,"killed_fraction":0.29317,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83102,"interval":[0.79145,0.87017],"hit_lines":138,"nonhit_lines":320,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":137,"median_ic50_uM":0.11849,"hit_lines_ic50_at_most_1uM":132}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":15,"hits_annotated":163,"lineage_tested":27,"tested_annotated":556,"enrichment":1.89502,"p_one_sided_uncorrected":0.00313}},{"compound":"BRD-K41783120","name":"STA-5326","moa":"interleukin synthesis inhibitor","target":"IL12A","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":61,"killed_fraction":0.11131,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82912,"interval":[0.76141,0.88863],"hit_lines":55,"nonhit_lines":394,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":46,"median_ic50_uM":0.54779,"hit_lines_ic50_at_most_1uM":34}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":10,"hits_annotated":61,"lineage_tested":33,"tested_annotated":548,"enrichment":2.72231,"p_one_sided_uncorrected":0.00166}},{"compound":"BRD-K76239644","name":"BMS-690514","moa":"EGFR inhibitor, VEGFR inhibitor","target":"EGFR, ERBB2, FLT3, KDR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":92,"killed_fraction":0.16399,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8289,"interval":[0.78141,0.87466],"hit_lines":77,"nonhit_lines":346,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":66,"median_ic50_uM":0.57859,"hit_lines_ic50_at_most_1uM":45}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":13,"hits_annotated":92,"lineage_tested":24,"tested_annotated":561,"enrichment":3.30299,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K25835157","name":"PRT062070","moa":"JAK inhibitor, syk inhibitor","target":"SYK","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":11,"killed_fraction":0.01961,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82854,"interval":[0.71609,0.91372],"hit_lines":10,"nonhit_lines":438,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":2.25955,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":11,"lineage_tested":9,"tested_annotated":561,"enrichment":5.66667,"p_one_sided_uncorrected":0.16433}},{"compound":"BRD-K83029223","name":"litronesib","moa":"kinesin-like spindle protein inhibitor","target":"KIF11","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.50003,"lines_tested":540,"lines_killed":172,"killed_fraction":0.31852,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82845,"interval":[0.78651,0.86738],"hit_lines":151,"nonhit_lines":287,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":119,"median_ic50_uM":0.00439,"hit_lines_ic50_at_most_1uM":119}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":7,"hits_annotated":172,"lineage_tested":10,"tested_annotated":540,"enrichment":2.19767,"p_one_sided_uncorrected":0.01429}},{"compound":"BRD-K36740062","name":"GSK1070916","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, AURKC, CYP2D6, CYP3A4","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":558,"lines_killed":72,"killed_fraction":0.12903,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82577,"interval":[0.77117,0.88058],"hit_lines":54,"nonhit_lines":387,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":54,"median_ic50_uM":0.09971,"hit_lines_ic50_at_most_1uM":53}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":10,"hits_annotated":72,"lineage_tested":23,"tested_annotated":558,"enrichment":3.36957,"p_one_sided_uncorrected":0.0002}},{"compound":"BRD-K42497885","name":"satraplatin","moa":"DNA alkylating agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":182,"killed_fraction":0.33212,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82322,"interval":[0.77993,0.8598],"hit_lines":155,"nonhit_lines":297,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":145,"median_ic50_uM":2.1346,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":182,"lineage_tested":23,"tested_annotated":548,"enrichment":1.96369,"p_one_sided_uncorrected":0.00134}},{"compound":"BRD-K53665955","name":"MK-5108","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, AURKC","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":69,"killed_fraction":0.12343,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82307,"interval":[0.7743,0.86713],"hit_lines":63,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":63,"median_ic50_uM":0.72258,"hit_lines_ic50_at_most_1uM":55}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":22,"hits_annotated":69,"lineage_tested":99,"tested_annotated":559,"enrichment":1.80032,"p_one_sided_uncorrected":0.00158}},{"compound":"BRD-K96123349","name":"brequinar","moa":"dihydroorotate dehydrogenase inhibitor","target":"DHODH","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":35,"killed_fraction":0.06206,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81902,"interval":[0.71944,0.89854],"hit_lines":27,"nonhit_lines":396,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":1.33513,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":4,"hits_annotated":35,"lineage_tested":23,"tested_annotated":564,"enrichment":2.80248,"p_one_sided_uncorrected":0.04724}},{"compound":"BRD-K30933884","name":"UNBS-5162","moa":"CC chemokine receptor antagonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":32,"killed_fraction":0.05704,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81893,"interval":[0.75436,0.8815],"hit_lines":29,"nonhit_lines":426,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":1.86257,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":5,"hits_annotated":32,"lineage_tested":23,"tested_annotated":561,"enrichment":3.81114,"p_one_sided_uncorrected":0.00707}},{"compound":"BRD-K37561857","name":"zardaverine","moa":"phosphodiesterase inhibitor","target":"PDE4D","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":25,"killed_fraction":0.04562,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81746,"interval":[0.70802,0.90118],"hit_lines":19,"nonhit_lines":440,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":18,"median_ic50_uM":0.87017,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":9,"hits_annotated":25,"lineage_tested":43,"tested_annotated":548,"enrichment":4.58791,"p_one_sided_uncorrected":4e-05}},{"compound":"BRD-K89015388","name":"GSK923295","moa":"centromere associated protein inhibitor","target":"CENPE","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":103,"killed_fraction":0.18426,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81742,"interval":[0.77233,0.85884],"hit_lines":82,"nonhit_lines":355,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":80,"median_ic50_uM":1.62007,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":11,"hits_annotated":103,"lineage_tested":23,"tested_annotated":559,"enrichment":2.59561,"p_one_sided_uncorrected":0.00096}},{"compound":"BRD-K20468903","name":"BNC105","moa":"tubulin polymerization inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49997,"lines_tested":541,"lines_killed":151,"killed_fraction":0.27911,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8135,"interval":[0.77296,0.85476],"hit_lines":134,"nonhit_lines":323,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":133,"median_ic50_uM":0.03158,"hit_lines_ic50_at_most_1uM":133}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":18,"hits_annotated":151,"lineage_tested":40,"tested_annotated":541,"enrichment":1.61225,"p_one_sided_uncorrected":0.01231}},{"compound":"BRD-K38527262","name":"atiprimod","moa":"JAK inhibitor, STAT inhibitor","target":"JAK2, STAT3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.30099,"lines_tested":540,"lines_killed":47,"killed_fraction":0.08704,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81314,"interval":[0.76344,0.8611],"hit_lines":41,"nonhit_lines":381,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":40,"median_ic50_uM":0.87676,"hit_lines_ic50_at_most_1uM":26}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":20,"hits_annotated":47,"lineage_tested":43,"tested_annotated":540,"enrichment":5.34389,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K03063480","name":"PF-477736","moa":"CHK inhibitor","target":"CHEK1, CHEK2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":239,"killed_fraction":0.42376,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81114,"interval":[0.77055,0.84632],"hit_lines":199,"nonhit_lines":252,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":198,"median_ic50_uM":0.1404,"hit_lines_ic50_at_most_1uM":194}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":239,"lineage_tested":23,"tested_annotated":564,"enrichment":1.74422,"p_one_sided_uncorrected":0.00182}},{"compound":"BRD-K09877029","name":"VS-4718","moa":"focal adhesion kinase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":31,"killed_fraction":0.05526,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81092,"interval":[0.70194,0.9003],"hit_lines":24,"nonhit_lines":422,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":1.85979,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":5,"hits_annotated":31,"lineage_tested":24,"tested_annotated":561,"enrichment":3.77016,"p_one_sided_uncorrected":0.00745}},{"compound":"BRD-K19061412","name":"mubritinib","moa":"protein tyrosine kinase inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":18,"killed_fraction":0.03237,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81086,"interval":[0.60936,0.93947],"hit_lines":9,"nonhit_lines":356,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":0.04958,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":12,"tested_annotated":556,"enrichment":7.72222,"p_one_sided_uncorrected":0.00524}},{"compound":"BRD-K68488863","name":"ENMD-2076","moa":"Aurora kinase inhibitor, FLT3 inhibitor, VEGFR inhibitor","target":"AURKA, FLT3, KDR, PDGFRA, PTK2, SRC","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":87,"killed_fraction":0.1548,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81034,"interval":[0.76136,0.85545],"hit_lines":61,"nonhit_lines":332,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":61,"median_ic50_uM":1.18967,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":8,"hits_annotated":87,"lineage_tested":24,"tested_annotated":562,"enrichment":2.15326,"p_one_sided_uncorrected":0.02111}},{"compound":"BRD-K21728777","name":"AMG900","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, AURKC","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":178,"killed_fraction":0.31786,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80995,"interval":[0.76385,0.85018],"hit_lines":148,"nonhit_lines":307,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":141,"median_ic50_uM":0.0367,"hit_lines_ic50_at_most_1uM":133}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":14,"hits_annotated":178,"lineage_tested":24,"tested_annotated":560,"enrichment":1.83521,"p_one_sided_uncorrected":0.00551}},{"compound":"BRD-K68870568","name":"flumatinib","moa":"Bcr-Abl kinase inhibitor","target":"ABL1, PDGFRB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":7,"killed_fraction":0.01246,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80787,"interval":[0.56009,0.99655],"hit_lines":6,"nonhit_lines":432,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.06654,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":7,"lineage_tested":12,"tested_annotated":562,"enrichment":20.07143,"p_one_sided_uncorrected":0.00025}},{"compound":"BRD-K82818427","name":"batimastat","moa":"matrix metalloprotease inhibitor","target":"ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":11,"killed_fraction":0.01961,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80052,"interval":[0.63539,0.93412],"hit_lines":9,"nonhit_lines":430,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":0.97475,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":24,"tested_annotated":561,"enrichment":6.375,"p_one_sided_uncorrected":0.00908}},{"compound":"BRD-K75009076","name":"SCH-900776","moa":"CHK inhibitor","target":"CDK2, CHEK1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.43,"lines_tested":530,"lines_killed":54,"killed_fraction":0.10189,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79618,"interval":[0.7261,0.86331],"hit_lines":45,"nonhit_lines":372,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":44,"median_ic50_uM":0.45385,"hit_lines_ic50_at_most_1uM":34}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":6,"hits_annotated":54,"lineage_tested":22,"tested_annotated":530,"enrichment":2.67677,"p_one_sided_uncorrected":0.01746}},{"compound":"BRD-K07881437","name":"danusertib","moa":"Aurora kinase inhibitor, growth factor receptor inhibitor","target":"AURKA, AURKB, AURKC, FGFR1, NTRK1, RET, SLK","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":200,"killed_fraction":0.36969,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79596,"interval":[0.75849,0.83614],"hit_lines":177,"nonhit_lines":270,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":177,"median_ic50_uM":0.01316,"hit_lines_ic50_at_most_1uM":177}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":200,"lineage_tested":23,"tested_annotated":541,"enrichment":1.76413,"p_one_sided_uncorrected":0.0047}},{"compound":"BRD-K07106112","name":"BMS-599626","moa":"EGFR inhibitor, protein tyrosine kinase inhibitor","target":"EGFR, ERBB2, ERBB4","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":18,"killed_fraction":0.0322,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79275,"interval":[0.66441,0.91087],"hit_lines":15,"nonhit_lines":414,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":2.64072,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":21,"tested_annotated":559,"enrichment":4.43651,"p_one_sided_uncorrected":0.02594}},{"compound":"BRD-K62304154","name":"deforolimus","moa":"mTOR inhibitor","target":"MTOR","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":11,"killed_fraction":0.02033,"class":"selective"},"secondary":{"status":"confirmed","separation":0.7927,"interval":[0.574,0.94232],"hit_lines":8,"nonhit_lines":442,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":0.01206,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":33,"tested_annotated":541,"enrichment":2.98072,"p_one_sided_uncorrected":0.1406}},{"compound":"BRD-K09372874","name":"merimepodib","moa":"inosine monophosphate dehydrogenase inhibitor","target":"IMPDH1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":60,"killed_fraction":0.11091,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79091,"interval":[0.73026,0.84428],"hit_lines":44,"nonhit_lines":380,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":43,"median_ic50_uM":1.24339,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":6,"hits_annotated":60,"lineage_tested":20,"tested_annotated":541,"enrichment":2.705,"p_one_sided_uncorrected":0.01622}},{"compound":"BRD-K14109347","name":"LY2603618","moa":"CHK inhibitor","target":"CHEK1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":234,"killed_fraction":0.41786,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78824,"interval":[0.74577,0.82899],"hit_lines":195,"nonhit_lines":242,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":119,"median_ic50_uM":1.2411,"hit_lines_ic50_at_most_1uM":51}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":13,"hits_annotated":234,"lineage_tested":23,"tested_annotated":560,"enrichment":1.35266,"p_one_sided_uncorrected":0.10679}},{"compound":"BRD-K14796088","name":"berberine","moa":"LDL receptor activator","target":"LDLR","disease_area":"NA","indication":"NA","phase":"Phase 2/Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":52,"killed_fraction":0.0922,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77695,"interval":[0.69925,0.84941],"hit_lines":42,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":39,"median_ic50_uM":0.60993,"hit_lines_ic50_at_most_1uM":33}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":8,"hits_annotated":52,"lineage_tested":27,"tested_annotated":564,"enrichment":3.21368,"p_one_sided_uncorrected":0.00172}},{"compound":"BRD-K04701033","name":"VE-822","moa":"ATR kinase inhibitor","target":"ATM, ATR, MTOR, PIK3CG","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49999,"lines_tested":541,"lines_killed":122,"killed_fraction":0.22551,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77615,"interval":[0.73057,0.81977],"hit_lines":112,"nonhit_lines":350,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":112,"median_ic50_uM":0.05556,"hit_lines_ic50_at_most_1uM":112}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":10,"hits_annotated":122,"lineage_tested":20,"tested_annotated":541,"enrichment":2.21721,"p_one_sided_uncorrected":0.0056}},{"compound":"BRD-K66241279","name":"cinromide","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77202,"interval":[0.58,0.93467],"hit_lines":3,"nonhit_lines":405,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bile_duct","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":7,"tested_annotated":564,"enrichment":16.11429,"p_one_sided_uncorrected":0.06075}},{"compound":"BRD-K72815923","name":"xanomeline","moa":"acetylcholine receptor agonist","target":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2B, HTR2C, HTR6, HTR7","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":253,"killed_fraction":0.45098,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77107,"interval":[0.73017,0.814],"hit_lines":218,"nonhit_lines":246,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":214,"median_ic50_uM":1.38167,"hit_lines_ic50_at_most_1uM":26}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":18,"hits_annotated":253,"lineage_tested":27,"tested_annotated":561,"enrichment":1.47826,"p_one_sided_uncorrected":0.01741}},{"compound":"BRD-K43578482","name":"defactinib","moa":"focal adhesion kinase inhibitor","target":"PTK2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":11,"killed_fraction":0.02007,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76831,"interval":[0.66722,0.87118],"hit_lines":8,"nonhit_lines":355,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":2.26395,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":24,"tested_annotated":548,"enrichment":4.15152,"p_one_sided_uncorrected":0.07944}},{"compound":"BRD-K23677682","name":"voreloxin","moa":"topoisomerase inhibitor","target":"TOP2A","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":174,"killed_fraction":0.30851,"class":"selective"},"secondary":{"status":"confirmed","separation":0.7682,"interval":[0.72039,0.8126],"hit_lines":135,"nonhit_lines":317,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":132,"median_ic50_uM":0.46467,"hit_lines_ic50_at_most_1uM":119}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":12,"hits_annotated":174,"lineage_tested":23,"tested_annotated":564,"enrichment":1.69115,"p_one_sided_uncorrected":0.02422}},{"compound":"BRD-K17203476","name":"LY2874455","moa":"FGFR antagonist","target":"FGFR1, FGFR2, FGFR3, FGFR4, KDR","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":224,"killed_fraction":0.39858,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76397,"interval":[0.7168,0.80708],"hit_lines":176,"nonhit_lines":268,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":176,"median_ic50_uM":0.33362,"hit_lines_ic50_at_most_1uM":160}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":24,"hits_annotated":224,"lineage_tested":41,"tested_annotated":562,"enrichment":1.46864,"p_one_sided_uncorrected":0.00946}},{"compound":"BRD-A55312468","name":"k-strophanthidin","moa":"ATPase inhibitor","target":"ATP1A1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":1.24,"lines_tested":556,"lines_killed":89,"killed_fraction":0.16007,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76389,"interval":[0.61055,0.88355],"hit_lines":13,"nonhit_lines":72,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":0.97173,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":31,"hits_annotated":89,"lineage_tested":100,"tested_annotated":556,"enrichment":1.93663,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K33882852","name":"ZK-93423","moa":"benzodiazepine receptor agonist","target":"GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":14,"killed_fraction":0.02527,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75771,"interval":[0.62533,0.86575],"hit_lines":10,"nonhit_lines":454,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":1.23704,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":14,"lineage_tested":3,"tested_annotated":554,"enrichment":13.19048,"p_one_sided_uncorrected":0.07404}},{"compound":"BRD-K91623615","name":"ABT-751","moa":"tubulin polymerization inhibitor","target":"TUBB","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.46,"lines_tested":530,"lines_killed":183,"killed_fraction":0.34528,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75564,"interval":[0.70589,0.80235],"hit_lines":152,"nonhit_lines":280,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":152,"median_ic50_uM":0.1232,"hit_lines_ic50_at_most_1uM":152}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":3,"hits_annotated":183,"lineage_tested":3,"tested_annotated":530,"enrichment":2.89617,"p_one_sided_uncorrected":0.04072}},{"compound":"BRD-K28061410","name":"beta-lapachone","moa":"topoisomerase inhibitor","target":"TOP1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":51,"killed_fraction":0.09427,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75536,"interval":[0.66649,0.83635],"hit_lines":42,"nonhit_lines":415,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":42,"median_ic50_uM":0.68262,"hit_lines_ic50_at_most_1uM":33}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":13,"hits_annotated":51,"lineage_tested":43,"tested_annotated":541,"enrichment":3.20702,"p_one_sided_uncorrected":4e-05}},{"compound":"BRD-K68502831","name":"dianhydrogalactitol","moa":"DNA alkylating agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":10,"killed_fraction":0.01887,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75052,"interval":[0.59206,0.89029],"hit_lines":9,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":0.95806,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":19,"tested_annotated":530,"enrichment":5.57895,"p_one_sided_uncorrected":0.04618}},{"compound":"BRD-K94485812","name":"LDN-57444","moa":"ubiquitin C-terminal hydrolase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.55,"lines_tested":530,"lines_killed":7,"killed_fraction":0.01321,"class":"selective"},"secondary":{"status":"confirmed","separation":0.96814,"interval":[0.92991,0.99755],"hit_lines":6,"nonhit_lines":408,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.5456,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":3,"hits_annotated":7,"lineage_tested":94,"tested_annotated":530,"enrichment":2.41641,"p_one_sided_uncorrected":0.11004}},{"compound":"BRD-K97365803","name":"PI-828","moa":"PI3K inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":8,"killed_fraction":0.01447,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94365,"interval":[0.89705,0.97983],"hit_lines":6,"nonhit_lines":417,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.65674,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":8,"lineage_tested":24,"tested_annotated":553,"enrichment":8.64062,"p_one_sided_uncorrected":0.0035}},{"compound":"BRD-K78809024","name":"SB-590885","moa":"RAF inhibitor","target":"BRAF","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":18,"killed_fraction":0.03191,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94342,"interval":[0.86853,0.99015],"hit_lines":16,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":1.27549,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":12,"hits_annotated":18,"lineage_tested":43,"tested_annotated":564,"enrichment":8.74419,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K23925186","name":"oridonin","moa":"BCL inhibitor","target":"BCL2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":8,"killed_fraction":0.01439,"class":"selective"},"secondary":{"status":"confirmed","separation":0.94023,"interval":[0.89464,0.98373],"hit_lines":6,"nonhit_lines":435,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":1.28561,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":12,"tested_annotated":556,"enrichment":11.58333,"p_one_sided_uncorrected":0.01114}},{"compound":"BRD-K05804044","name":"AZ-628","moa":"RAF inhibitor","target":"BRAF, RAF1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":34,"killed_fraction":0.06082,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93054,"interval":[0.89032,0.96114],"hit_lines":32,"nonhit_lines":386,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":30,"median_ic50_uM":0.26764,"hit_lines_ic50_at_most_1uM":25}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":19,"hits_annotated":34,"lineage_tested":43,"tested_annotated":559,"enrichment":7.26471,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K44665581","name":"bromosporine","moa":"bromodomain inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":24,"killed_fraction":0.04286,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92703,"interval":[0.88476,0.95599],"hit_lines":22,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":2.27284,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":24,"lineage_tested":12,"tested_annotated":560,"enrichment":3.88889,"p_one_sided_uncorrected":0.0894}},{"compound":"BRD-K95523387","name":"OLDA","moa":"TRPV agonist","target":"GPR119","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":31,"killed_fraction":0.05526,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92475,"interval":[0.86853,0.96884],"hit_lines":22,"nonhit_lines":357,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":20,"median_ic50_uM":2.32158,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":7,"hits_annotated":31,"lineage_tested":43,"tested_annotated":561,"enrichment":2.94599,"p_one_sided_uncorrected":0.00617}},{"compound":"BRD-K94441233","name":"mevastatin","moa":"HMGCR inhibitor","target":"HMGCR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":547,"lines_killed":42,"killed_fraction":0.07678,"class":"selective"},"secondary":{"status":"confirmed","separation":0.92235,"interval":[0.88457,0.95353],"hit_lines":35,"nonhit_lines":418,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":35,"median_ic50_uM":0.48682,"hit_lines_ic50_at_most_1uM":30}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":9,"hits_annotated":42,"lineage_tested":39,"tested_annotated":547,"enrichment":3.00549,"p_one_sided_uncorrected":0.00148}},{"compound":"BRD-K49049886","name":"CGS-15943","moa":"adenosine receptor antagonist","target":"ADORA1, ADORA2A, ADORA2B, ADORA3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":39,"killed_fraction":0.07014,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91492,"interval":[0.88034,0.94602],"hit_lines":34,"nonhit_lines":410,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":34,"median_ic50_uM":0.34728,"hit_lines_ic50_at_most_1uM":31}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":6,"hits_annotated":39,"lineage_tested":26,"tested_annotated":556,"enrichment":3.28994,"p_one_sided_uncorrected":0.00652}},{"compound":"BRD-K67173685","name":"4E1RCat","moa":"protein synthesis inhibitor","target":"EIF4E, EIF4G1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.39,"lines_tested":530,"lines_killed":7,"killed_fraction":0.01321,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91412,"interval":[0.84954,0.97291],"hit_lines":5,"nonhit_lines":347,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":5.45068,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":7,"lineage_tested":40,"tested_annotated":530,"enrichment":5.67857,"p_one_sided_uncorrected":0.0113}},{"compound":"BRD-K97714174","name":"P22077","moa":"ubiquitin specific protease inhibitor","target":"USP7","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":13,"killed_fraction":0.02305,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91096,"interval":[0.7663,0.98781],"hit_lines":10,"nonhit_lines":438,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":1.96964,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":21,"tested_annotated":564,"enrichment":6.1978,"p_one_sided_uncorrected":0.01003}},{"compound":"BRD-K14991967","name":"GSK650394","moa":"serum/glucocorticoid regulated kinase inhibitor","target":"SGK1, SGK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"confirmed","separation":0.91068,"interval":[0.83081,0.98096],"hit_lines":4,"nonhit_lines":459,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.94367,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":24,"tested_annotated":556,"enrichment":4.63333,"p_one_sided_uncorrected":0.19864}},{"compound":"BRD-K81225797","name":"SCH-58261","moa":"adenosine receptor antagonist","target":"ADORA1, ADORA2A, ADORA2B, ADORA3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":10,"killed_fraction":0.01783,"class":"selective"},"secondary":{"status":"confirmed","separation":0.90927,"interval":[0.83534,0.96992],"hit_lines":9,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.62754,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":21,"tested_annotated":561,"enrichment":5.34286,"p_one_sided_uncorrected":0.05013}},{"compound":"BRD-K91701654","name":"U-0126","moa":"MEK inhibitor","target":"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.38,"lines_tested":530,"lines_killed":22,"killed_fraction":0.04151,"class":"selective"},"secondary":{"status":"confirmed","separation":0.90329,"interval":[0.81867,0.96098],"hit_lines":17,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":1.80122,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":12,"hits_annotated":22,"lineage_tested":41,"tested_annotated":530,"enrichment":7.051,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K72726508","name":"arcyriaflavin-a","moa":"CDK inhibitor","target":"CCND1, CDK4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":21,"killed_fraction":0.03777,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89545,"interval":[0.79976,0.96072],"hit_lines":18,"nonhit_lines":432,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":0.65217,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":4,"hits_annotated":21,"lineage_tested":21,"tested_annotated":556,"enrichment":5.04308,"p_one_sided_uncorrected":0.00594}},{"compound":"BRD-K15424032","name":"SB-228357","moa":"serotonin receptor antagonist","target":"HTR2A, HTR2B, HTR2C","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":15,"killed_fraction":0.02708,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89405,"interval":[0.80726,0.95573],"hit_lines":11,"nonhit_lines":423,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":1.81548,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":15,"lineage_tested":21,"tested_annotated":554,"enrichment":5.27619,"p_one_sided_uncorrected":0.01595}},{"compound":"BRD-K43449605","name":"oncrasin-1","moa":"apoptosis stimulant","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":66,"killed_fraction":0.11871,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88755,"interval":[0.83727,0.93875],"hit_lines":58,"nonhit_lines":408,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":57,"median_ic50_uM":0.47509,"hit_lines_ic50_at_most_1uM":49}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":6,"hits_annotated":66,"lineage_tested":19,"tested_annotated":556,"enrichment":2.66029,"p_one_sided_uncorrected":0.01734}},{"compound":"BRD-K68395654","name":"EVP4593","moa":"NFkB pathway inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":19,"killed_fraction":0.03369,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8871,"interval":[0.83151,0.93017],"hit_lines":17,"nonhit_lines":446,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":0.05477,"hit_lines_ic50_at_most_1uM":17}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":19,"lineage_tested":3,"tested_annotated":564,"enrichment":9.89474,"p_one_sided_uncorrected":0.09787}},{"compound":"BRD-K06749501","name":"GSK1838705A","moa":"insulin growth factor receptor inhibitor","target":"ALK, IGF1R, INSR, RPS6KA1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":5,"killed_fraction":0.00893,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88253,"interval":[0.71947,0.99759],"hit_lines":4,"nonhit_lines":415,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.98354,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":11,"tested_annotated":560,"enrichment":10.18182,"p_one_sided_uncorrected":0.09476}},{"compound":"BRD-K96631475","name":"10-deacetylbaccatin","moa":"antitumor agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":43,"killed_fraction":0.07734,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87929,"interval":[0.83421,0.92557],"hit_lines":39,"nonhit_lines":431,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":39,"median_ic50_uM":0.80805,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":7,"hits_annotated":43,"lineage_tested":24,"tested_annotated":556,"enrichment":3.77132,"p_one_sided_uncorrected":0.0013}},{"compound":"BRD-K95581532","name":"RN-1734","moa":"TRPV antagonist","target":"TRPV4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":8,"killed_fraction":0.01439,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87697,"interval":[0.80982,0.945],"hit_lines":4,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.59515,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":9,"tested_annotated":556,"enrichment":7.72222,"p_one_sided_uncorrected":0.12313}},{"compound":"BRD-K88677950","name":"PD-198306","moa":"MAP kinase inhibitor, MEK inhibitor","target":"MAP2K1, MAP2K2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":30,"killed_fraction":0.05357,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87247,"interval":[0.7772,0.9367],"hit_lines":27,"nonhit_lines":442,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":1.03701,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":11,"hits_annotated":30,"lineage_tested":43,"tested_annotated":560,"enrichment":4.77519,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K49294207","name":"BIBU-1361","moa":"EGFR inhibitor","target":"EGFR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":14,"killed_fraction":0.02527,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87237,"interval":[0.69947,0.98264],"hit_lines":12,"nonhit_lines":444,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":0.6937,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":14,"lineage_tested":20,"tested_annotated":554,"enrichment":3.95714,"p_one_sided_uncorrected":0.0869}},{"compound":"BRD-K77943374","name":"NVP-BVU972","moa":"MET inhibitor","target":"MET","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":27,"killed_fraction":0.04787,"class":"selective"},"secondary":{"status":"confirmed","separation":0.87231,"interval":[0.76898,0.96209],"hit_lines":21,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":1.26022,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bile_duct","hits_in_lineage":2,"hits_annotated":27,"lineage_tested":7,"tested_annotated":564,"enrichment":5.96825,"p_one_sided_uncorrected":0.03997}},{"compound":"BRD-K37618799","name":"MRS-1220","moa":"adenosine receptor antagonist","target":"ADORA2B, ADORA3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":67,"killed_fraction":0.11986,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8678,"interval":[0.80348,0.92133],"hit_lines":56,"nonhit_lines":387,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":35,"median_ic50_uM":0.99049,"hit_lines_ic50_at_most_1uM":19}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":8,"hits_annotated":67,"lineage_tested":24,"tested_annotated":559,"enrichment":2.78109,"p_one_sided_uncorrected":0.0043}},{"compound":"BRD-K01773560","name":"UNC2250","moa":"MER tyrosine kinase inhibitor","target":"MERTK","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.59,"lines_tested":540,"lines_killed":30,"killed_fraction":0.05556,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8602,"interval":[0.77412,0.92138],"hit_lines":25,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":23,"median_ic50_uM":0.31127,"hit_lines_ic50_at_most_1uM":22}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":4,"hits_annotated":30,"lineage_tested":23,"tested_annotated":540,"enrichment":3.13043,"p_one_sided_uncorrected":0.03271}},{"compound":"BRD-A44500574","name":"FLI-06","moa":"notch signaling inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":80,"killed_fraction":0.14286,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8561,"interval":[0.81337,0.89292],"hit_lines":72,"nonhit_lines":377,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":71,"median_ic50_uM":1.44439,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":9,"hits_annotated":80,"lineage_tested":19,"tested_annotated":560,"enrichment":3.31579,"p_one_sided_uncorrected":0.00045}},{"compound":"BRD-K98521173","name":"desoxycortone","moa":"mineralocorticoid receptor agonist","target":"NR3C1, NR3C2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85142,"interval":[0.71482,0.95742],"hit_lines":5,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":4.62442,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":43,"tested_annotated":564,"enrichment":5.24651,"p_one_sided_uncorrected":0.04901}},{"compound":"BRD-K83834509","name":"PTC-209","moa":"BMI-1 inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":14,"killed_fraction":0.02496,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85126,"interval":[0.78845,0.91437],"hit_lines":13,"nonhit_lines":437,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":1.44555,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":14,"lineage_tested":20,"tested_annotated":561,"enrichment":4.00714,"p_one_sided_uncorrected":0.08502}},{"compound":"BRD-K68336408","name":"tyrphostin-AG-1478","moa":"EGFR inhibitor","target":"EGFR, MAPK14","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":16,"killed_fraction":0.02857,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84655,"interval":[0.76348,0.9246],"hit_lines":15,"nonhit_lines":454,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.42266,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":3,"hits_annotated":16,"lineage_tested":24,"tested_annotated":560,"enrichment":4.375,"p_one_sided_uncorrected":0.02685}},{"compound":"BRD-K61734568","name":"2,3-DCPE","moa":"Bcl-XL downregulator","target":"BCL2L1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":63,"killed_fraction":0.1127,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84516,"interval":[0.78756,0.89918],"hit_lines":54,"nonhit_lines":393,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":47,"median_ic50_uM":1.95446,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":4,"hits_annotated":63,"lineage_tested":11,"tested_annotated":559,"enrichment":3.22655,"p_one_sided_uncorrected":0.02635}},{"compound":"BRD-K22025381","name":"U-18666A","moa":"oxidosqualene cyclase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":15,"killed_fraction":0.02674,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84423,"interval":[0.67709,0.96365],"hit_lines":13,"nonhit_lines":440,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":2.37319,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":5,"hits_annotated":15,"lineage_tested":34,"tested_annotated":561,"enrichment":5.5,"p_one_sided_uncorrected":0.00118}},{"compound":"BRD-K17702546","name":"PD-168393","moa":"EGFR inhibitor","target":"EGFR, ERBB2, SRC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":31,"killed_fraction":0.05496,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84406,"interval":[0.76071,0.92579],"hit_lines":27,"nonhit_lines":442,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":27,"median_ic50_uM":0.46611,"hit_lines_ic50_at_most_1uM":20}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":5,"hits_annotated":31,"lineage_tested":27,"tested_annotated":564,"enrichment":3.36918,"p_one_sided_uncorrected":0.01227}},{"compound":"BRD-K49669041","name":"BX-912","moa":"pyruvate dehydrogenase kinase inhibitor","target":"CDK2, CHEK1, GSK3B, KDR, PDK1, PDPK1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":36,"killed_fraction":0.06475,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84401,"interval":[0.77476,0.90062],"hit_lines":31,"nonhit_lines":438,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":31,"median_ic50_uM":0.50389,"hit_lines_ic50_at_most_1uM":28}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":6,"hits_annotated":36,"lineage_tested":23,"tested_annotated":556,"enrichment":4.02899,"p_one_sided_uncorrected":0.00217}},{"compound":"BRD-K21164796","name":"beta-naphthol","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":16,"killed_fraction":0.02857,"class":"selective"},"secondary":{"status":"confirmed","separation":0.84071,"interval":[0.72305,0.94028],"hit_lines":9,"nonhit_lines":399,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.94307,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":3,"hits_annotated":16,"lineage_tested":26,"tested_annotated":560,"enrichment":4.03846,"p_one_sided_uncorrected":0.03329}},{"compound":"BRD-K30431096","name":"domiphen","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":5,"killed_fraction":0.00912,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83895,"interval":[0.75753,0.9224],"hit_lines":4,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":2.18293,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":38,"tested_annotated":548,"enrichment":5.76842,"p_one_sided_uncorrected":0.04101}},{"compound":"BRD-K77791657","name":"3-deazaneplanocin-A","moa":"histone lysine methyltransferase inhibitor","target":"EZH2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":31,"killed_fraction":0.05496,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83545,"interval":[0.74769,0.90795],"hit_lines":26,"nonhit_lines":442,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":26,"median_ic50_uM":0.60978,"hit_lines_ic50_at_most_1uM":23}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":11,"hits_annotated":31,"lineage_tested":101,"tested_annotated":564,"enrichment":1.98148,"p_one_sided_uncorrected":0.01267}},{"compound":"BRD-K07762753","name":"aminopurvalanol-a","moa":"CDK inhibitor, tyrosine kinase inhibitor","target":"CDK1, CDK2, CDK5, CDK6","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":32,"killed_fraction":0.05755,"class":"selective"},"secondary":{"status":"confirmed","separation":0.83292,"interval":[0.77027,0.89207],"hit_lines":23,"nonhit_lines":439,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":1.65035,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":4,"hits_annotated":32,"lineage_tested":21,"tested_annotated":556,"enrichment":3.30952,"p_one_sided_uncorrected":0.02708}},{"compound":"BRD-K45551181","name":"MPI-0479605","moa":"mitotic kinase inhibitor","target":"TTK","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49,"lines_tested":530,"lines_killed":67,"killed_fraction":0.12642,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82895,"interval":[0.78174,0.87515],"hit_lines":55,"nonhit_lines":363,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":55,"median_ic50_uM":0.01744,"hit_lines_ic50_at_most_1uM":55}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":8,"hits_annotated":67,"lineage_tested":33,"tested_annotated":530,"enrichment":1.91768,"p_one_sided_uncorrected":0.04381}},{"compound":"BRD-K76180386","name":"JIB04","moa":"histone lysine demethylase inhibitor","target":"KDM4E","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":17,"killed_fraction":0.0303,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82857,"interval":[0.6721,0.94105],"hit_lines":14,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":0.44632,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":17,"lineage_tested":20,"tested_annotated":561,"enrichment":3.3,"p_one_sided_uncorrected":0.11921}},{"compound":"BRD-K79930101","name":"GW-583340","moa":"EGFR inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":24,"killed_fraction":0.04255,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82708,"interval":[0.73437,0.90854],"hit_lines":20,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":1.65406,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":4,"hits_annotated":24,"lineage_tested":27,"tested_annotated":564,"enrichment":3.48148,"p_one_sided_uncorrected":0.02292}},{"compound":"BRD-K25279140","name":"MK-8745","moa":"Aurora kinase inhibitor","target":"AURKA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":536,"lines_killed":43,"killed_fraction":0.08022,"class":"selective"},"secondary":{"status":"confirmed","separation":0.82203,"interval":[0.77345,0.86742],"hit_lines":35,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":35,"median_ic50_uM":0.42159,"hit_lines_ic50_at_most_1uM":35}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":4,"hits_annotated":43,"lineage_tested":10,"tested_annotated":536,"enrichment":4.98605,"p_one_sided_uncorrected":0.00531}},{"compound":"BRD-K24715592","name":"ethacridine-lactate-monohydrate","moa":"DNA intercalating agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.53,"lines_tested":530,"lines_killed":129,"killed_fraction":0.2434,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81957,"interval":[0.76868,0.86663],"hit_lines":99,"nonhit_lines":321,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":94,"median_ic50_uM":1.74475,"hit_lines_ic50_at_most_1uM":26}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":20,"hits_annotated":129,"lineage_tested":40,"tested_annotated":530,"enrichment":2.05426,"p_one_sided_uncorrected":0.00022}},{"compound":"BRD-K62696033","name":"G-1","moa":"G protein-coupled receptor agonist","target":"GPER1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":148,"killed_fraction":0.26381,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81715,"interval":[0.77473,0.86176],"hit_lines":122,"nonhit_lines":328,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":113,"median_ic50_uM":1.73302,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":148,"lineage_tested":23,"tested_annotated":561,"enrichment":2.47209,"p_one_sided_uncorrected":7e-05}},{"compound":"BRD-K73309154","name":"OSI-420","moa":"EGFR inhibitor","target":"EGFR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":48,"killed_fraction":0.08511,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81604,"interval":[0.74957,0.87507],"hit_lines":40,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":38,"median_ic50_uM":1.10932,"hit_lines_ic50_at_most_1uM":17}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":9,"hits_annotated":48,"lineage_tested":24,"tested_annotated":564,"enrichment":4.40625,"p_one_sided_uncorrected":5e-05}},{"compound":"BRD-K79259477","name":"NVP-BHG712","moa":"ephrin inhibitor","target":"EPHB4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":20,"killed_fraction":0.03559,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8141,"interval":[0.71432,0.89559],"hit_lines":18,"nonhit_lines":416,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":3.16954,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":4,"hits_annotated":20,"lineage_tested":37,"tested_annotated":562,"enrichment":3.03784,"p_one_sided_uncorrected":0.03599}},{"compound":"BRD-K82823804","name":"PD-407824","moa":"PKC inhibitor","target":"WEE1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":63,"killed_fraction":0.11372,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81373,"interval":[0.75383,0.86157],"hit_lines":49,"nonhit_lines":385,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":1.64974,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":4,"hits_annotated":63,"lineage_tested":7,"tested_annotated":554,"enrichment":5.02494,"p_one_sided_uncorrected":0.00411}},{"compound":"BRD-A57886255","name":"golgicide-a","moa":"ARF inhibitor","target":"GBF1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":63,"killed_fraction":0.1127,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81297,"interval":[0.74902,0.87189],"hit_lines":52,"nonhit_lines":397,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":50,"median_ic50_uM":2.1888,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":16,"hits_annotated":63,"lineage_tested":43,"tested_annotated":559,"enrichment":3.30159,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K41876534","name":"tioxolone","moa":"carbonic anhydrase inhibitor","target":"CA2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":25,"killed_fraction":0.04472,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81185,"interval":[0.69553,0.90079],"hit_lines":17,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":14,"median_ic50_uM":2.982,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":5,"hits_annotated":25,"lineage_tested":34,"tested_annotated":559,"enrichment":3.28824,"p_one_sided_uncorrected":0.01355}},{"compound":"BRD-K13060017","name":"UNC0631","moa":"histone lysine methyltransferase inhibitor","target":"EHMT2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.49999,"lines_tested":541,"lines_killed":30,"killed_fraction":0.05545,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80259,"interval":[0.71376,0.88116],"hit_lines":27,"nonhit_lines":415,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":27,"median_ic50_uM":1.91057,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":30,"lineage_tested":43,"tested_annotated":541,"enrichment":3.35504,"p_one_sided_uncorrected":0.00129}},{"compound":"BRD-K13949769","name":"tenovin-6","moa":"SIRT inhibitor","target":"SIRT1, SIRT2, SIRT3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":11,"killed_fraction":0.0195,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79906,"interval":[0.67498,0.90128],"hit_lines":7,"nonhit_lines":455,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":1.72106,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":11,"tested_annotated":564,"enrichment":9.32231,"p_one_sided_uncorrected":0.0173}},{"compound":"BRD-K13606314","name":"P5091","moa":"ubiquitin specific protease inhibitor","target":"USP7","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":13,"killed_fraction":0.02305,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79667,"interval":[0.67567,0.89001],"hit_lines":8,"nonhit_lines":450,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":2.32273,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":5,"hits_annotated":13,"lineage_tested":21,"tested_annotated":564,"enrichment":10.32967,"p_one_sided_uncorrected":5e-05}},{"compound":"BRD-K94176593","name":"TWS-119","moa":"glycogen synthase kinase inhibitor","target":"GSK3B, JUN, MYC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":14,"killed_fraction":0.02518,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79574,"interval":[0.67466,0.89766],"hit_lines":13,"nonhit_lines":441,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":1.94366,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":3,"hits_annotated":14,"lineage_tested":19,"tested_annotated":556,"enrichment":6.27068,"p_one_sided_uncorrected":0.00973}},{"compound":"BRD-K89299012","name":"DCEBIO","moa":"potassium channel activator","target":"KCNN2, KCNN3, KCNN4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":23,"killed_fraction":0.04152,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79537,"interval":[0.68047,0.88322],"hit_lines":18,"nonhit_lines":420,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":0.76843,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":6,"hits_annotated":23,"lineage_tested":43,"tested_annotated":554,"enrichment":3.36097,"p_one_sided_uncorrected":0.00571}},{"compound":"BRD-K09900591","name":"caffeic-acid","moa":"HIV integrase inhibitor, lipoxygenase inhibitor, nitric oxide production inhibitor, tumor necrosis factor production inhibitor","target":"ALOX5, MIF","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":29,"killed_fraction":0.05472,"class":"selective"},"secondary":{"status":"confirmed","separation":0.7941,"interval":[0.69707,0.88753],"hit_lines":23,"nonhit_lines":382,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":2.49827,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":4,"hits_annotated":29,"lineage_tested":22,"tested_annotated":530,"enrichment":3.32288,"p_one_sided_uncorrected":0.02663}},{"compound":"BRD-A81370665","name":"BI-D1870","moa":"ribosomal protein inhibitor","target":"RPS6KA1, RPS6KA2, RPS6KA3, RPS6KA6","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":16,"killed_fraction":0.02837,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79283,"interval":[0.61718,0.93828],"hit_lines":12,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":2.6604,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":16,"lineage_tested":24,"tested_annotated":564,"enrichment":4.40625,"p_one_sided_uncorrected":0.02635}},{"compound":"BRD-K26997899","name":"D-64131","moa":"microtubule inhibitor","target":"TUBB","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":203,"killed_fraction":0.35993,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79244,"interval":[0.75215,0.83687],"hit_lines":164,"nonhit_lines":254,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":161,"median_ic50_uM":0.09489,"hit_lines_ic50_at_most_1uM":161}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":18,"hits_annotated":203,"lineage_tested":23,"tested_annotated":564,"enrichment":2.17434,"p_one_sided_uncorrected":3e-05}},{"compound":"BRD-K61228301","name":"SGI-1027","moa":"DNA methyltransferase inhibitor","target":"DNMT1, DNMT3A, DNMT3B","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":172,"killed_fraction":0.3066,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79153,"interval":[0.7466,0.83468],"hit_lines":146,"nonhit_lines":321,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":146,"median_ic50_uM":1.66933,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":12,"hits_annotated":172,"lineage_tested":20,"tested_annotated":561,"enrichment":1.95698,"p_one_sided_uncorrected":0.00543}},{"compound":"BRD-K13094524","name":"PFI-1","moa":"bromodomain inhibitor","target":"BRD4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.63,"lines_tested":530,"lines_killed":30,"killed_fraction":0.0566,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79028,"interval":[0.69418,0.86026],"hit_lines":25,"nonhit_lines":399,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":1.2078,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":5,"hits_annotated":30,"lineage_tested":40,"tested_annotated":530,"enrichment":2.20833,"p_one_sided_uncorrected":0.06605}},{"compound":"BRD-K18834913","name":"LB42708","moa":"farnesyltransferase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":31,"killed_fraction":0.05526,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77982,"interval":[0.67412,0.86113],"hit_lines":26,"nonhit_lines":436,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":26,"median_ic50_uM":0.35838,"hit_lines_ic50_at_most_1uM":24}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":4,"hits_annotated":31,"lineage_tested":21,"tested_annotated":561,"enrichment":3.447,"p_one_sided_uncorrected":0.02359}},{"compound":"BRD-K48488978","name":"YM-201636","moa":"PI3K inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":33,"killed_fraction":0.05946,"class":"selective"},"secondary":{"status":"confirmed","separation":0.7798,"interval":[0.69051,0.87195],"hit_lines":27,"nonhit_lines":422,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":24,"median_ic50_uM":2.19835,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":6,"hits_annotated":33,"lineage_tested":20,"tested_annotated":555,"enrichment":5.04545,"p_one_sided_uncorrected":0.00059}},{"compound":"BRD-K31866293","name":"TAK-632","moa":"RAF inhibitor","target":"BRAF","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":57,"killed_fraction":0.10179,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77807,"interval":[0.70222,0.85015],"hit_lines":44,"nonhit_lines":400,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":44,"median_ic50_uM":0.56874,"hit_lines_ic50_at_most_1uM":35}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":21,"hits_annotated":57,"lineage_tested":43,"tested_annotated":560,"enrichment":4.79804,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K22503835","name":"scriptaid","moa":"HDAC inhibitor","target":"HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":88,"killed_fraction":0.15686,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76935,"interval":[0.7135,0.82137],"hit_lines":79,"nonhit_lines":388,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":77,"median_ic50_uM":1.7358,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":3,"hits_annotated":88,"lineage_tested":3,"tested_annotated":561,"enrichment":6.375,"p_one_sided_uncorrected":0.00375}},{"compound":"BRD-K85849709","name":"AZD2858","moa":"glycogen synthase kinase inhibitor","target":"GSK3B","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":168,"killed_fraction":0.3,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76598,"interval":[0.72329,0.80725],"hit_lines":137,"nonhit_lines":310,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":132,"median_ic50_uM":1.34925,"hit_lines_ic50_at_most_1uM":36}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":168,"lineage_tested":23,"tested_annotated":560,"enrichment":2.17391,"p_one_sided_uncorrected":0.00039}},{"compound":"BRD-K36222532","name":"broxaldine","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":51,"killed_fraction":0.09427,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76348,"interval":[0.6994,0.81994],"hit_lines":45,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":45,"median_ic50_uM":1.02559,"hit_lines_ic50_at_most_1uM":20}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":5,"hits_annotated":51,"lineage_tested":23,"tested_annotated":541,"enrichment":2.30605,"p_one_sided_uncorrected":0.05542}},{"compound":"BRD-K09443272","name":"PHA-680632","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, AURKC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":82,"killed_fraction":0.14643,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76101,"interval":[0.70621,0.8141],"hit_lines":69,"nonhit_lines":373,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":69,"median_ic50_uM":0.60726,"hit_lines_ic50_at_most_1uM":53}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":10,"hits_annotated":82,"lineage_tested":38,"tested_annotated":560,"enrichment":1.79718,"p_one_sided_uncorrected":0.03732}},{"compound":"BRD-K42436189","name":"AZ20","moa":"ATR kinase inhibitor","target":"ATR, MTOR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":226,"killed_fraction":0.40071,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76068,"interval":[0.71297,0.8],"hit_lines":181,"nonhit_lines":278,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":181,"median_ic50_uM":1.33805,"hit_lines_ic50_at_most_1uM":54}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":14,"hits_annotated":226,"lineage_tested":24,"tested_annotated":564,"enrichment":1.45575,"p_one_sided_uncorrected":0.05049}},{"compound":"BRD-K26756394","name":"VE-821","moa":"ATR kinase inhibitor","target":"ATR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":12,"killed_fraction":0.02139,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75974,"interval":[0.62274,0.89585],"hit_lines":8,"nonhit_lines":449,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":2.38538,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":20,"tested_annotated":561,"enrichment":4.675,"p_one_sided_uncorrected":0.06435}},{"compound":"BRD-K43621685","name":"CP-673451","moa":"PDGFR tyrosine kinase receptor inhibitor","target":"KIT, PDGFRA, PDGFRB","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":26,"killed_fraction":0.04651,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75599,"interval":[0.599,0.88158],"hit_lines":22,"nonhit_lines":421,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":1.54364,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":26,"lineage_tested":12,"tested_annotated":559,"enrichment":5.375,"p_one_sided_uncorrected":0.01489}},{"compound":"BRD-K94455792","name":"ICG-001","moa":"beta-catenin inhibitor","target":"CTNNB1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":13,"killed_fraction":0.02321,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75076,"interval":[0.60072,0.8849],"hit_lines":11,"nonhit_lines":449,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":1.73616,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":13,"lineage_tested":20,"tested_annotated":560,"enrichment":4.30769,"p_one_sided_uncorrected":0.07468}},{"compound":"BRD-K55305701","name":"SC-144","moa":"P glycoprotein inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_pending","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":232,"killed_fraction":0.41135,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75024,"interval":[0.70308,0.79388],"hit_lines":188,"nonhit_lines":261,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":161,"median_ic50_uM":0.87259,"hit_lines_ic50_at_most_1uM":94}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":232,"lineage_tested":23,"tested_annotated":564,"enrichment":1.58546,"p_one_sided_uncorrected":0.01525}},{"compound":"BRD-K71035033","name":"masitinib","moa":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor","target":"FGFR3, KIT, PDGFRA, PDGFRB","disease_area":"dermatology","indication":"mastocytoma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":8,"killed_fraction":0.01423,"class":"selective"},"secondary":{"status":"confirmed","separation":0.90312,"interval":[0.71378,1.0],"hit_lines":8,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.46264,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_replicated","separation":0.72392,"interval":[0.44933,0.92515],"hit_lines":8,"nonhit_lines":465},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":12,"tested_annotated":562,"enrichment":11.70833,"p_one_sided_uncorrected":0.01091}},{"compound":"BRD-K37798499","name":"etoposide","moa":"topoisomerase inhibitor","target":"TOP2A, TOP2B","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":187,"killed_fraction":0.33453,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80789,"interval":[0.76759,0.84675],"hit_lines":160,"nonhit_lines":305,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":158,"median_ic50_uM":0.89457,"hit_lines_ic50_at_most_1uM":94}},"independent":{"status":"not_replicated","separation":0.65978,"interval":[0.61221,0.71194],"hit_lines":160,"nonhit_lines":321},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":187,"lineage_tested":23,"tested_annotated":559,"enrichment":2.20949,"p_one_sided_uncorrected":6e-05}},{"compound":"BRD-K24844714","name":"5-fluorouracil","moa":"thymidylate synthase inhibitor","target":"DPYD, TYMS","disease_area":"oncology","indication":"colorectal cancer, breast cancer, pancreatic cancer, gastric adenocarcinoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":30,"killed_fraction":0.05545,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79252,"interval":[0.6931,0.86781],"hit_lines":24,"nonhit_lines":392,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":1.50727,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_replicated","separation":0.6835,"interval":[0.55552,0.80416],"hit_lines":26,"nonhit_lines":439},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":5,"hits_annotated":30,"lineage_tested":20,"tested_annotated":541,"enrichment":4.50833,"p_one_sided_uncorrected":0.00321}},{"compound":"BRD-K35960502","name":"niclosamide","moa":"DNA replication inhibitor, STAT inhibitor","target":"STAT3","disease_area":"infectious disease","indication":"tapeworm","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":56,"killed_fraction":0.10018,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79204,"interval":[0.72937,0.84761],"hit_lines":51,"nonhit_lines":411,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":1.99744,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_replicated","separation":0.6025,"interval":[0.52204,0.67424],"hit_lines":48,"nonhit_lines":430},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":6,"hits_annotated":56,"lineage_tested":24,"tested_annotated":559,"enrichment":2.49554,"p_one_sided_uncorrected":0.02493}},{"compound":"BRD-K78431006","name":"crizotinib","moa":"ALK tyrosine kinase receptor inhibitor","target":"ALK, MET","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":29,"killed_fraction":0.05142,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78401,"interval":[0.64998,0.89906],"hit_lines":25,"nonhit_lines":404,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":0.73988,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_replicated","separation":0.66541,"interval":[0.55111,0.7784],"hit_lines":26,"nonhit_lines":454},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":2,"hits_annotated":29,"lineage_tested":11,"tested_annotated":564,"enrichment":3.53605,"p_one_sided_uncorrected":0.1053}},{"compound":"BRD-K49328571","name":"dasatinib","moa":"Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor","target":"ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1","disease_area":"hematologic malignancy","indication":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":267,"killed_fraction":0.48195,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78303,"interval":[0.74074,0.82423],"hit_lines":222,"nonhit_lines":217,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":121,"median_ic50_uM":0.08716,"hit_lines_ic50_at_most_1uM":107}},"independent":{"status":"not_replicated","separation":0.68276,"interval":[0.63242,0.73518],"hit_lines":240,"nonhit_lines":244},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":24,"hits_annotated":267,"lineage_tested":27,"tested_annotated":554,"enrichment":1.84436,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K92723993","name":"imatinib","moa":"Bcr-Abl kinase inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor","target":"ABL1, CSF1R, DDR1, KIT, NTRK1, PDGFRA, PDGFRB, RET","disease_area":"hematologic malignancy, oncology","indication":"chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL), myelodysplastic diseases (MDS), aggressive systemic mastocytosis (ASM), hypereosinophilic syndrome (HES), chronic eosinophilic leukemia (CEL), dermatofibrosarcoma protuberans (DFSP), gastrointestinal stromal tumors (GIST)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":12,"killed_fraction":0.02128,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77461,"interval":[0.59541,0.95695],"hit_lines":9,"nonhit_lines":351,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.45886,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_replicated","separation":0.6341,"interval":[0.42683,0.82334],"hit_lines":12,"nonhit_lines":467},"lineage":{"status":"estimable","lineage":"fibroblast","hits_in_lineage":1,"hits_annotated":12,"lineage_tested":1,"tested_annotated":564,"enrichment":47.0,"p_one_sided_uncorrected":0.02128}},{"compound":"BRD-K79254416","name":"decitabine","moa":"DNA methyltransferase inhibitor","target":"DNMT1, DNMT3A","disease_area":"hematologic malignancy, hematology","indication":"myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":558,"lines_killed":135,"killed_fraction":0.24194,"class":"selective"},"secondary":{"status":"confirmed","separation":0.756,"interval":[0.69934,0.80417],"hit_lines":114,"nonhit_lines":315,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":49,"median_ic50_uM":0.83691,"hit_lines_ic50_at_most_1uM":29}},"independent":{"status":"not_replicated","separation":0.52602,"interval":[0.46548,0.59294],"hit_lines":117,"nonhit_lines":369},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":10,"hits_annotated":135,"lineage_tested":22,"tested_annotated":558,"enrichment":1.87879,"p_one_sided_uncorrected":0.02139}},{"compound":"BRD-K92241597","name":"tosedostat","moa":"peptidase inhibitor","target":"ANPEP, LAP3, NPEPPS","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":33,"killed_fraction":0.05851,"class":"selective"},"secondary":{"status":"confirmed","separation":0.93371,"interval":[0.9005,0.96398],"hit_lines":30,"nonhit_lines":440,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":30,"median_ic50_uM":0.00717,"hit_lines_ic50_at_most_1uM":30}},"independent":{"status":"not_replicated","separation":0.61462,"interval":[0.48722,0.7244],"hit_lines":30,"nonhit_lines":439},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":33,"lineage_tested":43,"tested_annotated":564,"enrichment":3.1797,"p_one_sided_uncorrected":0.00195}},{"compound":"BRD-K59369769","name":"tozasertib","moa":"Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor","target":"AURKA, AURKB, AURKC, LCK","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":56,"killed_fraction":0.09929,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8977,"interval":[0.84555,0.93207],"hit_lines":47,"nonhit_lines":386,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":33,"median_ic50_uM":0.48309,"hit_lines_ic50_at_most_1uM":26}},"independent":{"status":"not_replicated","separation":0.6,"interval":[0.33953,0.86047],"hit_lines":5,"nonhit_lines":43},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":7,"hits_annotated":56,"lineage_tested":23,"tested_annotated":564,"enrichment":3.06522,"p_one_sided_uncorrected":0.00454}},{"compound":"BRD-K82746043","name":"navitoclax","moa":"BCL inhibitor","target":"BCL2, BCL2L1, BCL2L2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":42,"killed_fraction":0.07473,"class":"selective"},"secondary":{"status":"confirmed","separation":0.85865,"interval":[0.80021,0.91455],"hit_lines":31,"nonhit_lines":385,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":26,"median_ic50_uM":0.0305,"hit_lines_ic50_at_most_1uM":24}},"independent":{"status":"not_replicated","separation":0.6987,"interval":[0.61189,0.78344],"hit_lines":38,"nonhit_lines":446},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":5,"hits_annotated":42,"lineage_tested":19,"tested_annotated":562,"enrichment":3.5213,"p_one_sided_uncorrected":0.00973}},{"compound":"BRD-K12502280","name":"TG-101348","moa":"FLT3 inhibitor, JAK inhibitor","target":"BRD4, JAK1, JAK2, JAK3, TYK2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81919,"interval":[0.64563,0.94856],"hit_lines":4,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":2.25889,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_replicated","separation":0.51058,"interval":[0.22101,0.96614],"hit_lines":3,"nonhit_lines":457},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":24,"tested_annotated":541,"enrichment":9.01667,"p_one_sided_uncorrected":0.0174}},{"compound":"BRD-K93123848","name":"RAF265","moa":"RAF inhibitor, VEGFR inhibitor","target":"BRAF","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":35,"killed_fraction":0.06239,"class":"selective"},"secondary":{"status":"confirmed","separation":0.8177,"interval":[0.75288,0.86935],"hit_lines":32,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":32,"median_ic50_uM":0.66445,"hit_lines_ic50_at_most_1uM":22}},"independent":{"status":"not_replicated","separation":0.66419,"interval":[0.55488,0.78026],"hit_lines":25,"nonhit_lines":353},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":35,"lineage_tested":43,"tested_annotated":561,"enrichment":2.98206,"p_one_sided_uncorrected":0.00304}},{"compound":"BRD-K64800655","name":"PHA-793887","moa":"CDK inhibitor","target":"CDK1, CDK2, CDK4, CDK5, CDK7, CDK9","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":275,"killed_fraction":0.48759,"class":"selective"},"secondary":{"status":"confirmed","separation":0.81153,"interval":[0.77355,0.84963],"hit_lines":243,"nonhit_lines":229,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":236,"median_ic50_uM":0.42971,"hit_lines_ic50_at_most_1uM":170}},"independent":{"status":"not_replicated","separation":0.61329,"interval":[0.56519,0.66482],"hit_lines":237,"nonhit_lines":251},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":15,"hits_annotated":275,"lineage_tested":24,"tested_annotated":564,"enrichment":1.28182,"p_one_sided_uncorrected":0.12135}},{"compound":"BRD-K21718444","name":"KW-2449","moa":"Abl kinase inhibitor, Aurora kinase inhibitor, FLT3 inhibitor","target":"ABL1, AURKA, AURKB, FLT3","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":55,"killed_fraction":0.09752,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80966,"interval":[0.74708,0.86259],"hit_lines":41,"nonhit_lines":423,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":41,"median_ic50_uM":0.96306,"hit_lines_ic50_at_most_1uM":22}},"independent":{"status":"not_replicated","separation":0.6492,"interval":[0.56993,0.73918],"hit_lines":45,"nonhit_lines":437},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":7,"hits_annotated":55,"lineage_tested":23,"tested_annotated":564,"enrichment":3.12095,"p_one_sided_uncorrected":0.00408}},{"compound":"BRD-K29968218","name":"KX2-391","moa":"src inhibitor, tubulin polymerization inhibitor","target":"SRC","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":259,"killed_fraction":0.46583,"class":"selective"},"secondary":{"status":"confirmed","separation":0.80791,"interval":[0.76861,0.84895],"hit_lines":217,"nonhit_lines":231,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":215,"median_ic50_uM":0.09061,"hit_lines_ic50_at_most_1uM":215}},"independent":{"status":"not_replicated","separation":0.63908,"interval":[0.59036,0.68095],"hit_lines":223,"nonhit_lines":254},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":259,"lineage_tested":23,"tested_annotated":556,"enrichment":1.5867,"p_one_sided_uncorrected":0.00638}},{"compound":"BRD-K63923597","name":"barasertib-HQPA","moa":"Aurora kinase inhibitor","target":"AURKB","disease_area":"NA","indication":"NA","phase":"Phase 2/Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":145,"killed_fraction":0.26079,"class":"selective"},"secondary":{"status":"confirmed","separation":0.78075,"interval":[0.73186,0.82948],"hit_lines":121,"nonhit_lines":323,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":104,"median_ic50_uM":0.15112,"hit_lines_ic50_at_most_1uM":97}},"independent":{"status":"not_replicated","separation":0.60672,"interval":[0.5526,0.66595],"hit_lines":121,"nonhit_lines":345},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":17,"hits_annotated":145,"lineage_tested":41,"tested_annotated":556,"enrichment":1.58991,"p_one_sided_uncorrected":0.01883}},{"compound":"BRD-K12184916","name":"NVP-BEZ235","moa":"mTOR inhibitor, PI3K inhibitor","target":"ATR, MTOR, PIK3CA, PIK3CD, PIK3CG","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":239,"killed_fraction":0.42527,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77934,"interval":[0.73384,0.82797],"hit_lines":175,"nonhit_lines":250,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":107,"median_ic50_uM":0.01531,"hit_lines_ic50_at_most_1uM":99}},"independent":{"status":"not_replicated","separation":0.52391,"interval":[0.45602,0.58203],"hit_lines":150,"nonhit_lines":197},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":239,"lineage_tested":23,"tested_annotated":562,"enrichment":1.73804,"p_one_sided_uncorrected":0.00191}},{"compound":"BRD-K33379087","name":"tivantinib","moa":"tyrosine kinase inhibitor","target":"MET","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":266,"killed_fraction":0.48014,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75915,"interval":[0.71682,0.80509],"hit_lines":218,"nonhit_lines":228,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":133,"median_ic50_uM":0.844,"hit_lines_ic50_at_most_1uM":76}},"independent":{"status":"not_replicated","separation":0.67515,"interval":[0.60787,0.74237],"hit_lines":116,"nonhit_lines":112},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":16,"hits_annotated":266,"lineage_tested":24,"tested_annotated":554,"enrichment":1.38847,"p_one_sided_uncorrected":0.04788}},{"compound":"BRD-K13049116","name":"BMS-754807","moa":"IGF-1 inhibitor","target":"AKT1, IGF1R","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":99,"killed_fraction":0.17806,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75707,"interval":[0.69891,0.80772],"hit_lines":80,"nonhit_lines":343,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":1.18765,"hit_lines_ic50_at_most_1uM":19}},"independent":{"status":"not_replicated","separation":0.61,"interval":[0.55466,0.67053],"hit_lines":89,"nonhit_lines":393},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":8,"hits_annotated":99,"lineage_tested":24,"tested_annotated":556,"enrichment":1.87205,"p_one_sided_uncorrected":0.04632}},{"compound":"BRD-A81541225","name":"oligomycin-a","moa":"ATP synthase inhibitor, ATPase inhibitor","target":"ATP5A1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":36,"killed_fraction":0.06475,"class":"selective"},"secondary":{"status":"confirmed","separation":0.89972,"interval":[0.81911,0.95622],"hit_lines":28,"nonhit_lines":333,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":959.24416,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_replicated","separation":0.67457,"interval":[0.57398,0.76507],"hit_lines":33,"nonhit_lines":437},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":5,"hits_annotated":36,"lineage_tested":34,"tested_annotated":556,"enrichment":2.27124,"p_one_sided_uncorrected":0.06001}},{"compound":"BRD-K54606188","name":"JQ1-(+)","moa":"bromodomain inhibitor","target":"BRD4, BRDT","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":38,"killed_fraction":0.06738,"class":"selective"},"secondary":{"status":"confirmed","separation":0.88539,"interval":[0.827,0.9373],"hit_lines":33,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":31,"median_ic50_uM":0.53788,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_replicated","separation":0.67658,"interval":[0.57252,0.76264],"hit_lines":33,"nonhit_lines":457},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":12,"hits_annotated":38,"lineage_tested":101,"tested_annotated":564,"enrichment":1.76342,"p_one_sided_uncorrected":0.02494}},{"compound":"BRD-K59146805","name":"AZ3146","moa":"monopolar spindle 1 kinase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":58,"killed_fraction":0.1032,"class":"selective"},"secondary":{"status":"confirmed","separation":0.801,"interval":[0.73212,0.85636],"hit_lines":50,"nonhit_lines":401,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":45,"median_ic50_uM":1.74696,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_replicated","separation":0.61625,"interval":[0.53082,0.69915],"hit_lines":46,"nonhit_lines":426},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":6,"hits_annotated":58,"lineage_tested":23,"tested_annotated":562,"enrichment":2.52774,"p_one_sided_uncorrected":0.0233}},{"compound":"BRD-K37720887","name":"SB-525334","moa":"TGF beta receptor inhibitor","target":"TGFBR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":31,"killed_fraction":0.05546,"class":"selective"},"secondary":{"status":"confirmed","separation":0.79079,"interval":[0.70072,0.87008],"hit_lines":25,"nonhit_lines":369,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":3.02685,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_replicated","separation":0.67354,"interval":[0.56314,0.78374],"hit_lines":28,"nonhit_lines":451},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":13,"hits_annotated":31,"lineage_tested":43,"tested_annotated":559,"enrichment":5.45161,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-A80213327","name":"NSC-23766","moa":"Ras GTPase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":5,"killed_fraction":0.00894,"class":"selective"},"secondary":{"status":"confirmed","separation":0.7789,"interval":[0.60494,0.96842],"hit_lines":3,"nonhit_lines":395,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_replicated","separation":0.63783,"interval":[0.50833,0.72714],"hit_lines":3,"nonhit_lines":474},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":9,"tested_annotated":559,"enrichment":12.42222,"p_one_sided_uncorrected":0.07822}},{"compound":"BRD-K26818574","name":"BIX-01294","moa":"histone lysine methyltransferase inhibitor","target":"EHMT1, EHMT2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":36,"killed_fraction":0.06417,"class":"selective"},"secondary":{"status":"confirmed","separation":0.77711,"interval":[0.68651,0.8513],"hit_lines":31,"nonhit_lines":432,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":31,"median_ic50_uM":2.03921,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_replicated","separation":0.68354,"interval":[0.59726,0.77208],"hit_lines":31,"nonhit_lines":443},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":15,"hits_annotated":36,"lineage_tested":43,"tested_annotated":561,"enrichment":5.43605,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K90382497","name":"GW-843682X","moa":"PLK inhibitor","target":"PLK1, PLK3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":242,"killed_fraction":0.43682,"class":"selective"},"secondary":{"status":"confirmed","separation":0.76798,"interval":[0.72574,0.80971],"hit_lines":209,"nonhit_lines":258,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":205,"median_ic50_uM":0.69685,"hit_lines_ic50_at_most_1uM":162}},"independent":{"status":"not_replicated","separation":0.69427,"interval":[0.64883,0.74189],"hit_lines":206,"nonhit_lines":260},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":242,"lineage_tested":22,"tested_annotated":554,"enrichment":1.66491,"p_one_sided_uncorrected":0.00484}},{"compound":"BRD-K37865504","name":"LY2183240","moa":"FAAH inhibitor, FAAH reuptake inhibitor","target":"FAAH","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":252,"killed_fraction":0.45324,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75638,"interval":[0.71774,0.8018],"hit_lines":225,"nonhit_lines":244,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":208,"median_ic50_uM":1.88227,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"not_replicated","separation":0.62478,"interval":[0.57801,0.67414],"hit_lines":210,"nonhit_lines":259},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":4,"hits_annotated":252,"lineage_tested":5,"tested_annotated":556,"enrichment":1.76508,"p_one_sided_uncorrected":0.1334}},{"compound":"BRD-K47150025","name":"KI-8751","moa":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"KDR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"confirmed_independent_conflict","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":56,"killed_fraction":0.1,"class":"selective"},"secondary":{"status":"confirmed","separation":0.75352,"interval":[0.67821,0.82125],"hit_lines":46,"nonhit_lines":408,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":39,"median_ic50_uM":1.48443,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"not_replicated","separation":0.61948,"interval":[0.53465,0.7024],"hit_lines":49,"nonhit_lines":423},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":8,"hits_annotated":56,"lineage_tested":23,"tested_annotated":560,"enrichment":3.47826,"p_one_sided_uncorrected":0.00091}},{"compound":"BRD-A04506385","name":"stepronin","moa":"mucolytic agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":552,"lines_killed":5,"killed_fraction":0.00906,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":21,"tested_annotated":552,"enrichment":5.25714,"p_one_sided_uncorrected":0.17688}},{"compound":"BRD-A08660406","name":"iodixanol","moa":"radiopaque medium","target":"NA","disease_area":"radiology","indication":"contrast agent","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":515,"lines_killed":6,"killed_fraction":0.01165,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":4,"tested_annotated":515,"enrichment":21.45833,"p_one_sided_uncorrected":0.04593}},{"compound":"BRD-A27732521","name":"tolperisone","moa":"voltage-gated sodium channel blocker","target":"CYP2C19, CYP2D6","disease_area":"neurology/psychiatry, infectious disease, rheumatology, cardiology","indication":"muscle relaxant, multiple sclerosis, encephalomyelitis, ankylosing spondylitis, atherosclerosis, Raynaud's disease","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":5,"killed_fraction":0.00912,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":4,"tested_annotated":548,"enrichment":27.4,"p_one_sided_uncorrected":0.0361}},{"compound":"BRD-A41250306","name":"cyclopenthiazide","moa":"thiazide diuretic","target":"NA","disease_area":"cardiology","indication":"hypertension, congestive heart failure","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":8,"killed_fraction":0.01418,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":3,"tested_annotated":564,"enrichment":23.5,"p_one_sided_uncorrected":0.04203}},{"compound":"BRD-A42759514","name":"ornidazole","moa":"antiprotozoal agent","target":"NA","disease_area":"infectious disease","indication":"protozoan infection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":17,"killed_fraction":0.03014,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":4,"hits_annotated":17,"lineage_tested":34,"tested_annotated":564,"enrichment":3.90311,"p_one_sided_uncorrected":0.015}},{"compound":"BRD-A53951045","name":"butylscopolamine-bromide","moa":"cholinergic receptor antagonist","target":"NA","disease_area":"gastroenterology","indication":"abdominal pain","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":419,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":24,"tested_annotated":556,"enrichment":4.63333,"p_one_sided_uncorrected":0.19864}},{"compound":"BRD-A79768653","name":"sirolimus","moa":"mTOR inhibitor","target":"FGF2, FKBP1A, MTOR","disease_area":"transplant, pulmonary","indication":"organ rejection, lymphangioleiomyomatosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":11,"killed_fraction":0.01986,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":21,"tested_annotated":554,"enrichment":4.79654,"p_one_sided_uncorrected":0.06127}},{"compound":"BRD-A79803969","name":"memantine","moa":"glutamate receptor antagonist","target":"CHRFAM7A, DRD2, GRIN1, GRIN2A, GRIN2B, GRIN3A, HTR3A","disease_area":"neurology/psychiatry","indication":"Alzheimer's disease, senile dementia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":8,"killed_fraction":0.01439,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":34,"tested_annotated":556,"enrichment":4.08824,"p_one_sided_uncorrected":0.08062}},{"compound":"BRD-K06980535","name":"promazine","moa":"dopamine receptor antagonist","target":"ADRA1A, ADRA1B, ADRA1D, CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, DRD1, DRD2, DRD3, DRD4, HRH1, HTR2A, HTR2C","disease_area":"neurology/psychiatry","indication":"schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":33,"tested_annotated":541,"enrichment":6.55758,"p_one_sided_uncorrected":0.03216}},{"compound":"BRD-K12513978","name":"fenbufen","moa":"cyclooxygenase inhibitor","target":"PTGS1, PTGS2","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":6,"killed_fraction":0.01109,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":3,"hits_annotated":6,"lineage_tested":95,"tested_annotated":541,"enrichment":2.84737,"p_one_sided_uncorrected":0.07014}},{"compound":"BRD-K16277217","name":"piperacetazine","moa":"dopamine receptor antagonist","target":"NA","disease_area":"neurology/psychiatry","indication":"schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":532,"lines_killed":5,"killed_fraction":0.0094,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":371,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":21,"tested_annotated":532,"enrichment":5.06667,"p_one_sided_uncorrected":0.18302}},{"compound":"BRD-K32842773","name":"pemetrexed","moa":"dihydrofolate reductase inhibitor, thymidylate synthase inhibitor","target":"ATIC, DHFR, GART, TYMS","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC), mesothelioma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":5,"tested_annotated":541,"enrichment":21.64,"p_one_sided_uncorrected":0.04553}},{"compound":"BRD-K36627727","name":"tamibarotene","moa":"retinoid receptor agonist","target":"RARA, RARB","disease_area":"hematologic malignancy","indication":"acute promyelocytic leukemia (APL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":5,"killed_fraction":0.0089,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":412,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":21,"tested_annotated":562,"enrichment":10.70476,"p_one_sided_uncorrected":0.01244}},{"compound":"BRD-K45664306","name":"prednisolone-acetate","moa":"glucocorticoid receptor agonist","target":"NR3C1","disease_area":"ophthalmology, dermatology, infectious disease","indication":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.52,"lines_tested":529,"lines_killed":5,"killed_fraction":0.00945,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":11,"tested_annotated":529,"enrichment":19.23636,"p_one_sided_uncorrected":0.00381}},{"compound":"BRD-K48195008","name":"ethinyl-estradiol","moa":"estrogen receptor agonist, estrogenic hormone","target":"ESR1, ESR2, NR1I2","disease_area":"endocrinology","indication":"contraceptive","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":380,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":0.60317,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":19,"tested_annotated":541,"enrichment":4.06767,"p_one_sided_uncorrected":0.22251}},{"compound":"BRD-K51937257","name":"bilastine","moa":"histamine receptor antagonist","target":"HRH1","disease_area":"ophthalmology","indication":"conjunctivitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":6,"killed_fraction":0.01083,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":7,"tested_annotated":554,"enrichment":13.19048,"p_one_sided_uncorrected":0.07378}},{"compound":"BRD-K59456551","name":"methotrexate","moa":"dihydrofolate reductase inhibitor","target":"DHFR","disease_area":"oncology, hematologic malignancy, dermatology, rheumatology","indication":"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","phase":"Launched","phase_group":"launched","oncology":true,"tier":"primary_only","primary":{"dose_uM":2.51,"lines_tested":530,"lines_killed":123,"killed_fraction":0.23208,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_replicated","separation":0.55947,"interval":[0.49259,0.61869],"hit_lines":99,"nonhit_lines":330},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":28,"hits_annotated":123,"lineage_tested":94,"tested_annotated":530,"enrichment":1.28351,"p_one_sided_uncorrected":0.06506}},{"compound":"BRD-K77947974","name":"fluspirilene","moa":"dopamine receptor antagonist","target":"CACNG1, DRD2, HRH1, HTR1A, HTR1D, HTR1E, HTR2A","disease_area":"neurology/psychiatry","indication":"schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":552,"lines_killed":10,"killed_fraction":0.01812,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":10,"lineage_tested":4,"tested_annotated":552,"enrichment":13.8,"p_one_sided_uncorrected":0.07071}},{"compound":"BRD-K83245588","name":"pilsicainide","moa":"sodium channel blocker","target":"SCN5A","disease_area":"cardiology","indication":"cardiac arrythmia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":551,"lines_killed":9,"killed_fraction":0.01633,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":36,"tested_annotated":551,"enrichment":5.10185,"p_one_sided_uncorrected":0.01641}},{"compound":"BRD-K85178109","name":"fostamatinib","moa":"SYK inhibitor","target":"SYK","disease_area":"hematology","indication":"chronic immune thrombocytopenia (ITP)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":20,"killed_fraction":0.03571,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":3,"hits_annotated":20,"lineage_tested":19,"tested_annotated":560,"enrichment":4.42105,"p_one_sided_uncorrected":0.02621}},{"compound":"BRD-K97309399","name":"thiothixene","moa":"dopamine receptor antagonist","target":"DRD1, DRD2, HRH1, HTR2A","disease_area":"neurology/psychiatry","indication":"schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":42,"tested_annotated":564,"enrichment":5.37143,"p_one_sided_uncorrected":0.04691}},{"compound":"BRD-K08037784","name":"arbutin","moa":"melanin inhibitor","target":"TYR","disease_area":"NA","indication":"NA","phase":"Phase 2/Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":6,"killed_fraction":0.01109,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":5,"tested_annotated":541,"enrichment":18.03333,"p_one_sided_uncorrected":0.05443}},{"compound":"BRD-K11071038","name":"ICI-162846","moa":"histamine receptor antagonist","target":"HRH2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":5,"killed_fraction":0.00926,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":405,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":8,"tested_annotated":540,"enrichment":13.5,"p_one_sided_uncorrected":0.07217}},{"compound":"BRD-K15071410","name":"tiotidine","moa":"histamine receptor antagonist","target":"HRH2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":449,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":4.54089,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":36,"tested_annotated":554,"enrichment":6.15556,"p_one_sided_uncorrected":0.03629}},{"compound":"BRD-K19203487","name":"SPP301","moa":"endothelin receptor antagonist","target":"EDNRA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":6,"killed_fraction":0.0107,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":23,"tested_annotated":561,"enrichment":8.13043,"p_one_sided_uncorrected":0.02184}},{"compound":"BRD-K19284129","name":"salvinorin-a","moa":"opioid receptor agonist","target":"OPRD1, OPRK1, OPRM1","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":419,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":8.85098,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":23,"tested_annotated":541,"enrichment":4.70435,"p_one_sided_uncorrected":0.19591}},{"compound":"BRD-K24603946","name":"5-hydroxymethyl-tolterodine","moa":"acetylcholine receptor antagonist","target":"CHRM3","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":5,"killed_fraction":0.00893,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":388,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":43,"tested_annotated":560,"enrichment":5.2093,"p_one_sided_uncorrected":0.04966}},{"compound":"BRD-K25970317","name":"resibufogenin","moa":"Na/K-ATPase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":91,"killed_fraction":0.16852,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":28,"hits_annotated":91,"lineage_tested":97,"tested_annotated":540,"enrichment":1.71293,"p_one_sided_uncorrected":0.00073}},{"compound":"BRD-K28217197","name":"ganaxolone","moa":"GABA receptor modulator","target":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":10,"killed_fraction":0.01773,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":10,"lineage_tested":5,"tested_annotated":564,"enrichment":11.28,"p_one_sided_uncorrected":0.08586}},{"compound":"BRD-K29673530","name":"hypericin","moa":"tyrosine kinase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":5,"killed_fraction":0.00891,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":363,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":3,"tested_annotated":561,"enrichment":37.4,"p_one_sided_uncorrected":0.02655}},{"compound":"BRD-K34713073","name":"PD-123319","moa":"angiotensin antagonist","target":"AGTR2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":10,"killed_fraction":0.01779,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":24,"tested_annotated":562,"enrichment":4.68333,"p_one_sided_uncorrected":0.06382}},{"compound":"BRD-K35601925","name":"CS-917","moa":"fructose biphosphate inhibitor","target":"FBP1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":6,"killed_fraction":0.01079,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":12,"tested_annotated":556,"enrichment":15.44444,"p_one_sided_uncorrected":0.00611}},{"compound":"BRD-K37682401","name":"piromidic-acid","moa":"bacterial DNA gyrase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":8,"killed_fraction":0.01479,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":21,"tested_annotated":541,"enrichment":6.44048,"p_one_sided_uncorrected":0.03492}},{"compound":"BRD-K42679050","name":"Y-27152","moa":"potassium channel activator","target":"KCNJ8","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":6,"killed_fraction":0.01095,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":38,"tested_annotated":548,"enrichment":4.80702,"p_one_sided_uncorrected":0.05885}},{"compound":"BRD-K44771174","name":"ibutamoren","moa":"growth hormone secretagogue receptor agonist","target":"GHR, GHSR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":547,"lines_killed":7,"killed_fraction":0.0128,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":35,"tested_annotated":547,"enrichment":4.46531,"p_one_sided_uncorrected":0.06821}},{"compound":"BRD-K45163704","name":"midafotel","moa":"glutamate receptor antagonist","target":"GRIN2A, GRIN2B, GRIN2C, GRIN2D","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":532,"lines_killed":11,"killed_fraction":0.02068,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":19,"tested_annotated":532,"enrichment":7.63636,"p_one_sided_uncorrected":0.00533}},{"compound":"BRD-K51486818","name":"lazabemide","moa":"monoamine oxidase inhibitor","target":"MAOB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":8,"killed_fraction":0.01439,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":20,"tested_annotated":556,"enrichment":6.95,"p_one_sided_uncorrected":0.03025}},{"compound":"BRD-K53448858","name":"acadesine","moa":"AMPK activator","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":528,"lines_killed":6,"killed_fraction":0.01136,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":22,"tested_annotated":528,"enrichment":8.0,"p_one_sided_uncorrected":0.02248}},{"compound":"BRD-K65639003","name":"icariin","moa":"phosphodiesterase inhibitor","target":"PDE5A","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":8,"killed_fraction":0.01439,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":34,"tested_annotated":556,"enrichment":4.08824,"p_one_sided_uncorrected":0.08062}},{"compound":"BRD-K81458380","name":"CX-4945","moa":"casein kinase inhibitor","target":"CSNK2A1, CSNK2A2, DAPK3, HIPK3","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":378,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_replicated","separation":0.53227,"interval":[0.33725,0.76461],"hit_lines":5,"nonhit_lines":440},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":20,"tested_annotated":541,"enrichment":5.41,"p_one_sided_uncorrected":0.17226}},{"compound":"BRD-K88358234","name":"xaliproden","moa":"serotonin receptor agonist","target":"HTR1A","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":5,"killed_fraction":0.00891,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":5,"tested_annotated":561,"enrichment":22.44,"p_one_sided_uncorrected":0.04393}},{"compound":"BRD-K94534639","name":"LY2811376","moa":"beta-secretase inhibitor","target":"BACE1","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":42,"tested_annotated":564,"enrichment":5.37143,"p_one_sided_uncorrected":0.04691}},{"compound":"BRD-K95053546","name":"tempol","moa":"free radical scavenger","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":36,"killed_fraction":0.06383,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":11,"hits_annotated":36,"lineage_tested":101,"tested_annotated":564,"enrichment":1.70627,"p_one_sided_uncorrected":0.04014}},{"compound":"BRD-M89827113","name":"cromakalim","moa":"NA","target":"KCNJ8","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":8,"killed_fraction":0.0146,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":219,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":9,"tested_annotated":548,"enrichment":7.61111,"p_one_sided_uncorrected":0.12483}},{"compound":"BRD-A45107007","name":"salubrinal","moa":"eukaryotic translation initiation factor inhibitor","target":"EIF2S1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":9,"tested_annotated":556,"enrichment":12.35556,"p_one_sided_uncorrected":0.07863}},{"compound":"BRD-A70407468","name":"PSB-36","moa":"adenosine receptor antagonist","target":"ADORA1, ADORA2A, ADORA2B, ADORA3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":7,"killed_fraction":0.01259,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":25,"tested_annotated":556,"enrichment":3.17714,"p_one_sided_uncorrected":0.27663}},{"compound":"BRD-A71033472","name":"fendiline","moa":"calcium channel blocker","target":"HTR2B","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":558,"lines_killed":6,"killed_fraction":0.01075,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":384,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bile_duct","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":7,"tested_annotated":558,"enrichment":13.28571,"p_one_sided_uncorrected":0.07327}},{"compound":"BRD-A75769826","name":"SDM25N","moa":"opioid receptor antagonist","target":"OPRD1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":35,"tested_annotated":554,"enrichment":6.33143,"p_one_sided_uncorrected":0.0344}},{"compound":"BRD-A78588743","name":"editol","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":6,"killed_fraction":0.01064,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":24,"tested_annotated":564,"enrichment":7.83333,"p_one_sided_uncorrected":0.02347}},{"compound":"BRD-K02988401","name":"UNC0737","moa":"histone lysine methyltransferase inhibitor","target":"EHMT1, EHMT2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":13,"killed_fraction":0.02407,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":4,"hits_annotated":13,"lineage_tested":43,"tested_annotated":540,"enrichment":3.86404,"p_one_sided_uncorrected":0.01472}},{"compound":"BRD-K03739921","name":"hypoxanthine","moa":"PARP inhibitor","target":"PNP","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":40,"tested_annotated":556,"enrichment":5.56,"p_one_sided_uncorrected":0.04396}},{"compound":"BRD-K08223200","name":"WAY-200070","moa":"estrogen receptor agonist","target":"ERBB2, ERBB3, ERBB4, ESR2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":21,"tested_annotated":554,"enrichment":10.55238,"p_one_sided_uncorrected":0.01279}},{"compound":"BRD-K08996725","name":"zolantidine","moa":"histamine receptor antagonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":5,"killed_fraction":0.00894,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":244,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":6.36886,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":4,"tested_annotated":559,"enrichment":27.95,"p_one_sided_uncorrected":0.03539}},{"compound":"BRD-K15519488","name":"CS-110266","moa":"dopamine receptor agonist","target":"SLC6A3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":5,"killed_fraction":0.00891,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":417,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":21,"tested_annotated":561,"enrichment":5.34286,"p_one_sided_uncorrected":0.17424}},{"compound":"BRD-K21452876","name":"chlorazanil","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":36,"tested_annotated":541,"enrichment":4.29365,"p_one_sided_uncorrected":0.0732}},{"compound":"BRD-K26168087","name":"magnolol","moa":"PPAR receptor agonist","target":"GABRA1, PPARG","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":15,"killed_fraction":0.02698,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":15,"lineage_tested":34,"tested_annotated":556,"enrichment":3.27059,"p_one_sided_uncorrected":0.05735}},{"compound":"BRD-K30977212","name":"PIK-293","moa":"PI3K inhibitor","target":"PIK3CA, PIK3CB, PIK3CD, PIK3CG","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":563,"lines_killed":6,"killed_fraction":0.01066,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":42,"tested_annotated":563,"enrichment":4.46825,"p_one_sided_uncorrected":0.06729}},{"compound":"BRD-K42756753","name":"epiandrosterone","moa":"steroid","target":"G6PD","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":405,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":23,"tested_annotated":541,"enrichment":4.70435,"p_one_sided_uncorrected":0.19591}},{"compound":"BRD-K51770398","name":"JNJ-17203212","moa":"TRPV antagonist","target":"TRPV1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":7,"killed_fraction":0.01264,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":35,"tested_annotated":554,"enrichment":4.52245,"p_one_sided_uncorrected":0.06667}},{"compound":"BRD-K58685305","name":"emodin","moa":"11-beta hydroxysteroid dehydrogenase inhibitor","target":"CSNK2A1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":12,"killed_fraction":0.02162,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":12,"lineage_tested":34,"tested_annotated":555,"enrichment":4.08088,"p_one_sided_uncorrected":0.03162}},{"compound":"BRD-K60130390","name":"UNC0642","moa":"histone lysine methyltransferase inhibitor","target":"EHMT1, EHMT2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":5,"killed_fraction":0.00926,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":19,"tested_annotated":540,"enrichment":5.68421,"p_one_sided_uncorrected":0.16454}},{"compound":"BRD-K62537556","name":"4-IBP","moa":"sigma receptor agonist","target":"SIGMAR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":35,"tested_annotated":554,"enrichment":3.16571,"p_one_sided_uncorrected":0.2793}},{"compound":"BRD-K68997413","name":"PF-3845","moa":"FAAH inhibitor","target":"FAAH","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":5,"killed_fraction":0.00893,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":2,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":34,"tested_annotated":560,"enrichment":6.58824,"p_one_sided_uncorrected":0.0319}},{"compound":"BRD-K70821460","name":"4-methylhistamine","moa":"histamine receptor agonist","target":"HRH4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":5,"tested_annotated":556,"enrichment":22.24,"p_one_sided_uncorrected":0.04432}},{"compound":"BRD-K73789395","name":"ZM-336372","moa":"RAF inhibitor","target":"BRAF, LCK, MAPK14, RAF1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":12,"killed_fraction":0.02166,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":35,"tested_annotated":554,"enrichment":2.6381,"p_one_sided_uncorrected":0.17199}},{"compound":"BRD-K74236984","name":"UNC0321","moa":"histone lysine methyltransferase inhibitor","target":"EHMT2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":8,"killed_fraction":0.01481,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_replicated","separation":0.48871,"interval":[0.34993,0.63941],"hit_lines":8,"nonhit_lines":465},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":3,"tested_annotated":540,"enrichment":22.5,"p_one_sided_uncorrected":0.04387}},{"compound":"BRD-K79905821","name":"gabazine","moa":"GABA receptor antagonist","target":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRG2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":3,"hits_annotated":5,"lineage_tested":99,"tested_annotated":554,"enrichment":3.35758,"p_one_sided_uncorrected":0.04211}},{"compound":"BRD-K85479953","name":"STF-62247","moa":"autophagy inducer","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":18,"killed_fraction":0.03237,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":4,"hits_annotated":18,"lineage_tested":38,"tested_annotated":556,"enrichment":3.25146,"p_one_sided_uncorrected":0.02837}},{"compound":"BRD-K87535339","name":"5-Amino-3-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.53,"lines_tested":552,"lines_killed":7,"killed_fraction":0.01268,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":40,"tested_annotated":552,"enrichment":3.94286,"p_one_sided_uncorrected":0.08528}},{"compound":"BRD-K89306950","name":"ML130","moa":"NOD1 inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":38,"tested_annotated":564,"enrichment":5.93684,"p_one_sided_uncorrected":0.03887}},{"compound":"BRD-K89665618","name":"1-deoxymannojirimycin","moa":"alpha mannosidase inhibitor","target":"MAN2A1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":9,"tested_annotated":554,"enrichment":12.31111,"p_one_sided_uncorrected":0.07891}},{"compound":"BRD-M02075109","name":"chromanol-(+/-)","moa":"potassium channel blocker","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"primary_only","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":13,"killed_fraction":0.02338,"class":"selective"},"secondary":{"status":"not_retested"},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":2,"hits_annotated":13,"lineage_tested":19,"tested_annotated":556,"enrichment":4.50202,"p_one_sided_uncorrected":0.06897}},{"compound":"BRD-K97010173","name":"deferasirox","moa":"chelating agent","target":"CYP3A4","disease_area":"hematology","indication":"transfusional hemosiderosis, thalassemia, iron overload","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":563,"lines_killed":7,"killed_fraction":0.01243,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.77506,"interval":[0.45822,0.95307],"hit_lines":5,"nonhit_lines":441,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":2.4794,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":42,"tested_annotated":563,"enrichment":3.82993,"p_one_sided_uncorrected":0.08981}},{"compound":"BRD-A72711497","name":"lasalocid","moa":"bacterial permeability inducer","target":"NA","disease_area":"infectious disease","indication":"coccidiosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":35,"killed_fraction":0.06228,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74723,"interval":[0.66167,0.82242],"hit_lines":27,"nonhit_lines":434,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":27,"median_ic50_uM":1.63916,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":5,"hits_annotated":35,"lineage_tested":19,"tested_annotated":562,"enrichment":4.22556,"p_one_sided_uncorrected":0.00432}},{"compound":"BRD-K28537285","name":"chidamide","moa":"HDAC inhibitor","target":"HDAC10, HDAC3","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.49997,"lines_tested":541,"lines_killed":12,"killed_fraction":0.02218,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74554,"interval":[0.63834,0.84403],"hit_lines":11,"nonhit_lines":433,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":0.97958,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":12,"lineage_tested":5,"tested_annotated":541,"enrichment":9.01667,"p_one_sided_uncorrected":0.10647}},{"compound":"BRD-K72723676","name":"benzethonium","moa":"sodium channel blocker","target":"SCN10A","disease_area":"infectious disease","indication":"first-aid antiseptic","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":258,"killed_fraction":0.46154,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7454,"interval":[0.69621,0.79233],"hit_lines":176,"nonhit_lines":204,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":176,"median_ic50_uM":0.81431,"hit_lines_ic50_at_most_1uM":113}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":38,"hits_annotated":258,"lineage_tested":43,"tested_annotated":559,"enrichment":1.91473,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K51471001","name":"demecarium","moa":"acetylcholinesterase inhibitor","target":"ACHE, BCHE","disease_area":"ophthalmology","indication":"intraocular pressure, glaucoma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":15,"killed_fraction":0.02698,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74503,"interval":[0.56204,0.93949],"hit_lines":9,"nonhit_lines":414,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":4.76675,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":15,"lineage_tested":40,"tested_annotated":556,"enrichment":2.78,"p_one_sided_uncorrected":0.08575}},{"compound":"BRD-K55696337","name":"topotecan","moa":"topoisomerase inhibitor","target":"TOP1, TOP1MT","disease_area":"oncology","indication":"small cell lung cancer, cervical cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.50002,"lines_tested":541,"lines_killed":235,"killed_fraction":0.43438,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74439,"interval":[0.6985,0.78362],"hit_lines":210,"nonhit_lines":249,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":210,"median_ic50_uM":0.03133,"hit_lines_ic50_at_most_1uM":209}},"independent":{"status":"not_replicated","separation":0.64252,"interval":[0.59285,0.69275],"hit_lines":207,"nonhit_lines":266},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":14,"hits_annotated":235,"lineage_tested":20,"tested_annotated":541,"enrichment":1.61149,"p_one_sided_uncorrected":0.01358}},{"compound":"BRD-K13044802","name":"ciclopirox","moa":"membrane integrity inhibitor","target":"ATP1A1","disease_area":"infectious disease","indication":"onychomycosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":155,"killed_fraction":0.27482,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73894,"interval":[0.6912,0.78446],"hit_lines":132,"nonhit_lines":328,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":122,"median_ic50_uM":1.535,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_replicated","separation":0.57122,"interval":[0.50775,0.62936],"hit_lines":133,"nonhit_lines":355},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":155,"lineage_tested":23,"tested_annotated":564,"enrichment":2.53128,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K07265709","name":"dexrazoxane","moa":"chelating agent, topoisomerase inhibitor","target":"TOP2A, TOP2B","disease_area":"cardiology","indication":"cardiomyopathy","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.61,"lines_tested":530,"lines_killed":115,"killed_fraction":0.21698,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73882,"interval":[0.68559,0.7881],"hit_lines":82,"nonhit_lines":288,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":82,"median_ic50_uM":1.62599,"hit_lines_ic50_at_most_1uM":19}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":13,"hits_annotated":115,"lineage_tested":22,"tested_annotated":530,"enrichment":2.72332,"p_one_sided_uncorrected":0.00011}},{"compound":"BRD-K11630072","name":"carmofur","moa":"thymidylate synthase inhibitor","target":"TYMS","disease_area":"oncology","indication":"breast cancer, colorectal cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":136,"killed_fraction":0.2566,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73569,"interval":[0.67825,0.7886],"hit_lines":120,"nonhit_lines":293,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":57,"median_ic50_uM":1.80116,"hit_lines_ic50_at_most_1uM":17}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":10,"hits_annotated":136,"lineage_tested":22,"tested_annotated":530,"enrichment":1.77139,"p_one_sided_uncorrected":0.03199}},{"compound":"BRD-K29905972","name":"axitinib","moa":"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"CSF1, FLT1, FLT4, KDR, PLK4","disease_area":"oncology","indication":"renal cell carcinoma (RCC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":80,"killed_fraction":0.14388,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7295,"interval":[0.66733,0.79425],"hit_lines":65,"nonhit_lines":364,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":26,"median_ic50_uM":1.76871,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"replicated","separation":0.75149,"interval":[0.69505,0.80619],"hit_lines":70,"nonhit_lines":402},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":8,"hits_annotated":80,"lineage_tested":23,"tested_annotated":556,"enrichment":2.41739,"p_one_sided_uncorrected":0.01028}},{"compound":"BRD-A31095847","name":"mozavaptan","moa":"vasopressin receptor antagonist","target":"AVPR1A, AVPR1B, AVPR2","disease_area":"endocrinology","indication":"hyponatremia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":9,"killed_fraction":0.01619,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72247,"interval":[0.61119,0.83549],"hit_lines":9,"nonhit_lines":442,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":2.31526,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":24,"tested_annotated":556,"enrichment":7.72222,"p_one_sided_uncorrected":0.00502}},{"compound":"BRD-K47079459","name":"cetrimonium","moa":"NA","target":"NA","disease_area":"dermatology","indication":"cosmetic","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":189,"killed_fraction":0.34489,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71914,"interval":[0.67468,0.76006],"hit_lines":170,"nonhit_lines":295,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":164,"median_ic50_uM":1.80638,"hit_lines_ic50_at_most_1uM":29}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":17,"hits_annotated":189,"lineage_tested":27,"tested_annotated":548,"enrichment":1.82559,"p_one_sided_uncorrected":0.00185}},{"compound":"BRD-K13646352","name":"midostaurin","moa":"FLT3 inhibitor, KIT inhibitor, PKC inhibitor","target":"FLT3, PRKCG","disease_area":"hematologic malignancy","indication":"acute myeloid leukemia (AML)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":212,"killed_fraction":0.38129,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7156,"interval":[0.6677,0.75796],"hit_lines":188,"nonhit_lines":276,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":187,"median_ic50_uM":0.38479,"hit_lines_ic50_at_most_1uM":181}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":25,"hits_annotated":212,"lineage_tested":41,"tested_annotated":556,"enrichment":1.59917,"p_one_sided_uncorrected":0.00177}},{"compound":"BRD-K58049875","name":"thiostrepton","moa":"FOXM1 inhibitor, protein synthesis inhibitor","target":"FOXM1","disease_area":"obstetrics/gynecology","indication":"mastitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":176,"killed_fraction":0.31429,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71368,"interval":[0.66319,0.76166],"hit_lines":115,"nonhit_lines":286,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":111,"median_ic50_uM":1.38711,"hit_lines_ic50_at_most_1uM":33}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":14,"hits_annotated":176,"lineage_tested":24,"tested_annotated":560,"enrichment":1.85606,"p_one_sided_uncorrected":0.00489}},{"compound":"BRD-K77685957","name":"dequalinium","moa":"PKC inhibitor","target":"KCNN1, KCNN3","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":165,"killed_fraction":0.30109,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71272,"interval":[0.65989,0.75826],"hit_lines":138,"nonhit_lines":318,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":120,"median_ic50_uM":1.37484,"hit_lines_ic50_at_most_1uM":41}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":19,"hits_annotated":165,"lineage_tested":38,"tested_annotated":548,"enrichment":1.66061,"p_one_sided_uncorrected":0.00612}},{"compound":"BRD-K29254801","name":"thiram","moa":"NA","target":"JAK2","disease_area":"ophthalmology","indication":"contact dermatitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":238,"killed_fraction":0.42576,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71074,"interval":[0.66387,0.76403],"hit_lines":176,"nonhit_lines":244,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":176,"median_ic50_uM":0.13815,"hit_lines_ic50_at_most_1uM":167}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":14,"hits_annotated":238,"lineage_tested":21,"tested_annotated":559,"enrichment":1.56583,"p_one_sided_uncorrected":0.02058}},{"compound":"BRD-K84937637","name":"sirolimus","moa":"mTOR inhibitor","target":"FGF2, FKBP1A, MTOR","disease_area":"transplant, pulmonary","indication":"organ rejection, lymphangioleiomyomatosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":94,"killed_fraction":0.17736,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70697,"interval":[0.64218,0.77256],"hit_lines":69,"nonhit_lines":342,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":69,"median_ic50_uM":0.01187,"hit_lines_ic50_at_most_1uM":63}},"independent":{"status":"not_replicated","separation":0.64629,"interval":[0.58506,0.70956],"hit_lines":78,"nonhit_lines":375},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":10,"hits_annotated":94,"lineage_tested":35,"tested_annotated":530,"enrichment":1.61094,"p_one_sided_uncorrected":0.07116}},{"compound":"BRD-K32744045","name":"disulfiram","moa":"aldehyde dehydrogenase inhibitor, DNA methyltransferase inhibitor, TRPV agonist","target":"ALDH2, DBH","disease_area":"neurology/psychiatry","indication":"abstinence from alcohol","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":76,"killed_fraction":0.13523,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70165,"interval":[0.6392,0.75662],"hit_lines":63,"nonhit_lines":402,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":63,"median_ic50_uM":0.44161,"hit_lines_ic50_at_most_1uM":60}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":11,"hits_annotated":76,"lineage_tested":43,"tested_annotated":562,"enrichment":1.89168,"p_one_sided_uncorrected":0.02034}},{"compound":"BRD-K59632282","name":"quinidine","moa":"sodium channel blocker","target":"KCNA5, KCNA7, KCNH1, KCNH2, KCNH5, KCNK1, KCNK6, SCN5A, SLC29A4","disease_area":"infectious disease, cardiology","indication":"malaria, atrial fibrillation (AF), ventricular arrhythmias","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":7,"killed_fraction":0.01241,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69039,"interval":[0.46165,0.86682],"hit_lines":4,"nonhit_lines":411,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":27,"tested_annotated":564,"enrichment":5.96825,"p_one_sided_uncorrected":0.03997}},{"compound":"BRD-K89839824","name":"raltitrexed","moa":"thymidylate synthase inhibitor","target":"FPGS, TYMS","disease_area":"oncology","indication":"mesothelioma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":18,"killed_fraction":0.03237,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6861,"interval":[0.52692,0.83611],"hit_lines":17,"nonhit_lines":452,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":0.03743,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":24,"tested_annotated":556,"enrichment":3.86111,"p_one_sided_uncorrected":0.03765}},{"compound":"BRD-A03932035","name":"methscopolamine","moa":"acetylcholine receptor antagonist","target":"CHRM1, CHRM2, CHRM3","disease_area":"gastroenterology","indication":"peptic ulcer disease (PUD)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":9,"killed_fraction":0.01664,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68454,"interval":[0.4844,0.88658],"hit_lines":6,"nonhit_lines":401,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":4.15787,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":9,"lineage_tested":40,"tested_annotated":541,"enrichment":3.00556,"p_one_sided_uncorrected":0.13795}},{"compound":"BRD-K89714990","name":"tepoxalin","moa":"cyclooxygenase inhibitor, lipoxygenase inhibitor","target":"ALOX5","disease_area":"rheumatology, orthopedics","indication":"rheumatoid arthritis, hip dysplasia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":5,"killed_fraction":0.00893,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68243,"interval":[0.39502,0.95339],"hit_lines":5,"nonhit_lines":444,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":1.23598,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":19,"tested_annotated":560,"enrichment":5.89474,"p_one_sided_uncorrected":0.15905}},{"compound":"BRD-K77987382","name":"mebendazole","moa":"tubulin polymerization inhibitor","target":"TUBA1A, TUBB, TUBB4B","disease_area":"infectious disease","indication":"pinworm, whipworm, hookworm, ascariasis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":217,"killed_fraction":0.38475,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68094,"interval":[0.62238,0.73339],"hit_lines":145,"nonhit_lines":193,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":140,"median_ic50_uM":1.37017,"hit_lines_ic50_at_most_1uM":37}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":217,"lineage_tested":23,"tested_annotated":564,"enrichment":1.92106,"p_one_sided_uncorrected":0.00047}},{"compound":"BRD-K03406345","name":"azacitidine","moa":"DNA methyltransferase inhibitor","target":"DNMT1, DNMT3A","disease_area":"hematologic malignancy, hematology","indication":"myelodysplastic diseases (MDS), anemia, chronic myelomonocytic leukemia (CMMoL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":20,"killed_fraction":0.03578,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67644,"interval":[0.49824,0.84365],"hit_lines":14,"nonhit_lines":419,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.34469,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_replicated","separation":0.54611,"interval":[0.40442,0.69042],"hit_lines":16,"nonhit_lines":450},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":3,"hits_annotated":20,"lineage_tested":24,"tested_annotated":559,"enrichment":3.49375,"p_one_sided_uncorrected":0.04901}},{"compound":"BRD-A48300215","name":"ajmaline","moa":"sodium channel blocker","target":"SCN5A","disease_area":"cardiology","indication":"Wolff-Parkinson-White Syndrome (WPW)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":13,"killed_fraction":0.02372,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67399,"interval":[0.541,0.78538],"hit_lines":10,"nonhit_lines":396,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":5.19492,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":11,"tested_annotated":548,"enrichment":11.4965,"p_one_sided_uncorrected":0.00155}},{"compound":"BRD-A58193911","name":"oxyphencyclimine","moa":"cholinergic receptor antagonist","target":"CHRM1, CHRM2, CHRM3","disease_area":"gastroenterology","indication":"peptic ulcer disease (PUD)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":252,"killed_fraction":0.4658,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66823,"interval":[0.61723,0.71583],"hit_lines":218,"nonhit_lines":218,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":200,"median_ic50_uM":0.71137,"hit_lines_ic50_at_most_1uM":128}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":17,"hits_annotated":252,"lineage_tested":26,"tested_annotated":541,"enrichment":1.40369,"p_one_sided_uncorrected":0.03832}},{"compound":"BRD-K78126613","name":"menadione","moa":"mitochondrial DNA polymerase inhibitor, phosphatase inhibitor","target":"AOX1, BGLAP, F10, F2, F7, F9, GGCX, NQO1, NQO2, PROC, PROS1, PROZ, VKORC1, VKORC1L1","disease_area":"gastroenterology, neurology/psychiatry, dermatology, rheumatology","indication":"ulcerative colitis, diarrhea, headache, varicose veins, rheumatoid arthritis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":30,"killed_fraction":0.05319,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66752,"interval":[0.54807,0.78473],"hit_lines":25,"nonhit_lines":404,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":2.73075,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":30,"lineage_tested":43,"tested_annotated":564,"enrichment":3.49767,"p_one_sided_uncorrected":0.00098}},{"compound":"BRD-K32007074","name":"enocitabine","moa":"DNA synthesis inhibitor","target":"CMPK1, RRM1, TYMS","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":3.16,"lines_tested":541,"lines_killed":10,"killed_fraction":0.01848,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66667,"interval":[0.40216,0.90691],"hit_lines":7,"nonhit_lines":399,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":2.34875,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":23,"tested_annotated":541,"enrichment":4.70435,"p_one_sided_uncorrected":0.06324}},{"compound":"BRD-K35520305","name":"dacarbazine","moa":"DNA alkylating agent","target":"PGD, POLA2","disease_area":"oncology, hematologic malignancy","indication":"melanoma, Hodgkin's lymphoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66415,"interval":[0.37903,0.98992],"hit_lines":3,"nonhit_lines":397,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_replicated","separation":0.63263,"interval":[0.33472,0.89343],"hit_lines":5,"nonhit_lines":472},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":3,"tested_annotated":554,"enrichment":36.93333,"p_one_sided_uncorrected":0.02688}},{"compound":"BRD-K29458283","name":"chlorambucil","moa":"DNA inhibitor","target":"NA","disease_area":"hematologic malignancy","indication":"chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":16,"killed_fraction":0.02878,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66413,"interval":[0.52741,0.804],"hit_lines":13,"nonhit_lines":415,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.97849,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_replicated","separation":0.65135,"interval":[0.47947,0.79937],"hit_lines":12,"nonhit_lines":457},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":3,"hits_annotated":16,"lineage_tested":23,"tested_annotated":556,"enrichment":4.53261,"p_one_sided_uncorrected":0.02437}},{"compound":"BRD-A55424491","name":"methotrexate","moa":"dihydrofolate reductase inhibitor","target":"DHFR","disease_area":"oncology, hematologic malignancy, dermatology, rheumatology","indication":"gestational choriocarcinoma, hydatidiform mole, acute lymphoblastic leukemia (ALL), psoriasis, rheumatoid arthritis","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":239,"killed_fraction":0.43219,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66302,"interval":[0.61062,0.71574],"hit_lines":167,"nonhit_lines":171,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":157,"median_ic50_uM":0.29458,"hit_lines_ic50_at_most_1uM":155}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":14,"hits_annotated":239,"lineage_tested":21,"tested_annotated":553,"enrichment":1.54254,"p_one_sided_uncorrected":0.02382}},{"compound":"BRD-K36788280","name":"ribociclib","moa":"CDK inhibitor","target":"CDK4, CDK6","disease_area":"oncology","indication":"breast cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":260,"killed_fraction":0.46763,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66235,"interval":[0.61313,0.71026],"hit_lines":201,"nonhit_lines":228,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":2.39244,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":29,"hits_annotated":260,"lineage_tested":43,"tested_annotated":556,"enrichment":1.44222,"p_one_sided_uncorrected":0.00368}},{"compound":"BRD-K04568635","name":"octenidine","moa":"membrane integrity inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":244,"killed_fraction":0.44043,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65606,"interval":[0.59358,0.71697],"hit_lines":123,"nonhit_lines":174,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":121,"median_ic50_uM":1.49682,"hit_lines_ic50_at_most_1uM":49}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":33,"hits_annotated":244,"lineage_tested":43,"tested_annotated":554,"enrichment":1.74247,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K81418486","name":"vorinostat","moa":"HDAC inhibitor","target":"HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9","disease_area":"hematologic malignancy","indication":"cutaneous T-cell lymphoma (CTCL)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":254,"killed_fraction":0.47925,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65592,"interval":[0.60357,0.70275],"hit_lines":209,"nonhit_lines":197,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":128,"median_ic50_uM":2.05251,"hit_lines_ic50_at_most_1uM":40}},"independent":{"status":"not_replicated","separation":0.6334,"interval":[0.58276,0.68356],"hit_lines":214,"nonhit_lines":222},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":254,"lineage_tested":22,"tested_annotated":530,"enrichment":1.61238,"p_one_sided_uncorrected":0.0042}},{"compound":"BRD-K18574842","name":"nafcillin","moa":"bacterial cell wall synthesis inhibitor","target":"CYP1A2, CYP3A4, SLC22A6","disease_area":"infectious disease","indication":"gram-positive bacterial infections","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":13,"killed_fraction":0.02403,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.64822,"interval":[0.4416,0.82734],"hit_lines":8,"nonhit_lines":366,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":18110.19727,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":33,"tested_annotated":541,"enrichment":3.78322,"p_one_sided_uncorrected":0.03891}},{"compound":"BRD-K61443650","name":"thiomersal","moa":"other antibiotic","target":"OXCT1","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":215,"killed_fraction":0.38121,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6473,"interval":[0.60017,0.6978],"hit_lines":193,"nonhit_lines":268,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":191,"median_ic50_uM":3.18001,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":26,"hits_annotated":215,"lineage_tested":43,"tested_annotated":564,"enrichment":1.58615,"p_one_sided_uncorrected":0.00169}},{"compound":"BRD-K92428153","name":"mycophenolate-mofetil","moa":"dehydrogenase inhibitor, inositol monophosphatase inhibitor","target":"IMPDH1, IMPDH2","disease_area":"transplant","indication":"organ rejection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":118,"killed_fraction":0.20996,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.64511,"interval":[0.57552,0.71998],"hit_lines":70,"nonhit_lines":279,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":2.82577,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":8,"hits_annotated":118,"lineage_tested":20,"tested_annotated":562,"enrichment":1.90508,"p_one_sided_uncorrected":0.039}},{"compound":"BRD-A13133631","name":"fluorometholone","moa":"glucocorticoid receptor agonist","target":"NR3C1","disease_area":"ophthalmology","indication":"eye inflammation","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":10,"killed_fraction":0.01799,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.64446,"interval":[0.47862,0.77513],"hit_lines":8,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":1.02063,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":20,"tested_annotated":556,"enrichment":5.56,"p_one_sided_uncorrected":0.04655}},{"compound":"BRD-K66808046","name":"oxyquinoline","moa":"chelating agent","target":"METAP2","disease_area":"dermatology","indication":"cosmetic","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":84,"killed_fraction":0.15527,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.64017,"interval":[0.575,0.70193],"hit_lines":73,"nonhit_lines":370,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":63,"median_ic50_uM":6.01455,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":9,"hits_annotated":84,"lineage_tested":20,"tested_annotated":541,"enrichment":2.89821,"p_one_sided_uncorrected":0.00136}},{"compound":"BRD-K50853363","name":"dienogest","moa":"progesterone receptor agonist","target":"PGR","disease_area":"endocrinology, obstetrics/gynecology","indication":"contraceptive, endometriosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":198,"killed_fraction":0.3542,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63908,"interval":[0.58404,0.69065],"hit_lines":164,"nonhit_lines":288,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":111,"median_ic50_uM":3.10327,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":198,"lineage_tested":23,"tested_annotated":559,"enrichment":1.84124,"p_one_sided_uncorrected":0.00289}},{"compound":"BRD-K58148589","name":"betamethasone-dipropionate","moa":"anti-inflammatory agent","target":"NA","disease_area":"dermatology","indication":"corticosteroid-responsive dermatoses","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":6,"killed_fraction":0.01073,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63745,"interval":[0.35559,0.89497],"hit_lines":6,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":0.15282,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":27,"tested_annotated":559,"enrichment":6.90123,"p_one_sided_uncorrected":0.02991}},{"compound":"BRD-K18779551","name":"bifemelane","moa":"acetylcholine release enhancer","target":"MAOA, MAOB","disease_area":"ophthalmology, neurology/psychiatry","indication":"glaucoma, senile dementia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":563,"lines_killed":18,"killed_fraction":0.03197,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63646,"interval":[0.46968,0.76712],"hit_lines":14,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":4.72439,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":18,"lineage_tested":2,"tested_annotated":563,"enrichment":15.63889,"p_one_sided_uncorrected":0.06298}},{"compound":"BRD-K82181219","name":"pyritinol","moa":"NA","target":"NA","disease_area":"rheumatology, neurology/psychiatry","indication":"rheumatoid arthritis, senile dementia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":22,"killed_fraction":0.03929,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62582,"interval":[0.43277,0.81559],"hit_lines":9,"nonhit_lines":272,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":3,"hits_annotated":22,"lineage_tested":26,"tested_annotated":560,"enrichment":2.93706,"p_one_sided_uncorrected":0.07601}},{"compound":"BRD-K13387373","name":"thonzonium","moa":"ATPase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":74,"killed_fraction":0.13309,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62526,"interval":[0.55882,0.69169],"hit_lines":60,"nonhit_lines":380,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":60,"median_ic50_uM":1.5707,"hit_lines_ic50_at_most_1uM":10}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":8,"hits_annotated":74,"lineage_tested":27,"tested_annotated":556,"enrichment":2.22623,"p_one_sided_uncorrected":0.01812}},{"compound":"BRD-A11990600","name":"lorazepam","moa":"benzodiazepine receptor agonist","target":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, TSPO","disease_area":"neurology/psychiatry","indication":"status epilepticus","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":81,"killed_fraction":0.14972,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6191,"interval":[0.53916,0.68891],"hit_lines":65,"nonhit_lines":344,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":1.30535,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":10,"hits_annotated":81,"lineage_tested":39,"tested_annotated":541,"enrichment":1.71257,"p_one_sided_uncorrected":0.05049}},{"compound":"BRD-A57382968","name":"piroxicam","moa":"cyclooxygenase inhibitor","target":"PTGS1, PTGS2","disease_area":"rheumatology","indication":"osteoarthritis, rheumatoid arthritis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":10,"killed_fraction":0.01773,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61675,"interval":[0.31091,0.91478],"hit_lines":4,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":10,"lineage_tested":11,"tested_annotated":564,"enrichment":5.12727,"p_one_sided_uncorrected":0.1801}},{"compound":"BRD-K84091759","name":"candesartan","moa":"angiotensin receptor antagonist","target":"AGTR1","disease_area":"cardiology","indication":"hypertension, congestive heart failure","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":532,"lines_killed":14,"killed_fraction":0.02632,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61303,"interval":[0.45441,0.78294],"hit_lines":10,"nonhit_lines":353,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":4,"hits_annotated":14,"lineage_tested":40,"tested_annotated":532,"enrichment":3.8,"p_one_sided_uncorrected":0.01586}},{"compound":"BRD-K05524748","name":"dronedarone","moa":"adrenergic receptor antagonist","target":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, CACNA1C, CACNA1D, CACNA1F, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, KCNA5, KCNH2, KCNK2, SCN1A","disease_area":"cardiology","indication":"atrial fibrillation (AF)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":537,"lines_killed":14,"killed_fraction":0.02607,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6107,"interval":[0.45333,0.76123],"hit_lines":9,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":2.11517,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":14,"lineage_tested":4,"tested_annotated":537,"enrichment":9.58929,"p_one_sided_uncorrected":0.10055}},{"compound":"BRD-A00758722","name":"noretynodrel","moa":"progestogen hormone","target":"PGR","disease_area":"endocrinology","indication":"contraceptive","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":39,"killed_fraction":0.07209,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.60923,"interval":[0.48315,0.73598],"hit_lines":29,"nonhit_lines":373,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":23,"median_ic50_uM":3.17021,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":7,"hits_annotated":39,"lineage_tested":39,"tested_annotated":541,"enrichment":2.48981,"p_one_sided_uncorrected":0.01602}},{"compound":"BRD-K15409150","name":"penfluridol","moa":"T-type calcium channel blocker","target":"CACNA1G","disease_area":"neurology/psychiatry","indication":"schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":85,"killed_fraction":0.15712,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.60765,"interval":[0.53602,0.6763],"hit_lines":69,"nonhit_lines":375,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":69,"median_ic50_uM":0.64315,"hit_lines_ic50_at_most_1uM":55}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":7,"hits_annotated":85,"lineage_tested":22,"tested_annotated":541,"enrichment":2.02513,"p_one_sided_uncorrected":0.0425}},{"compound":"BRD-K13314656","name":"ebastine","moa":"histamine receptor antagonist","target":"CYP3A4, HRH1","disease_area":"allergy","indication":"allergic rhinitis, urticaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":546,"lines_killed":12,"killed_fraction":0.02198,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.60081,"interval":[0.40709,0.7917],"hit_lines":8,"nonhit_lines":434,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":4.35641,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":12,"lineage_tested":20,"tested_annotated":546,"enrichment":6.825,"p_one_sided_uncorrected":0.00751}},{"compound":"BRD-K12829205","name":"mechlorethamine","moa":"DNA inhibitor","target":"NA","disease_area":"hematologic malignancy, hematology, infectious disease, oncology","indication":"Hodgkin's lymphoma, chronic myeloid leukemia (CML), chronic lymphocytic leukemia (CLL), polycythemia vera, mycosis, bronchogenic carcinoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":184,"killed_fraction":0.34717,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6,"interval":[0.53991,0.65468],"hit_lines":135,"nonhit_lines":248,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":61,"median_ic50_uM":5.91622,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":13,"hits_annotated":184,"lineage_tested":22,"tested_annotated":530,"enrichment":1.70208,"p_one_sided_uncorrected":0.01485}},{"compound":"BRD-K51318897","name":"fenbendazole","moa":"tubulin polymerization inhibitor","target":"TUBB","disease_area":"infectious disease","indication":"gastrointestinal parasites, gastrointestinal roundworms","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":251,"killed_fraction":0.46396,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.59601,"interval":[0.53929,0.65022],"hit_lines":192,"nonhit_lines":214,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":190,"median_ic50_uM":0.88117,"hit_lines_ic50_at_most_1uM":116}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":15,"hits_annotated":251,"lineage_tested":22,"tested_annotated":541,"enrichment":1.46958,"p_one_sided_uncorrected":0.03019}},{"compound":"BRD-K62607865","name":"aztreonam","moa":"bacterial cell wall synthesis inhibitor","target":"NA","disease_area":"infectious disease","indication":"urinary tract infections, respiratory tract infections, bacterial septicemia, skin infections, intra-abdominal infections, gynecologic infections","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.62,"lines_tested":541,"lines_killed":12,"killed_fraction":0.02218,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.59136,"interval":[0.39678,0.77579],"hit_lines":11,"nonhit_lines":404,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.80369,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":22,"tested_annotated":541,"enrichment":4.09848,"p_one_sided_uncorrected":0.08142}},{"compound":"BRD-K11973162","name":"tipiracil","moa":"thymidine phosphorylase inhibitor","target":"TYMP","disease_area":"oncology","indication":"colorectal cancer","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":539,"lines_killed":63,"killed_fraction":0.11688,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5896,"interval":[0.5035,0.68229],"hit_lines":52,"nonhit_lines":393,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":51,"median_ic50_uM":1.59746,"hit_lines_ic50_at_most_1uM":9}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":5,"hits_annotated":63,"lineage_tested":22,"tested_annotated":539,"enrichment":1.94444,"p_one_sided_uncorrected":0.10142}},{"compound":"BRD-K45252063","name":"clofibrate","moa":"PPAR receptor agonist","target":"LPL, PPARA","disease_area":"endocrinology, cardiology","indication":"hyperlipidemia, cholesterol","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":8,"killed_fraction":0.01444,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58598,"interval":[0.25359,0.88158],"hit_lines":4,"nonhit_lines":346,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":43,"tested_annotated":554,"enrichment":3.22093,"p_one_sided_uncorrected":0.12221}},{"compound":"BRD-K71075609","name":"dorzolamide","moa":"carbonic anhydrase inhibitor","target":"CA1, CA12, CA14, CA2, CA4, CA7","disease_area":"ophthalmology","indication":"intraocular pressure, glaucoma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":19,"killed_fraction":0.03381,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58417,"interval":[0.44268,0.70438],"hit_lines":14,"nonhit_lines":342,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":6.28596,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":3,"hits_annotated":19,"lineage_tested":23,"tested_annotated":562,"enrichment":3.85812,"p_one_sided_uncorrected":0.0378}},{"compound":"BRD-K08525451","name":"sarafloxacin","moa":"bacterial DNA gyrase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":68,"killed_fraction":0.1223,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56949,"interval":[0.4843,0.64488],"hit_lines":49,"nonhit_lines":327,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":8.53418,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":8,"hits_annotated":68,"lineage_tested":34,"tested_annotated":556,"enrichment":1.92388,"p_one_sided_uncorrected":0.04352}},{"compound":"BRD-K33127281","name":"adapalene","moa":"retinoid receptor agonist","target":"RARA, RARB, RARG, RXRA, RXRB, RXRG","disease_area":"dermatology","indication":"acne vulgaris (AV)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":22,"killed_fraction":0.03957,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56348,"interval":[0.41346,0.70775],"hit_lines":17,"nonhit_lines":411,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":4,"hits_annotated":22,"lineage_tested":35,"tested_annotated":556,"enrichment":2.88831,"p_one_sided_uncorrected":0.0427}},{"compound":"BRD-K10961822","name":"latanoprost","moa":"prostanoid receptor agonist","target":"PTGFR","disease_area":"ophthalmology","indication":"ocular hypertension, glaucoma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":171,"killed_fraction":0.31608,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55756,"interval":[0.50577,0.60768],"hit_lines":140,"nonhit_lines":255,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":39,"median_ic50_uM":5.36527,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":14,"hits_annotated":171,"lineage_tested":26,"tested_annotated":541,"enrichment":1.70355,"p_one_sided_uncorrected":0.0133}},{"compound":"BRD-K13249881","name":"piperazine","moa":"benzodiazepine receptor agonist","target":"GABRB3","disease_area":"infectious disease","indication":"gastrointestinal roundworms","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":17,"killed_fraction":0.03142,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55619,"interval":[0.42255,0.70381],"hit_lines":11,"nonhit_lines":381,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":17,"lineage_tested":22,"tested_annotated":541,"enrichment":4.33957,"p_one_sided_uncorrected":0.02743}},{"compound":"BRD-A06426627","name":"diclazuril","moa":"antiprotozoal agent","target":"NA","disease_area":"infectious disease","indication":"equine protozoal myeloencephalitis (EPM)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":12,"killed_fraction":0.02158,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55456,"interval":[0.37035,0.72162],"hit_lines":8,"nonhit_lines":433,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":1.24587,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":27,"tested_annotated":556,"enrichment":3.4321,"p_one_sided_uncorrected":0.11104}},{"compound":"BRD-A36267905","name":"buphenine","moa":"adrenergic receptor agonist","target":"ADRB2","disease_area":"rheumatology","indication":"Raynaud's disease","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":236,"killed_fraction":0.43623,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54887,"interval":[0.49439,0.60312],"hit_lines":177,"nonhit_lines":214,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":34,"median_ic50_uM":2.35226,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":14,"hits_annotated":236,"lineage_tested":23,"tested_annotated":541,"enrichment":1.39536,"p_one_sided_uncorrected":0.06872}},{"compound":"BRD-A70083328","name":"secnidazole","moa":"acetylcholinesterase inhibitor, microtubule inhibitor","target":"NA","disease_area":"infectious disease","indication":"protozoan infection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":270,"killed_fraction":0.48649,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54876,"interval":[0.49429,0.60472],"hit_lines":222,"nonhit_lines":222,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":122,"median_ic50_uM":4.73429,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":27,"hits_annotated":270,"lineage_tested":43,"tested_annotated":555,"enrichment":1.2907,"p_one_sided_uncorrected":0.03782}},{"compound":"BRD-K19615002","name":"creatine","moa":"NA","target":"CKB, CKM, CKMT1A, CKMT2, GAMT, SLC6A8","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":25,"killed_fraction":0.04472,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53974,"interval":[0.37694,0.67921],"hit_lines":17,"nonhit_lines":376,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":4,"hits_annotated":25,"lineage_tested":23,"tested_annotated":559,"enrichment":3.8887,"p_one_sided_uncorrected":0.01551}},{"compound":"BRD-K49111258","name":"prazosin","moa":"adrenergic receptor antagonist","target":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, KCNH2, KCNH6, KCNH7","disease_area":"cardiology","indication":"hypertension","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":557,"lines_killed":18,"killed_fraction":0.03232,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53939,"interval":[0.42035,0.67259],"hit_lines":13,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":6.69813,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":33,"tested_annotated":557,"enrichment":2.81313,"p_one_sided_uncorrected":0.08403}},{"compound":"BRD-K55044200","name":"amoxicillin","moa":"penicillin binding protein inhibitor","target":"CYP2C19, SLC15A1, SLC15A2, SLC22A6","disease_area":"infectious disease, gastroenterology","indication":"skin infections, duodenal ulcer disease, gonorrhea, ear infections, throat infections, genitourinary tract infections, respiratory tract infections","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":101,"killed_fraction":0.17908,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5328,"interval":[0.46781,0.61149],"hit_lines":75,"nonhit_lines":348,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":7.87451,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":5,"hits_annotated":101,"lineage_tested":9,"tested_annotated":564,"enrichment":3.10231,"p_one_sided_uncorrected":0.01156}},{"compound":"BRD-A60197193","name":"amisulpride","moa":"dopamine receptor antagonist","target":"DRD2, DRD3, HTR2A, HTR7","disease_area":"neurology/psychiatry","indication":"psychosis, bipolar disorder, schizophrenia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":88,"killed_fraction":0.15827,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5326,"interval":[0.45454,0.61153],"hit_lines":62,"nonhit_lines":335,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":6.66864,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":10,"hits_annotated":88,"lineage_tested":38,"tested_annotated":556,"enrichment":1.66268,"p_one_sided_uncorrected":0.06032}},{"compound":"BRD-K67977190","name":"eprosartan","moa":"angiotensin receptor antagonist","target":"AGTR1","disease_area":"cardiology","indication":"hypertension","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":91,"killed_fraction":0.16606,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53184,"interval":[0.46604,0.59325],"hit_lines":69,"nonhit_lines":353,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":1.5123,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":6,"hits_annotated":91,"lineage_tested":11,"tested_annotated":548,"enrichment":3.28472,"p_one_sided_uncorrected":0.0041}},{"compound":"BRD-A59303141","name":"quinethazone","moa":"thiazide diuretic","target":"CA1, CA2, SLC12A1, SLC12A2, SLC12A3","disease_area":"cardiology","indication":"hypertension","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":6,"killed_fraction":0.01109,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53177,"interval":[0.16081,0.92272],"hit_lines":4,"nonhit_lines":362,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":6.19652,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":8,"tested_annotated":541,"enrichment":11.27083,"p_one_sided_uncorrected":0.08589}},{"compound":"BRD-K96253961","name":"metaraminol","moa":"adrenergic receptor agonist","target":"ADRA1A","disease_area":"cardiology","indication":"hypotension","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":53,"killed_fraction":0.09464,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53058,"interval":[0.4419,0.6129],"hit_lines":42,"nonhit_lines":422,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":41,"median_ic50_uM":0.99882,"hit_lines_ic50_at_most_1uM":21}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":6,"hits_annotated":53,"lineage_tested":34,"tested_annotated":560,"enrichment":1.86459,"p_one_sided_uncorrected":0.09049}},{"compound":"BRD-K08586861","name":"ramatroban","moa":"prostanoid receptor antagonist","target":"PTGDR2, TBXA2R","disease_area":"cardiology, pulmonary","indication":"coronary artery disease (CAD), asthma","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":540,"lines_killed":5,"killed_fraction":0.00926,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52832,"interval":[0.27542,0.69826],"hit_lines":3,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":5.18264,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":23,"tested_annotated":540,"enrichment":9.3913,"p_one_sided_uncorrected":0.01607}},{"compound":"BRD-K02594908","name":"sulfanilamide","moa":"carbonic anhydrase inhibitor","target":"CYP2C19, CYP2C9, CYP2D6, CYP2E1, CYP3A4","disease_area":"infectious disease","indication":"vulvovaginal candidiasis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":22,"killed_fraction":0.04015,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52813,"interval":[0.36816,0.67264],"hit_lines":16,"nonhit_lines":391,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":3.17682,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":22,"lineage_tested":23,"tested_annotated":548,"enrichment":2.16601,"p_one_sided_uncorrected":0.23444}},{"compound":"BRD-K97440753","name":"dihydroergocristine","moa":"adrenergic receptor antagonist, prolactin inhibitor","target":"ADRA1A, ADRB1, DRD1, DRD2, DRD3, DRD4, DRD5, HTR1A, HTR2A, HTR3A, HTR4, HTR5A, HTR6, HTR7","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52767,"interval":[0.17663,0.88229],"hit_lines":5,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":9,"tested_annotated":564,"enrichment":25.06667,"p_one_sided_uncorrected":0.00221}},{"compound":"BRD-K87349682","name":"norepinephrine","moa":"adrenergic receptor agonist","target":"ADRA1A, ADRA1B, ADRA1D, ADRA2A, ADRA2B, ADRA2C, ADRB1, ADRB2, ADRB3, PAH, SLC18A1, SLC18A2","disease_area":"cardiology, allergy, neurology/psychiatry","indication":"hypertension, urticaria, headache, seasonal affective disorder","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.36,"lines_tested":530,"lines_killed":90,"killed_fraction":0.16981,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52702,"interval":[0.46842,0.58819],"hit_lines":73,"nonhit_lines":360,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":2.78695,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":3,"hits_annotated":90,"lineage_tested":5,"tested_annotated":530,"enrichment":3.53333,"p_one_sided_uncorrected":0.0366}},{"compound":"BRD-K39252998","name":"atipamezole","moa":"adrenergic receptor antagonist","target":"NA","disease_area":"neurology/psychiatry","indication":"reverse sedative","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":8,"killed_fraction":0.0146,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52683,"interval":[0.38068,0.66059],"hit_lines":6,"nonhit_lines":441,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":4.69726,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":24,"tested_annotated":548,"enrichment":5.70833,"p_one_sided_uncorrected":0.04383}},{"compound":"BRD-K31812033","name":"levobunolol","moa":"adrenergic receptor antagonist","target":"ADRB1, ADRB2, ADRB3","disease_area":"ophthalmology","indication":"glaucoma, ocular hypertension","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":58,"killed_fraction":0.10469,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52211,"interval":[0.4403,0.60865],"hit_lines":49,"nonhit_lines":377,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":26,"median_ic50_uM":6.14543,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":6,"hits_annotated":58,"lineage_tested":21,"tested_annotated":554,"enrichment":2.72906,"p_one_sided_uncorrected":0.01581}},{"compound":"BRD-K97746869","name":"chlorpropamide","moa":"ATP channel blocker","target":"ABCC8, KCNJ10, KCNJ11","disease_area":"endocrinology","indication":"diabetes mellitus","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":41,"killed_fraction":0.0727,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5217,"interval":[0.40598,0.63866],"hit_lines":28,"nonhit_lines":400,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":4.0532,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":3,"hits_annotated":41,"lineage_tested":9,"tested_annotated":564,"enrichment":4.58537,"p_one_sided_uncorrected":0.02206}},{"compound":"BRD-K25837718","name":"josamycin","moa":"bacterial 50S ribosomal subunit inhibitor","target":"NA","disease_area":"pulmonary","indication":"bronchitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":19,"killed_fraction":0.03467,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52143,"interval":[0.37425,0.67638],"hit_lines":14,"nonhit_lines":410,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":11.50604,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":19,"lineage_tested":20,"tested_annotated":548,"enrichment":2.88421,"p_one_sided_uncorrected":0.14929}},{"compound":"BRD-K76037122","name":"guanidine","moa":"HSP inhibitor","target":"ALDH2, DLG4, GAMT, RNASE1","disease_area":"neurology/psychiatry","indication":"Lambert-Eaton myasthenic syndrome (LEMS)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":6,"killed_fraction":0.01064,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52007,"interval":[0.1535,0.88822],"hit_lines":4,"nonhit_lines":436,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":20,"tested_annotated":564,"enrichment":9.4,"p_one_sided_uncorrected":0.01647}},{"compound":"BRD-K52020312","name":"metronidazole","moa":"DNA inhibitor","target":"CYP2C9, CYP3A4","disease_area":"dermatology","indication":"rosacea","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":9,"killed_fraction":0.01596,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51815,"interval":[0.29416,0.72669],"hit_lines":7,"nonhit_lines":421,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":3.69513,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":2,"hits_annotated":9,"lineage_tested":19,"tested_annotated":564,"enrichment":6.59649,"p_one_sided_uncorrected":0.03364}},{"compound":"BRD-K45033733","name":"famciclovir","moa":"DNA polymerase inhibitor","target":"NA","disease_area":"dental, infectious disease","indication":"cold sore, genitial herpes, shingles","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":67,"killed_fraction":0.12094,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51157,"interval":[0.42355,0.59689],"hit_lines":47,"nonhit_lines":297,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":9,"hits_annotated":67,"lineage_tested":41,"tested_annotated":554,"enrichment":1.81507,"p_one_sided_uncorrected":0.04632}},{"compound":"BRD-K10784860","name":"temocapril","moa":"angiotensin converting enzyme inhibitor","target":"ACE","disease_area":"cardiology, nephrology","indication":"hypertension, congestive heart failure, diabetic nephropathy, coronary artery disease (CAD)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":50,"killed_fraction":0.08993,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51117,"interval":[0.41899,0.59789],"hit_lines":33,"nonhit_lines":388,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":5.26936,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":50,"lineage_tested":12,"tested_annotated":556,"enrichment":2.78,"p_one_sided_uncorrected":0.08435}},{"compound":"BRD-K47114202","name":"chlorogenic-acid","moa":"antioxidant","target":"SLC37A4","disease_area":"neurology/psychiatry, pulmonary, allergy","indication":"headache, chest congestion, allergic rhinitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.58,"lines_tested":524,"lines_killed":24,"killed_fraction":0.0458,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50951,"interval":[0.36973,0.63717],"hit_lines":20,"nonhit_lines":405,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":2.07193,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":4,"hits_annotated":24,"lineage_tested":33,"tested_annotated":524,"enrichment":2.64646,"p_one_sided_uncorrected":0.05648}},{"compound":"BRD-K95785345","name":"thiamine","moa":"vitamin B","target":"SLC19A2, SLC19A3, TPK1","disease_area":"metabolism","indication":"thiamine deficiency","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":12,"killed_fraction":0.02128,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50629,"interval":[0.33871,0.67123],"hit_lines":9,"nonhit_lines":406,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":25.83279,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":23,"tested_annotated":564,"enrichment":4.08696,"p_one_sided_uncorrected":0.08191}},{"compound":"BRD-A17846016","name":"trolox","moa":"antioxidant","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":67,"killed_fraction":0.11986,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50174,"interval":[0.4114,0.58365],"hit_lines":51,"nonhit_lines":338,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":11.07814,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":6,"hits_annotated":67,"lineage_tested":27,"tested_annotated":559,"enrichment":1.85406,"p_one_sided_uncorrected":0.09095}},{"compound":"BRD-K60369935","name":"ribavirin","moa":"antiviral","target":"ADK, ENPP1, IMPDH1, IMPDH2, NT5C2","disease_area":"infectious disease","indication":"hepatitis C","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":563,"lines_killed":10,"killed_fraction":0.01776,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.49861,"interval":[0.27413,0.69567],"hit_lines":7,"nonhit_lines":410,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":12,"tested_annotated":563,"enrichment":9.38333,"p_one_sided_uncorrected":0.01706}},{"compound":"BRD-K11433652","name":"aspirin","moa":"cyclooxygenase inhibitor","target":"AKR1C1, ASIC3, EDNRA, HSPA5, IKBKB, NFKB1, NFKB2, NFKBIA, PRKAA1, PRKAA2, PRKAB1, PRKAB2, PRKAG1, PRKAG2, PRKAG3, PTGS1, PTGS2, RPS6KA3, TP53","disease_area":"neurology/psychiatry, endocrinology, dental","indication":"headache, fever, toothache, muscle pain","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":19,"killed_fraction":0.03512,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.49442,"interval":[0.3451,0.63705],"hit_lines":15,"nonhit_lines":382,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":3.02786,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":5,"hits_annotated":19,"lineage_tested":39,"tested_annotated":541,"enrichment":3.65047,"p_one_sided_uncorrected":0.00826}},{"compound":"BRD-A51964809","name":"halofantrine","moa":"antimalarial agent","target":"KCNH2, KCNN4","disease_area":"infectious disease","indication":"malaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":46,"killed_fraction":0.08156,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4936,"interval":[0.39348,0.59277],"hit_lines":40,"nonhit_lines":418,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":3.97136,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":15,"hits_annotated":46,"lineage_tested":101,"tested_annotated":564,"enrichment":1.82092,"p_one_sided_uncorrected":0.00878}},{"compound":"BRD-A50157456","name":"terbutaline","moa":"adrenergic receptor agonist","target":"ADRB2","disease_area":"pulmonary","indication":"bronchospasm, bronchitis, emphysema","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":65,"killed_fraction":0.11754,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.49184,"interval":[0.40841,0.57795],"hit_lines":51,"nonhit_lines":369,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":1.10073,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":5,"hits_annotated":65,"lineage_tested":19,"tested_annotated":553,"enrichment":2.23887,"p_one_sided_uncorrected":0.06036}},{"compound":"BRD-K92657060","name":"zaleplon","moa":"benzodiazepine receptor agonist","target":"GABRA1, GABRB1, GABRG2, TSPO","disease_area":"neurology/psychiatry","indication":"insomnia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":89,"killed_fraction":0.1578,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48975,"interval":[0.42317,0.55728],"hit_lines":78,"nonhit_lines":374,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":32,"median_ic50_uM":5.06459,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":12,"hits_annotated":89,"lineage_tested":37,"tested_annotated":564,"enrichment":2.05527,"p_one_sided_uncorrected":0.0071}},{"compound":"BRD-K26619122","name":"thiocolchicoside","moa":"GABA receptor antagonist","target":"GABRA1, GABRB2, GABRG2, GLRA1, GLRB","disease_area":"neurology/psychiatry","indication":"muscle relaxant","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":5,"killed_fraction":0.00912,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48404,"interval":[0.2375,0.77012],"hit_lines":4,"nonhit_lines":423,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":9,"tested_annotated":548,"enrichment":12.17778,"p_one_sided_uncorrected":0.07975}},{"compound":"BRD-K11267252","name":"alectinib","moa":"ALK tyrosine kinase receptor inhibitor","target":"ALK, MET","disease_area":"oncology","indication":"non-small cell lung cancer (NSCLC)","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":8,"killed_fraction":0.01479,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48346,"interval":[0.24701,0.72682],"hit_lines":7,"nonhit_lines":393,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":4.82431,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":4,"hits_annotated":8,"lineage_tested":95,"tested_annotated":541,"enrichment":2.84737,"p_one_sided_uncorrected":0.03543}},{"compound":"BRD-A01643550","name":"prednisolone-acetate","moa":"glucocorticoid receptor agonist","target":"NR3C1","disease_area":"ophthalmology, dermatology, infectious disease","indication":"conjunctivitis, rosacea, punctate keratitis, shingles, iritis, cyclitis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":47,"killed_fraction":0.08688,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48317,"interval":[0.40193,0.57589],"hit_lines":37,"nonhit_lines":342,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":5,"hits_annotated":47,"lineage_tested":22,"tested_annotated":541,"enrichment":2.61605,"p_one_sided_uncorrected":0.03401}},{"compound":"BRD-K23779958","name":"dichlorvos","moa":"acetylcholinesterase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":26,"killed_fraction":0.04906,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.47958,"interval":[0.35073,0.60958],"hit_lines":20,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":0.95654,"hit_lines_ic50_at_most_1uM":11}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":26,"lineage_tested":22,"tested_annotated":530,"enrichment":2.77972,"p_one_sided_uncorrected":0.08669}},{"compound":"BRD-K74141488","name":"naftifine","moa":"fungal squalene epoxidase inhibitor","target":"SQLE","disease_area":"infectious disease","indication":"tinea pedis, tinea cruris, tinea corporis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":16,"killed_fraction":0.02837,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.47315,"interval":[0.34077,0.60394],"hit_lines":13,"nonhit_lines":444,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":6.30886,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":2,"hits_annotated":16,"lineage_tested":5,"tested_annotated":564,"enrichment":14.1,"p_one_sided_uncorrected":0.00719}},{"compound":"BRD-K42938903","name":"acetophenazine","moa":"dopamine receptor antagonist","target":"DRD1, DRD2","disease_area":"neurology/psychiatry","indication":"psychosis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":37,"killed_fraction":0.06839,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4694,"interval":[0.36206,0.59731],"hit_lines":28,"nonhit_lines":356,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":5.93773,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":4,"hits_annotated":37,"lineage_tested":23,"tested_annotated":541,"enrichment":2.54289,"p_one_sided_uncorrected":0.06405}},{"compound":"BRD-K28542495","name":"benzydamine","moa":"prostanoid receptor antagonist","target":"NA","disease_area":"dental, otolaryngology","indication":"mouth inflammation, throat inflammation","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":53,"killed_fraction":0.09672,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.46671,"interval":[0.38353,0.55822],"hit_lines":44,"nonhit_lines":383,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":5.46812,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":7,"hits_annotated":53,"lineage_tested":33,"tested_annotated":548,"enrichment":2.19325,"p_one_sided_uncorrected":0.03103}},{"compound":"BRD-K81916719","name":"triclabendazole","moa":"microtubule inhibitor","target":"DNMT1","disease_area":"infectious disease","indication":"tapeworm","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":16,"killed_fraction":0.02957,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.46594,"interval":[0.28289,0.65454],"hit_lines":14,"nonhit_lines":432,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":0.98433,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":16,"lineage_tested":22,"tested_annotated":541,"enrichment":3.07386,"p_one_sided_uncorrected":0.13424}},{"compound":"BRD-K65781196","name":"avanafil","moa":"phosphodiesterase inhibitor","target":"PDE5A","disease_area":"urology","indication":"erectile dysfunction","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":119,"killed_fraction":0.2148,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.46583,"interval":[0.4078,0.52387],"hit_lines":94,"nonhit_lines":306,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":6.62093,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":10,"hits_annotated":119,"lineage_tested":23,"tested_annotated":554,"enrichment":2.02411,"p_one_sided_uncorrected":0.013}},{"compound":"BRD-A91452556","name":"estradiol-cypionate","moa":"estrogen receptor agonist","target":"ESR1","disease_area":"endocrinology","indication":"hypoestrogenism, menopause","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":9,"killed_fraction":0.01607,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.46514,"interval":[0.23596,0.74123],"hit_lines":7,"nonhit_lines":418,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":9,"lineage_tested":23,"tested_annotated":560,"enrichment":5.41063,"p_one_sided_uncorrected":0.04876}},{"compound":"BRD-A08187463","name":"racecadotril","moa":"enkephalinase inhibitor","target":"MME","disease_area":"gastroenterology","indication":"diarrhea","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.46368,"interval":[0.24486,0.75412],"hit_lines":5,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":0.46594,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":24,"tested_annotated":541,"enrichment":9.01667,"p_one_sided_uncorrected":0.0174}},{"compound":"BRD-A03623303","name":"metoprolol","moa":"adrenergic receptor antagonist","target":"ADRB1, ADRB2","disease_area":"cardiology","indication":"hypertension, angina pectoris, myocardial infarction","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":14,"killed_fraction":0.02504,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4607,"interval":[0.27557,0.63797],"hit_lines":10,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":14,"lineage_tested":12,"tested_annotated":559,"enrichment":6.65476,"p_one_sided_uncorrected":0.03333}},{"compound":"BRD-K95773607","name":"darifenacin","moa":"acetylcholine receptor antagonist","target":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5","disease_area":"urology","indication":"urinary incontinence","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":26,"killed_fraction":0.0461,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.45843,"interval":[0.34384,0.5835],"hit_lines":21,"nonhit_lines":437,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":3.28671,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":26,"lineage_tested":5,"tested_annotated":564,"enrichment":4.33846,"p_one_sided_uncorrected":0.21088}},{"compound":"BRD-K46862739","name":"metyrapone","moa":"cytochrome P450 inhibitor","target":"CYP11B1","disease_area":"nephrology","indication":"adrenal diagnostic agent","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.49995,"lines_tested":540,"lines_killed":5,"killed_fraction":0.00926,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.44772,"interval":[0.13564,0.77713],"hit_lines":4,"nonhit_lines":416,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":19,"tested_annotated":540,"enrichment":5.68421,"p_one_sided_uncorrected":0.16454}},{"compound":"BRD-A54275602","name":"lanoconazole","moa":"sterol demethylase inhibitor","target":"NA","disease_area":"infectious disease","indication":"fungal infection","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":42,"killed_fraction":0.07581,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.44745,"interval":[0.33959,0.55387],"hit_lines":23,"nonhit_lines":302,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":3.34072,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":3,"hits_annotated":42,"lineage_tested":11,"tested_annotated":554,"enrichment":3.5974,"p_one_sided_uncorrected":0.04361}},{"compound":"BRD-A16700644","name":"isoxsuprine","moa":"adrenergic receptor agonist","target":"ADRB2","disease_area":"rheumatology, cardiology","indication":"Raynaud's disease, arteriosclerosis, Buerger's disease","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":24,"killed_fraction":0.04293,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.44415,"interval":[0.23645,0.68351],"hit_lines":8,"nonhit_lines":282,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":4.21363,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":2,"hits_annotated":24,"lineage_tested":8,"tested_annotated":559,"enrichment":5.82292,"p_one_sided_uncorrected":0.04226}},{"compound":"BRD-K60237333","name":"niacin","moa":"NAD precursor, vitamin B","target":"DGAT2, HCAR1, HCAR2, HCAR3, NNMT, QPRT","disease_area":"endocrinology","indication":"hypertriglyceridemia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":5,"killed_fraction":0.00887,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.44315,"interval":[0.25472,0.74237],"hit_lines":4,"nonhit_lines":343,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":4.15771,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":3,"tested_annotated":564,"enrichment":37.6,"p_one_sided_uncorrected":0.02641}},{"compound":"BRD-K50388907","name":"fenofibrate","moa":"PPAR receptor agonist","target":"MMP25, PPARA","disease_area":"endocrinology","indication":"hypercholesterolemia, hypertriglyceridemia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":15,"killed_fraction":0.02773,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.44189,"interval":[0.27572,0.60458],"hit_lines":12,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":3,"hits_annotated":15,"lineage_tested":26,"tested_annotated":541,"enrichment":4.16154,"p_one_sided_uncorrected":0.03054}},{"compound":"BRD-K63736853","name":"acipimox","moa":"cholesterol inhibitor","target":"HCAR2","disease_area":"endocrinology","indication":"hyperlipidemia","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":7,"killed_fraction":0.01277,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.43827,"interval":[0.23796,0.60985],"hit_lines":5,"nonhit_lines":439,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":4.9442,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":33,"tested_annotated":548,"enrichment":4.74459,"p_one_sided_uncorrected":0.06109}},{"compound":"BRD-K27184429","name":"levocetirizine","moa":"histamine receptor antagonist","target":"HRH1","disease_area":"allergy","indication":"allergic rhinitis, urticaria","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":13,"killed_fraction":0.02305,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.42477,"interval":[0.27804,0.57307],"hit_lines":10,"nonhit_lines":440,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":5.09058,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":21,"tested_annotated":564,"enrichment":6.1978,"p_one_sided_uncorrected":0.01003}},{"compound":"BRD-A03216249","name":"mepivacaine","moa":"potassium channel blocker, sodium channel blocker","target":"SCN10A","disease_area":"neurology/psychiatry","indication":"local anesthetic","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":557,"lines_killed":11,"killed_fraction":0.01975,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.42184,"interval":[0.17131,0.68311],"hit_lines":5,"nonhit_lines":412,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":36,"tested_annotated":557,"enrichment":4.2197,"p_one_sided_uncorrected":0.0286}},{"compound":"BRD-K36234266","name":"carmustine","moa":"DNA alkylating agent, DNA inhibitor","target":"GSR","disease_area":"hematologic malignancy, oncology","indication":"non-Hodgkin lymphoma (NHL), Hodgkin's lymphoma, multiple myeloma, glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma","phase":"Launched","phase_group":"launched","oncology":true,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":9,"killed_fraction":0.01698,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.41201,"interval":[0.18131,0.65032],"hit_lines":7,"nonhit_lines":414,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":5.78529,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":35,"tested_annotated":530,"enrichment":5.04762,"p_one_sided_uncorrected":0.01687}},{"compound":"BRD-A84174393","name":"meloxicam","moa":"cyclooxygenase inhibitor","target":"PTGS1, PTGS2","disease_area":"rheumatology","indication":"osteoarthritis, rheumatoid arthritis","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":6,"killed_fraction":0.01109,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.40937,"interval":[0.13561,0.70351],"hit_lines":4,"nonhit_lines":411,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":3.72124,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":11,"tested_annotated":541,"enrichment":8.19697,"p_one_sided_uncorrected":0.11647}},{"compound":"BRD-K85146014","name":"foscarnet","moa":"DNA polymerase inhibitor","target":"NA","disease_area":"infectious disease","indication":"cytomegalovirus retinitis, acquired immunodeficiency syndrome (AIDS), virus herpes simplex (HSV)","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":528,"lines_killed":5,"killed_fraction":0.00947,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.39458,"interval":[0.12015,0.65651],"hit_lines":5,"nonhit_lines":406,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":3.48735,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":19,"tested_annotated":528,"enrichment":5.55789,"p_one_sided_uncorrected":0.16802}},{"compound":"BRD-K73425385","name":"bekanamycin","moa":"bacterial 30S ribosomal subunit inhibitor","target":"NA","disease_area":"infectious disease","indication":"gram-negative bacterial infections","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.38196,"interval":[0.23204,0.57647],"hit_lines":3,"nonhit_lines":425,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":22,"tested_annotated":541,"enrichment":4.91818,"p_one_sided_uncorrected":0.18809}},{"compound":"BRD-K35189033","name":"levonorgestrel","moa":"estrogen receptor agonist, glucocorticoid receptor antagonist, progesterone receptor agonist, progesterone receptor antagonist","target":"AR, ESR1, PGR, SRD5A1","disease_area":"endocrinology","indication":"contraceptive","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":5,"killed_fraction":0.0089,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.37618,"interval":[0.07141,0.67312],"hit_lines":5,"nonhit_lines":319,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":2.16904,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":41,"tested_annotated":562,"enrichment":5.48293,"p_one_sided_uncorrected":0.04513}},{"compound":"BRD-A83937277","name":"mephenytoin","moa":"hydantoin antiepileptic","target":"SCN10A, SCN11A, SCN1A, SCN2A, SCN3A, SCN4A, SCN5A, SCN7A, SCN8A, SCN9A","disease_area":"neurology/psychiatry","indication":"seizures","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.35262,"interval":[0.29612,0.40636],"hit_lines":3,"nonhit_lines":363,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":26,"tested_annotated":541,"enrichment":4.16154,"p_one_sided_uncorrected":0.21902}},{"compound":"BRD-K82846253","name":"repaglinide","moa":"insulin secretagogue","target":"ABCC8, KCNJ11, PPARG","disease_area":"endocrinology","indication":"diabetes mellitus","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":535,"lines_killed":15,"killed_fraction":0.02804,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.35115,"interval":[0.18351,0.52485],"hit_lines":12,"nonhit_lines":393,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":4,"hits_annotated":15,"lineage_tested":40,"tested_annotated":535,"enrichment":3.56667,"p_one_sided_uncorrected":0.02007}},{"compound":"BRD-A50311610","name":"meclizine","moa":"constitutive androstane receptor (CAR) agonist","target":"HRH1, NR1I3","disease_area":"gastroenterology, neurology/psychiatry","indication":"nausea, vomiting, motion sickness","phase":"Launched","phase_group":"launched","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":5,"killed_fraction":0.00912,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.19637,"interval":[0.05446,0.43812],"hit_lines":3,"nonhit_lines":404,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":5.79494,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":23,"tested_annotated":548,"enrichment":9.53043,"p_one_sided_uncorrected":0.01562}},{"compound":"BRD-K25244359","name":"apatinib","moa":"RET tyrosine kinase inhibitor","target":"CSK, KDR, KIT, RET","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.68,"lines_tested":530,"lines_killed":5,"killed_fraction":0.00943,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.81884,"interval":[0.49514,0.99275],"hit_lines":4,"nonhit_lines":414,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":0.48484,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":12,"tested_annotated":530,"enrichment":8.83333,"p_one_sided_uncorrected":0.10859}},{"compound":"BRD-K67844266","name":"pevonedistat","moa":"nedd activating enzyme inhibitor","target":"NAE1, UBA3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":281,"killed_fraction":0.5,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74951,"interval":[0.70159,0.79403],"hit_lines":230,"nonhit_lines":203,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":146,"median_ic50_uM":0.22293,"hit_lines_ic50_at_most_1uM":124}},"independent":{"status":"not_replicated","separation":0.63844,"interval":[0.58778,0.68532],"hit_lines":239,"nonhit_lines":238},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":281,"lineage_tested":23,"tested_annotated":562,"enrichment":1.3913,"p_one_sided_uncorrected":0.04324}},{"compound":"BRD-K20463415","name":"LY2606368","moa":"CHK inhibitor","target":"CHEK1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.49997,"lines_tested":541,"lines_killed":196,"killed_fraction":0.36229,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74866,"interval":[0.70248,0.79541],"hit_lines":179,"nonhit_lines":277,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":179,"median_ic50_uM":0.01473,"hit_lines_ic50_at_most_1uM":179}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":7,"hits_annotated":196,"lineage_tested":10,"tested_annotated":541,"enrichment":1.93214,"p_one_sided_uncorrected":0.03041}},{"compound":"BRD-K43236057","name":"polydatin","moa":"ICAM1 expression inhibitor","target":"ICAM1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.6,"lines_tested":530,"lines_killed":109,"killed_fraction":0.20566,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7477,"interval":[0.69656,0.80092],"hit_lines":96,"nonhit_lines":331,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":96,"median_ic50_uM":1.90824,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":9,"hits_annotated":109,"lineage_tested":22,"tested_annotated":530,"enrichment":1.98916,"p_one_sided_uncorrected":0.02147}},{"compound":"BRD-K28352084","name":"CH5132799","moa":"PI3K inhibitor","target":"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":60,"killed_fraction":0.10714,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74196,"interval":[0.68039,0.80556],"hit_lines":46,"nonhit_lines":354,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":46,"median_ic50_uM":0.86074,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":8,"hits_annotated":60,"lineage_tested":24,"tested_annotated":560,"enrichment":3.11111,"p_one_sided_uncorrected":0.00203}},{"compound":"BRD-K56032964","name":"AP26113","moa":"ALK tyrosine kinase receptor inhibitor","target":"ALK, EGFR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":80,"killed_fraction":0.14235,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73849,"interval":[0.6841,0.79634],"hit_lines":63,"nonhit_lines":385,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":61,"median_ic50_uM":1.98126,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":9,"hits_annotated":80,"lineage_tested":27,"tested_annotated":562,"enrichment":2.34167,"p_one_sided_uncorrected":0.00823}},{"compound":"BRD-K01029106","name":"picolinic-acid","moa":"chelating agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.52,"lines_tested":559,"lines_killed":6,"killed_fraction":0.01073,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73653,"interval":[0.40405,0.99008],"hit_lines":4,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":4,"hits_annotated":6,"lineage_tested":100,"tested_annotated":559,"enrichment":3.72667,"p_one_sided_uncorrected":0.01086}},{"compound":"BRD-K56301217","name":"ABT-737","moa":"BCL inhibitor","target":"BCL2, BCL2L1, BCL2L2","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":10,"killed_fraction":0.01773,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73571,"interval":[0.41815,0.95185],"hit_lines":5,"nonhit_lines":448,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":3.07423,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_replicated","separation":0.59142,"interval":[0.43602,0.77759],"hit_lines":6,"nonhit_lines":443},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":4,"hits_annotated":10,"lineage_tested":42,"tested_annotated":564,"enrichment":5.37143,"p_one_sided_uncorrected":0.00403}},{"compound":"BRD-K18157228","name":"fdcyd","moa":"DNA methyltransferase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":223,"killed_fraction":0.3968,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73054,"interval":[0.68312,0.77949],"hit_lines":155,"nonhit_lines":249,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":151,"median_ic50_uM":0.16372,"hit_lines_ic50_at_most_1uM":150}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":223,"lineage_tested":23,"tested_annotated":562,"enrichment":1.6436,"p_one_sided_uncorrected":0.01037}},{"compound":"BRD-K56334280","name":"amonafide","moa":"topoisomerase inhibitor","target":"TOP2A, TOP2B","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":72,"killed_fraction":0.12766,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72722,"interval":[0.65348,0.80184],"hit_lines":61,"nonhit_lines":397,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":46,"median_ic50_uM":2.1442,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":9,"hits_annotated":72,"lineage_tested":23,"tested_annotated":564,"enrichment":3.06522,"p_one_sided_uncorrected":0.00103}},{"compound":"BRD-K85402309","name":"dovitinib","moa":"EGFR inhibitor, FGFR inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"CSF1R, EGFR, FGFR1, FGFR2, FGFR3, FLT1, FLT3, FLT4, INSR, KDR, KIT, PDGFRA, PDGFRB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":56,"killed_fraction":0.09964,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72622,"interval":[0.64371,0.79265],"hit_lines":48,"nonhit_lines":389,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":0.70563,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":56,"lineage_tested":12,"tested_annotated":562,"enrichment":3.34524,"p_one_sided_uncorrected":0.0239}},{"compound":"BRD-K41278234","name":"CUDC-101","moa":"EGFR inhibitor","target":"EGFR, ERBB2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":217,"killed_fraction":0.39029,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72575,"interval":[0.64405,0.79803],"hit_lines":65,"nonhit_lines":115,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":63,"median_ic50_uM":0.78239,"hit_lines_ic50_at_most_1uM":38}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":14,"hits_annotated":217,"lineage_tested":20,"tested_annotated":556,"enrichment":1.79355,"p_one_sided_uncorrected":0.00432}},{"compound":"BRD-K08799216","name":"pelitinib","moa":"EGFR inhibitor","target":"EGFR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":67,"killed_fraction":0.12384,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72443,"interval":[0.65249,0.79793],"hit_lines":57,"nonhit_lines":335,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":40,"median_ic50_uM":0.39409,"hit_lines_ic50_at_most_1uM":28}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":10,"hits_annotated":67,"lineage_tested":26,"tested_annotated":541,"enrichment":3.10563,"p_one_sided_uncorrected":0.00046}},{"compound":"BRD-K63068307","name":"ZSTK-474","moa":"PI3K inhibitor","target":"PIK3CB, PIK3CD, PIK3CG","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":81,"killed_fraction":0.14568,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72404,"interval":[0.65261,0.79406],"hit_lines":63,"nonhit_lines":397,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":52,"median_ic50_uM":0.97099,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_replicated","separation":0.62505,"interval":[0.55247,0.69774],"hit_lines":68,"nonhit_lines":408},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":11,"hits_annotated":81,"lineage_tested":38,"tested_annotated":556,"enrichment":1.987,"p_one_sided_uncorrected":0.01358}},{"compound":"BRD-K01669786","name":"triapine","moa":"ribonucleotide reductase inhibitor","target":"RRM1, RRM2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":211,"killed_fraction":0.39811,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72392,"interval":[0.67391,0.77235],"hit_lines":178,"nonhit_lines":259,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":175,"median_ic50_uM":0.96326,"hit_lines_ic50_at_most_1uM":91}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":47,"hits_annotated":211,"lineage_tested":94,"tested_annotated":530,"enrichment":1.25592,"p_one_sided_uncorrected":0.01804}},{"compound":"BRD-K28822270","name":"resminostat","moa":"HDAC inhibitor","target":"HDAC1, HDAC3, HDAC6, HDAC8","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":226,"killed_fraction":0.40647,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72342,"interval":[0.68063,0.77143],"hit_lines":182,"nonhit_lines":243,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":147,"median_ic50_uM":0.97283,"hit_lines_ic50_at_most_1uM":77}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":15,"hits_annotated":226,"lineage_tested":23,"tested_annotated":556,"enrichment":1.60446,"p_one_sided_uncorrected":0.01342}},{"compound":"BRD-K28392481","name":"AZD4547","moa":"FGFR inhibitor","target":"FGFR1, FGFR2, FGFR3, FGFR4, IGF1R, KDR","disease_area":"NA","indication":"NA","phase":"Phase 2/Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":21,"killed_fraction":0.03784,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72331,"interval":[0.58485,0.85253],"hit_lines":13,"nonhit_lines":330,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":2.11711,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_replicated","separation":0.68596,"interval":[0.54806,0.82321],"hit_lines":17,"nonhit_lines":434},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":4,"hits_annotated":21,"lineage_tested":24,"tested_annotated":555,"enrichment":4.40476,"p_one_sided_uncorrected":0.00985}},{"compound":"BRD-K48988407","name":"cytochlor","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":13,"killed_fraction":0.02347,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72296,"interval":[0.52676,0.90138],"hit_lines":10,"nonhit_lines":453,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":1.04124,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":13,"lineage_tested":12,"tested_annotated":554,"enrichment":7.10256,"p_one_sided_uncorrected":0.02941}},{"compound":"BRD-K87782578","name":"AVL-292","moa":"Bruton's tyrosine kinase (BTK) inhibitor","target":"BTK, YES1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":8,"killed_fraction":0.01426,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72049,"interval":[0.31287,0.95806],"hit_lines":4,"nonhit_lines":432,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":2.28573,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":9,"tested_annotated":561,"enrichment":7.79167,"p_one_sided_uncorrected":0.12208}},{"compound":"BRD-K80700417","name":"SGI-1776","moa":"Pim kinase inhibitor","target":"FLT3, PIM1, PIM2, PIM3","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":12,"killed_fraction":0.02135,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71929,"interval":[0.61064,0.83549],"hit_lines":10,"nonhit_lines":420,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":2.77728,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":12,"tested_annotated":562,"enrichment":7.80556,"p_one_sided_uncorrected":0.02452}},{"compound":"BRD-K71164191","name":"KD-023","moa":"ACAT inhibitor","target":"ACACA, ACACB","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":6,"killed_fraction":0.01079,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7191,"interval":[0.4986,0.887],"hit_lines":5,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.33973,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":1,"hits_annotated":6,"lineage_tested":12,"tested_annotated":556,"enrichment":7.72222,"p_one_sided_uncorrected":0.12323}},{"compound":"BRD-K25340465","name":"OSI-930","moa":"KIT inhibitor, VEGFR inhibitor","target":"KDR, KIT","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.58,"lines_tested":530,"lines_killed":224,"killed_fraction":0.42264,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7173,"interval":[0.66464,0.76515],"hit_lines":185,"nonhit_lines":237,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":159,"median_ic50_uM":2.14,"hit_lines_ic50_at_most_1uM":31}},"independent":{"status":"not_replicated","separation":0.50754,"interval":[0.45221,0.56104],"hit_lines":156,"nonhit_lines":236},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":224,"lineage_tested":22,"tested_annotated":530,"enrichment":1.72078,"p_one_sided_uncorrected":0.00318}},{"compound":"BRD-K74057757","name":"indibulin","moa":"tubulin polymerization inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":243,"killed_fraction":0.43085,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71586,"interval":[0.66651,0.76073],"hit_lines":202,"nonhit_lines":260,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":202,"median_ic50_uM":0.19317,"hit_lines_ic50_at_most_1uM":202}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":243,"lineage_tested":23,"tested_annotated":564,"enrichment":1.6146,"p_one_sided_uncorrected":0.00824}},{"compound":"BRD-K99545815","name":"PF-562271","moa":"focal adhesion kinase inhibitor","target":"PTK2, PTK2B","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":128,"killed_fraction":0.22695,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71133,"interval":[0.66391,0.76277],"hit_lines":116,"nonhit_lines":348,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":112,"median_ic50_uM":1.99349,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":9,"hits_annotated":128,"lineage_tested":23,"tested_annotated":564,"enrichment":1.72418,"p_one_sided_uncorrected":0.05336}},{"compound":"BRD-K23228615","name":"GDC-0980","moa":"mTOR inhibitor, PI3K inhibitor","target":"FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":236,"killed_fraction":0.42599,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71022,"interval":[0.66435,0.759],"hit_lines":205,"nonhit_lines":241,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":149,"median_ic50_uM":1.01625,"hit_lines_ic50_at_most_1uM":72}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":17,"hits_annotated":236,"lineage_tested":27,"tested_annotated":554,"enrichment":1.47803,"p_one_sided_uncorrected":0.02359}},{"compound":"BRD-A39935389","name":"teroxirone","moa":"DNA inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":42,"killed_fraction":0.07487,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70951,"interval":[0.63503,0.78904],"hit_lines":37,"nonhit_lines":429,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":36,"median_ic50_uM":1.11269,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":5,"hits_annotated":42,"lineage_tested":22,"tested_annotated":561,"enrichment":3.03571,"p_one_sided_uncorrected":0.01872}},{"compound":"BRD-K18961567","name":"LY2801653","moa":"MET inhibitor","target":"MET","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":182,"killed_fraction":0.32734,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70787,"interval":[0.65503,0.75841],"hit_lines":149,"nonhit_lines":272,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":72,"median_ic50_uM":2.0179,"hit_lines_ic50_at_most_1uM":20}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":14,"hits_annotated":182,"lineage_tested":24,"tested_annotated":556,"enrichment":1.78205,"p_one_sided_uncorrected":0.00744}},{"compound":"BRD-K44408410","name":"2-methoxyestradiol","moa":"hypoxia inducible factor inhibitor","target":"COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":51,"killed_fraction":0.09043,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70583,"interval":[0.63679,0.78286],"hit_lines":39,"nonhit_lines":400,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":2.99683,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":7,"hits_annotated":51,"lineage_tested":23,"tested_annotated":564,"enrichment":3.36573,"p_one_sided_uncorrected":0.00259}},{"compound":"BRD-K82967180","name":"LY3023414","moa":"PI3K inhibitor, mTOR inhibitor","target":"MTOR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.50002,"lines_tested":541,"lines_killed":221,"killed_fraction":0.4085,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70143,"interval":[0.65526,0.75211],"hit_lines":196,"nonhit_lines":262,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":196,"median_ic50_uM":0.12139,"hit_lines_ic50_at_most_1uM":195}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":27,"hits_annotated":221,"lineage_tested":43,"tested_annotated":541,"enrichment":1.53709,"p_one_sided_uncorrected":0.0021}},{"compound":"BRD-K90497590","name":"AR-12","moa":"phosphoinositide dependent kinase inhibitor","target":"PDPK1","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":38,"killed_fraction":0.06835,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70105,"interval":[0.58309,0.80165],"hit_lines":28,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":0.7696,"hit_lines_ic50_at_most_1uM":17}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":4,"hits_annotated":38,"lineage_tested":24,"tested_annotated":556,"enrichment":2.4386,"p_one_sided_uncorrected":0.07312}},{"compound":"BRD-K65924316","name":"serdemetan","moa":"MDM inhibitor","target":"MDM2","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":138,"killed_fraction":0.2482,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69969,"interval":[0.63522,0.77127],"hit_lines":76,"nonhit_lines":227,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":74,"median_ic50_uM":1.41037,"hit_lines_ic50_at_most_1uM":30}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":14,"hits_annotated":138,"lineage_tested":23,"tested_annotated":556,"enrichment":2.45243,"p_one_sided_uncorrected":0.00019}},{"compound":"BRD-K47000838","name":"cytochalasin-b","moa":"microtubule inhibitor","target":"ACTB","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":1.04,"lines_tested":541,"lines_killed":24,"killed_fraction":0.04436,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69812,"interval":[0.61218,0.78123],"hit_lines":21,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":21,"median_ic50_uM":0.49657,"hit_lines_ic50_at_most_1uM":18}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":2,"hits_annotated":24,"lineage_tested":5,"tested_annotated":541,"enrichment":9.01667,"p_one_sided_uncorrected":0.0174}},{"compound":"BRD-K42495768","name":"tasisulam","moa":"apoptosis stimulant","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":8,"killed_fraction":0.0146,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6978,"interval":[0.51535,0.85801],"hit_lines":7,"nonhit_lines":416,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":4.21977,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":8,"tested_annotated":548,"enrichment":17.125,"p_one_sided_uncorrected":0.005}},{"compound":"BRD-K82928847","name":"ACY-1215","moa":"HDAC inhibitor","target":"HDAC1, HDAC2, HDAC3, HDAC6, HDAC8","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":14,"killed_fraction":0.02555,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69633,"interval":[0.51558,0.84276],"hit_lines":12,"nonhit_lines":441,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":2.34816,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":14,"lineage_tested":24,"tested_annotated":548,"enrichment":4.89286,"p_one_sided_uncorrected":0.01958}},{"compound":"BRD-K43187018","name":"GDC-0349","moa":"Pim kinase inhibitor","target":"PIK3CA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.52,"lines_tested":530,"lines_killed":190,"killed_fraction":0.35849,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69605,"interval":[0.6483,0.74798],"hit_lines":163,"nonhit_lines":276,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":163,"median_ic50_uM":0.30355,"hit_lines_ic50_at_most_1uM":163}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":11,"hits_annotated":190,"lineage_tested":21,"tested_annotated":530,"enrichment":1.46115,"p_one_sided_uncorrected":0.08576}},{"compound":"BRD-K62374002","name":"PI3K-IN-2","moa":"PI3K inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.49997,"lines_tested":541,"lines_killed":48,"killed_fraction":0.08872,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69476,"interval":[0.61862,0.76636],"hit_lines":46,"nonhit_lines":415,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":46,"median_ic50_uM":0.29893,"hit_lines_ic50_at_most_1uM":45}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":8,"hits_annotated":48,"lineage_tested":27,"tested_annotated":541,"enrichment":3.33951,"p_one_sided_uncorrected":0.00129}},{"compound":"BRD-K99749624","name":"linifanib","moa":"PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"CSF1, CSF1R, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RET, TEK","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":15,"killed_fraction":0.02674,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69441,"interval":[0.51569,0.86579],"hit_lines":13,"nonhit_lines":403,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":0.40144,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"replicated","separation":0.82144,"interval":[0.70523,0.91667],"hit_lines":15,"nonhit_lines":471},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":15,"lineage_tested":20,"tested_annotated":561,"enrichment":5.61,"p_one_sided_uncorrected":0.01343}},{"compound":"BRD-K74305673","name":"IKK-2-inhibitor-V","moa":"IKK inhibitor, NFkB pathway inhibitor","target":"IKBKB","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":188,"killed_fraction":0.33935,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69046,"interval":[0.63936,0.73735],"hit_lines":163,"nonhit_lines":310,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":145,"median_ic50_uM":0.99134,"hit_lines_ic50_at_most_1uM":75}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":14,"hits_annotated":188,"lineage_tested":27,"tested_annotated":554,"enrichment":1.52797,"p_one_sided_uncorrected":0.03787}},{"compound":"BRD-K83963101","name":"MLN-8054","moa":"Aurora kinase inhibitor","target":"AURKA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":95,"killed_fraction":0.1756,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68893,"interval":[0.60073,0.76925],"hit_lines":63,"nonhit_lines":293,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":56,"median_ic50_uM":0.13355,"hit_lines_ic50_at_most_1uM":52}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":8,"hits_annotated":95,"lineage_tested":26,"tested_annotated":541,"enrichment":1.75223,"p_one_sided_uncorrected":0.06696}},{"compound":"BRD-K70163715","name":"vatalanib","moa":"KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor","target":"EGFR, FLT1, FLT4, KDR, PDGFRB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.42,"lines_tested":524,"lines_killed":8,"killed_fraction":0.01527,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68804,"interval":[0.49875,0.87146],"hit_lines":6,"nonhit_lines":421,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":1.91158,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":22,"tested_annotated":524,"enrichment":5.95455,"p_one_sided_uncorrected":0.04045}},{"compound":"BRD-K51324732","name":"meglitinide","moa":"potassium channel blocker","target":"CCR2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":13,"killed_fraction":0.02326,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68291,"interval":[0.4702,0.86197],"hit_lines":9,"nonhit_lines":431,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":2.78902,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":21,"tested_annotated":559,"enrichment":6.14286,"p_one_sided_uncorrected":0.01028}},{"compound":"BRD-K11215326","name":"tazemetostat","moa":"histone lysine methyltransferase inhibitor","target":"EZH2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.31,"lines_tested":530,"lines_killed":37,"killed_fraction":0.06981,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68218,"interval":[0.58838,0.77933],"hit_lines":31,"nonhit_lines":393,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":2.76901,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":4,"hits_annotated":37,"lineage_tested":19,"tested_annotated":530,"enrichment":3.01565,"p_one_sided_uncorrected":0.03654}},{"compound":"BRD-K63504947","name":"semaxanib","moa":"VEGFR inhibitor","target":"FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":16,"killed_fraction":0.02888,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67982,"interval":[0.50006,0.84655],"hit_lines":10,"nonhit_lines":394,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":2.82538,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":16,"lineage_tested":21,"tested_annotated":554,"enrichment":3.29762,"p_one_sided_uncorrected":0.1193}},{"compound":"BRD-K64866502","name":"CYC116","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, KDR","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":133,"killed_fraction":0.23921,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6713,"interval":[0.6144,0.72313],"hit_lines":99,"nonhit_lines":336,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":86,"median_ic50_uM":3.48662,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":10,"hits_annotated":133,"lineage_tested":23,"tested_annotated":556,"enrichment":1.81759,"p_one_sided_uncorrected":0.02786}},{"compound":"BRD-K12787259","name":"CX-5461","moa":"RNA polymerase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":34,"killed_fraction":0.06285,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67093,"interval":[0.58867,0.753],"hit_lines":30,"nonhit_lines":399,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":29,"median_ic50_uM":1.26371,"hit_lines_ic50_at_most_1uM":13}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":3,"hits_annotated":34,"lineage_tested":20,"tested_annotated":541,"enrichment":2.38676,"p_one_sided_uncorrected":0.12402}},{"compound":"BRD-K20958582","name":"TH-302","moa":"DNA alkylating agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":213,"killed_fraction":0.38309,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67046,"interval":[0.61523,0.72563],"hit_lines":168,"nonhit_lines":229,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":165,"median_ic50_uM":1.82884,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":13,"hits_annotated":213,"lineage_tested":23,"tested_annotated":556,"enrichment":1.4754,"p_one_sided_uncorrected":0.05478}},{"compound":"BRD-K12885236","name":"dapivirine","moa":"non-nucleoside reverse transcriptase inhibitor","target":"CYP3A4, CYP3A5","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":19,"killed_fraction":0.03417,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66512,"interval":[0.55354,0.7747],"hit_lines":16,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":1.81537,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":5,"hits_annotated":19,"lineage_tested":38,"tested_annotated":556,"enrichment":3.85042,"p_one_sided_uncorrected":0.00656}},{"compound":"BRD-K25630527","name":"LY2784544","moa":"JAK inhibitor","target":"JAK2, JAK3","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":95,"killed_fraction":0.16844,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65959,"interval":[0.59737,0.71775],"hit_lines":80,"nonhit_lines":374,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":77,"median_ic50_uM":1.0122,"hit_lines_ic50_at_most_1uM":38}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":9,"hits_annotated":95,"lineage_tested":23,"tested_annotated":564,"enrichment":2.32311,"p_one_sided_uncorrected":0.00789}},{"compound":"BRD-K53414658","name":"tivozanib","moa":"VEGFR inhibitor","target":"FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":29,"killed_fraction":0.0536,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65644,"interval":[0.54251,0.79502],"hit_lines":23,"nonhit_lines":387,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":0.88555,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_replicated","separation":0.5477,"interval":[0.41882,0.68127],"hit_lines":25,"nonhit_lines":431},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":29,"lineage_tested":12,"tested_annotated":541,"enrichment":4.66379,"p_one_sided_uncorrected":0.022}},{"compound":"BRD-K56291712","name":"voxtalisib","moa":"mTOR inhibitor, PI3K inhibitor","target":"MTOR, PIK3CA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":8,"killed_fraction":0.01418,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.64474,"interval":[0.46264,0.85052],"hit_lines":8,"nonhit_lines":456,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":2.07346,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":11,"tested_annotated":564,"enrichment":6.40909,"p_one_sided_uncorrected":0.14663}},{"compound":"BRD-K04993719","name":"LY2334737","moa":"antitumor agent, ribonucleotide reductase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":557,"lines_killed":8,"killed_fraction":0.01436,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6427,"interval":[0.45739,0.81034],"hit_lines":7,"nonhit_lines":453,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":1.42317,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":3,"hits_annotated":8,"lineage_tested":38,"tested_annotated":557,"enrichment":5.49671,"p_one_sided_uncorrected":0.01295}},{"compound":"BRD-K81405859","name":"JTE-607","moa":"cytokine production inhibitor","target":"IL10, IL1B, IL6, TNF","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":19,"killed_fraction":0.03512,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63791,"interval":[0.54523,0.72185],"hit_lines":16,"nonhit_lines":426,"screen_id":"MTS006","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":1.04957,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":7,"hits_annotated":19,"lineage_tested":97,"tested_annotated":541,"enrichment":2.0548,"p_one_sided_uncorrected":0.03749}},{"compound":"BRD-M97302542","name":"dichloroacetate","moa":"pyruvate dehydrogenase kinase inhibitor","target":"PDK1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":6,"killed_fraction":0.01132,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63291,"interval":[0.33668,0.92181],"hit_lines":5,"nonhit_lines":395,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":35,"tested_annotated":530,"enrichment":5.04762,"p_one_sided_uncorrected":0.05376}},{"compound":"BRD-K52313696","name":"tacedinaline","moa":"HDAC inhibitor","target":"HDAC1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":11,"killed_fraction":0.02033,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62978,"interval":[0.44138,0.78356],"hit_lines":8,"nonhit_lines":405,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":3.58933,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"replicated","separation":0.83333,"interval":[0.75138,0.90749],"hit_lines":6,"nonhit_lines":317},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":23,"tested_annotated":541,"enrichment":6.41502,"p_one_sided_uncorrected":0.00888}},{"compound":"BRD-K85014146","name":"AZD2461","moa":"PARP inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":492,"lines_killed":5,"killed_fraction":0.01016,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6276,"interval":[0.0806,0.94664],"hit_lines":3,"nonhit_lines":384,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":1.52489,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":3,"tested_annotated":492,"enrichment":32.8,"p_one_sided_uncorrected":0.03024}},{"compound":"BRD-K27182532","name":"metatinib","moa":"Bcr-Abl kinase inhibitor","target":"ABL1, BCR","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":12,"killed_fraction":0.02128,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6201,"interval":[0.39365,0.80815],"hit_lines":8,"nonhit_lines":459,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":0.75501,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":12,"lineage_tested":12,"tested_annotated":564,"enrichment":7.83333,"p_one_sided_uncorrected":0.02435}},{"compound":"BRD-K68408467","name":"proflavine-hemisulfate","moa":"topical anesthetic","target":"F2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":43,"killed_fraction":0.07679,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6148,"interval":[0.5267,0.70791],"hit_lines":30,"nonhit_lines":358,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":29,"median_ic50_uM":2.81,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":5,"hits_annotated":43,"lineage_tested":20,"tested_annotated":560,"enrichment":3.25581,"p_one_sided_uncorrected":0.01374}},{"compound":"BRD-K03449891","name":"foretinib","moa":"VEGFR inhibitor","target":"FLT1, FLT4, KDR, MET","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":249,"killed_fraction":0.44784,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61278,"interval":[0.56371,0.66016],"hit_lines":219,"nonhit_lines":224,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":127,"median_ic50_uM":1.26352,"hit_lines_ic50_at_most_1uM":51}},"independent":{"status":"not_replicated","separation":0.54086,"interval":[0.48711,0.58821],"hit_lines":219,"nonhit_lines":257},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":12,"hits_annotated":249,"lineage_tested":20,"tested_annotated":556,"enrichment":1.33976,"p_one_sided_uncorrected":0.1223}},{"compound":"BRD-K13756951","name":"bitopertin","moa":"glycine transporter inhibitor, GlyT-1 inhibitor","target":"SLC6A5, SLC6A9","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":110,"killed_fraction":0.19504,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61141,"interval":[0.55198,0.67274],"hit_lines":96,"nonhit_lines":361,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":83,"median_ic50_uM":3.52548,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":10,"hits_annotated":110,"lineage_tested":24,"tested_annotated":564,"enrichment":2.13636,"p_one_sided_uncorrected":0.00907}},{"compound":"BRD-K35629949","name":"SR-27897","moa":"CCK receptor antagonist","target":"CCKAR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":71,"killed_fraction":0.12816,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6104,"interval":[0.53,0.68941],"hit_lines":61,"nonhit_lines":375,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":6.80971,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":7,"hits_annotated":71,"lineage_tested":23,"tested_annotated":554,"enrichment":2.37477,"p_one_sided_uncorrected":0.01905}},{"compound":"BRD-K84892605","name":"IOWH032","moa":"CFTR channel antagonist","target":"CFTR","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":5,"killed_fraction":0.00924,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.60817,"interval":[0.31572,0.87652],"hit_lines":4,"nonhit_lines":416,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":23,"tested_annotated":541,"enrichment":9.4087,"p_one_sided_uncorrected":0.01601}},{"compound":"BRD-K48195801","name":"tecastemizole","moa":"histamine receptor antagonist","target":"KCNH2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":547,"lines_killed":28,"killed_fraction":0.05119,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.59986,"interval":[0.48445,0.71815],"hit_lines":21,"nonhit_lines":397,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":6.33363,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":28,"lineage_tested":11,"tested_annotated":547,"enrichment":5.32792,"p_one_sided_uncorrected":0.01506}},{"compound":"BRD-K17555800","name":"talmapimod","moa":"p38 MAPK inhibitor","target":"MAPK11, MAPK14","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":26,"killed_fraction":0.04626,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.59197,"interval":[0.46681,0.71507],"hit_lines":19,"nonhit_lines":376,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":5,"hits_annotated":26,"lineage_tested":27,"tested_annotated":562,"enrichment":4.00285,"p_one_sided_uncorrected":0.00571}},{"compound":"BRD-K05444225","name":"E7449","moa":"PARP inhibitor","target":"PARP1, PARP2, TNKS, TNKS2","disease_area":"NA","indication":"NA","phase":"Phase 1/Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":34,"killed_fraction":0.06204,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58726,"interval":[0.47722,0.69842],"hit_lines":29,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":22,"median_ic50_uM":1.73712,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":5,"hits_annotated":34,"lineage_tested":20,"tested_annotated":548,"enrichment":4.02941,"p_one_sided_uncorrected":0.00539}},{"compound":"BRD-A22081593","name":"sulmazole","moa":"adenosine receptor antagonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":8,"killed_fraction":0.01479,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58635,"interval":[0.42869,0.76671],"hit_lines":7,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":3.24827,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":36,"tested_annotated":541,"enrichment":3.75694,"p_one_sided_uncorrected":0.09358}},{"compound":"BRD-K55703048","name":"latrepirdine","moa":"glutamate receptor antagonist","target":"HRH1, HTR6","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":14,"killed_fraction":0.02482,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5762,"interval":[0.40877,0.73923],"hit_lines":11,"nonhit_lines":343,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":23988.94454,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":14,"lineage_tested":21,"tested_annotated":564,"enrichment":3.83673,"p_one_sided_uncorrected":0.09179}},{"compound":"BRD-A73427433","name":"adaprev","moa":"TGF beta receptor inhibitor","target":"IGF2R, M6PR","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":8,"killed_fraction":0.01479,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.57551,"interval":[0.30519,0.84833],"hit_lines":5,"nonhit_lines":441,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":0.23926,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":8,"lineage_tested":40,"tested_annotated":541,"enrichment":5.07187,"p_one_sided_uncorrected":0.0162}},{"compound":"BRD-K53581288","name":"baricitinib","moa":"JAK inhibitor","target":"JAK1, JAK2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":114,"killed_fraction":0.20213,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.57078,"interval":[0.4997,0.62728],"hit_lines":99,"nonhit_lines":343,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":82,"median_ic50_uM":2.56513,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":7,"hits_annotated":114,"lineage_tested":19,"tested_annotated":564,"enrichment":1.82271,"p_one_sided_uncorrected":0.06756}},{"compound":"BRD-K81613478","name":"gastrodin","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":75,"killed_fraction":0.13489,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56847,"interval":[0.49592,0.63425],"hit_lines":56,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":1.91995,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":6,"hits_annotated":75,"lineage_tested":23,"tested_annotated":556,"enrichment":1.93391,"p_one_sided_uncorrected":0.07523}},{"compound":"BRD-K03384561","name":"roquinimex","moa":"angiogenesis inhibitor, tumor necrosis factor production inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":258,"killed_fraction":0.46154,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56467,"interval":[0.51685,0.62097],"hit_lines":192,"nonhit_lines":216,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":0.00065,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":51,"hits_annotated":258,"lineage_tested":100,"tested_annotated":559,"enrichment":1.105,"p_one_sided_uncorrected":0.16797}},{"compound":"BRD-K69726595","name":"mericitabine","moa":"HCV inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":23,"killed_fraction":0.04093,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56021,"interval":[0.41633,0.69445],"hit_lines":18,"nonhit_lines":418,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":2.43316,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":23,"lineage_tested":12,"tested_annotated":562,"enrichment":4.07246,"p_one_sided_uncorrected":0.08242}},{"compound":"BRD-K38350380","name":"FK-3311","moa":"cyclooxygenase inhibitor","target":"PTGS2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":9,"killed_fraction":0.01619,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.559,"interval":[0.27688,0.79372],"hit_lines":6,"nonhit_lines":452,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":4.21383,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":34,"tested_annotated":556,"enrichment":5.45098,"p_one_sided_uncorrected":0.01365}},{"compound":"BRD-K83508485","name":"FK-888","moa":"tachykinin antagonist","target":"TACR1, TACR2","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":8,"killed_fraction":0.0146,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55889,"interval":[0.35052,0.75683],"hit_lines":7,"nonhit_lines":410,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":4,"tested_annotated":548,"enrichment":17.125,"p_one_sided_uncorrected":0.05728}},{"compound":"BRD-K09090949","name":"CP-945,598","moa":"cannabinoid receptor antagonist","target":"CNR1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":11,"killed_fraction":0.02033,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55348,"interval":[0.37172,0.71131],"hit_lines":9,"nonhit_lines":429,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":2.48551,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":22,"tested_annotated":541,"enrichment":6.70661,"p_one_sided_uncorrected":0.00781}},{"compound":"BRD-A51571244","name":"hypoestoxide","moa":"IKK inhibitor","target":"IKBKB, IL1B, TNF","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":13,"killed_fraction":0.02372,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55074,"interval":[0.31611,0.78034],"hit_lines":7,"nonhit_lines":359,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":3.80438,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":43,"tested_annotated":548,"enrichment":2.94097,"p_one_sided_uncorrected":0.07396}},{"compound":"BRD-K37590257","name":"GSK256066","moa":"phosphodiesterase inhibitor","target":"PDE4A","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":23,"killed_fraction":0.04197,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54947,"interval":[0.41897,0.69653],"hit_lines":14,"nonhit_lines":309,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":3.42029,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":5,"hits_annotated":23,"lineage_tested":35,"tested_annotated":548,"enrichment":3.40373,"p_one_sided_uncorrected":0.01156}},{"compound":"BRD-K32372024","name":"D-7193","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":524,"lines_killed":31,"killed_fraction":0.05916,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54839,"interval":[0.44742,0.6616],"hit_lines":28,"nonhit_lines":400,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":21,"median_ic50_uM":1.86073,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":31,"lineage_tested":20,"tested_annotated":524,"enrichment":2.53548,"p_one_sided_uncorrected":0.10771}},{"compound":"BRD-K81330143","name":"tideglusib","moa":"glycogen synthase kinase inhibitor","target":"GSK3B","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.38,"lines_tested":530,"lines_killed":11,"killed_fraction":0.02075,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54761,"interval":[0.38562,0.70099],"hit_lines":11,"nonhit_lines":421,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":2.84452,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":11,"lineage_tested":3,"tested_annotated":530,"enrichment":16.06061,"p_one_sided_uncorrected":0.06109}},{"compound":"BRD-K20545304","name":"bardoxolone","moa":"nuclear factor erythroid derived, like (NRF2) activator","target":"NOS2, PPARG","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":179,"killed_fraction":0.32194,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54566,"interval":[0.47122,0.61757],"hit_lines":86,"nonhit_lines":218,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":86,"median_ic50_uM":1.38995,"hit_lines_ic50_at_most_1uM":35}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":6,"hits_annotated":179,"lineage_tested":11,"tested_annotated":556,"enrichment":1.69426,"p_one_sided_uncorrected":0.10348}},{"compound":"BRD-A26032986","name":"zaldaride","moa":"calmodulin antagonist","target":"CALM1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":22,"killed_fraction":0.03922,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5336,"interval":[0.40145,0.65543],"hit_lines":20,"nonhit_lines":430,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":3.26813,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":22,"lineage_tested":23,"tested_annotated":561,"enrichment":3.32609,"p_one_sided_uncorrected":0.05566}},{"compound":"BRD-K81694556","name":"VTP-27999","moa":"renin inhibitor","target":"REN","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":49,"killed_fraction":0.09057,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52702,"interval":[0.41758,0.63426],"hit_lines":32,"nonhit_lines":318,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":3.04561,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":6,"hits_annotated":49,"lineage_tested":36,"tested_annotated":541,"enrichment":1.84014,"p_one_sided_uncorrected":0.09525}},{"compound":"BRD-K95573441","name":"PFK-015","moa":"phosphofructokinase inhibitor","target":"PFKFB3","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":191,"killed_fraction":0.34046,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52643,"interval":[0.46542,0.58898],"hit_lines":117,"nonhit_lines":250,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":102,"median_ic50_uM":2.33311,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":14,"hits_annotated":191,"lineage_tested":23,"tested_annotated":561,"enrichment":1.78784,"p_one_sided_uncorrected":0.00659}},{"compound":"BRD-K17705806","name":"JTC-801","moa":"opioid receptor antagonist","target":"OPRL1","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":142,"killed_fraction":0.25267,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52374,"interval":[0.46699,0.5844],"hit_lines":121,"nonhit_lines":341,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":119,"median_ic50_uM":2.51666,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":26,"hits_annotated":142,"lineage_tested":43,"tested_annotated":562,"enrichment":2.39306,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K32501161","name":"vanoxerine","moa":"dopamine uptake inhibitor","target":"SLC6A3","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":29,"killed_fraction":0.05235,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52154,"interval":[0.40902,0.62924],"hit_lines":23,"nonhit_lines":445,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":23,"median_ic50_uM":1.53663,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":2,"hits_annotated":29,"lineage_tested":4,"tested_annotated":554,"enrichment":9.55172,"p_one_sided_uncorrected":0.01488}},{"compound":"BRD-K32405725","name":"etomoxir","moa":"carnitine palmitoyltransferase inhibitor","target":"CPT1A","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":128,"killed_fraction":0.23105,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51869,"interval":[0.45405,0.58094],"hit_lines":98,"nonhit_lines":339,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":10.1859,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":4,"hits_annotated":128,"lineage_tested":9,"tested_annotated":554,"enrichment":1.92361,"p_one_sided_uncorrected":0.1304}},{"compound":"BRD-K49555808","name":"BMS-707035","moa":"HIV integrase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":53,"killed_fraction":0.09672,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51076,"interval":[0.38763,0.63453],"hit_lines":30,"nonhit_lines":347,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":5.60856,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":5,"hits_annotated":53,"lineage_tested":11,"tested_annotated":548,"enrichment":4.69983,"p_one_sided_uncorrected":0.00207}},{"compound":"BRD-K78096648","name":"oxiperomide","moa":"dopamine receptor antagonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":7,"killed_fraction":0.01264,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5016,"interval":[0.26232,0.76562],"hit_lines":6,"nonhit_lines":416,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":2.88793,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":27,"tested_annotated":554,"enrichment":5.86243,"p_one_sided_uncorrected":0.04131}},{"compound":"BRD-K50850824","name":"acesulfame-potassium","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":81,"killed_fraction":0.15283,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.49713,"interval":[0.42277,0.58083],"hit_lines":63,"nonhit_lines":326,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":2,"hits_annotated":81,"lineage_tested":2,"tested_annotated":530,"enrichment":6.54321,"p_one_sided_uncorrected":0.02311}},{"compound":"BRD-K31476763","name":"AZD9668","moa":"elastase inhibitor","target":"ELANE","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":555,"lines_killed":9,"killed_fraction":0.01622,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.49655,"interval":[0.27312,0.72625],"hit_lines":6,"nonhit_lines":435,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":4.00471,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":9,"lineage_tested":23,"tested_annotated":555,"enrichment":8.04348,"p_one_sided_uncorrected":0.00445}},{"compound":"BRD-K76210423","name":"resiquimod","moa":"toll-like receptor agonist","target":"TLR7, TLR8","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":23,"killed_fraction":0.04197,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48474,"interval":[0.32048,0.65654],"hit_lines":15,"nonhit_lines":380,"screen_id":"MTS010","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":2,"hits_annotated":23,"lineage_tested":4,"tested_annotated":548,"enrichment":11.91304,"p_one_sided_uncorrected":0.00962}},{"compound":"BRD-K94420399","name":"PF-04136309","moa":"CC chemokine receptor antagonist","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":45,"killed_fraction":0.07979,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48238,"interval":[0.36107,0.58961],"hit_lines":36,"nonhit_lines":391,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":10.4298,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":4,"hits_annotated":45,"lineage_tested":23,"tested_annotated":564,"enrichment":2.17971,"p_one_sided_uncorrected":0.10201}},{"compound":"BRD-K65928735","name":"AZD1480","moa":"JAK inhibitor","target":"JAK1, JAK2, JAK3","disease_area":"NA","indication":"NA","phase":"Phase 1","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":6,"killed_fraction":0.01073,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4799,"interval":[0.10514,0.86388],"hit_lines":4,"nonhit_lines":398,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":2.28991,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":224},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":12,"tested_annotated":559,"enrichment":15.52778,"p_one_sided_uncorrected":0.00605}},{"compound":"BRD-K83022601","name":"CI-844","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Phase 2","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":31,"killed_fraction":0.05596,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4617,"interval":[0.36307,0.55351],"hit_lines":20,"nonhit_lines":393,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":4,"hits_annotated":31,"lineage_tested":21,"tested_annotated":554,"enrichment":3.40399,"p_one_sided_uncorrected":0.02459}},{"compound":"BRD-K26011976","name":"licochalcone-a","moa":"topoisomerase inhibitor","target":"PTPN1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":523,"lines_killed":5,"killed_fraction":0.00956,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.41648,"interval":[0.06287,0.62664],"hit_lines":3,"nonhit_lines":437,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":3.65483,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":3,"hits_annotated":5,"lineage_tested":98,"tested_annotated":523,"enrichment":3.20204,"p_one_sided_uncorrected":0.04785}},{"compound":"BRD-K84810405","name":"almorexant","moa":"orexin receptor antagonist","target":"HCRTR1, HCRTR2","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":539,"lines_killed":8,"killed_fraction":0.01484,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.36642,"interval":[0.20113,0.56675],"hit_lines":5,"nonhit_lines":411,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":3,"hits_annotated":8,"lineage_tested":33,"tested_annotated":539,"enrichment":6.125,"p_one_sided_uncorrected":0.00951}},{"compound":"BRD-K65678996","name":"nefiracetam","moa":"acetylcholine receptor agonist, benzodiazepine receptor agonist","target":"CHRM1","disease_area":"NA","indication":"NA","phase":"Phase 3","phase_group":"clinical","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":553,"lines_killed":5,"killed_fraction":0.00904,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.16884,"interval":[0.09123,0.26247],"hit_lines":4,"nonhit_lines":422,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bile_duct","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":7,"tested_annotated":553,"enrichment":15.8,"p_one_sided_uncorrected":0.06193}},{"compound":"BRD-A68304895","name":"BTS-54505","moa":"dopamine reuptake inhibitor","target":"SLC6A2, SLC6A3, SLC6A4","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":6,"killed_fraction":0.01068,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69968,"interval":[0.52568,0.856],"hit_lines":5,"nonhit_lines":315,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":4.51077,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":20,"tested_annotated":562,"enrichment":9.36667,"p_one_sided_uncorrected":0.01658}},{"compound":"BRD-K10843433","name":"phenylbutazone","moa":"cyclooxygenase inhibitor, prostanoid receptor antagonist","target":"PTGIS, PTGS1, PTGS2","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":15,"killed_fraction":0.02773,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66038,"interval":[0.55168,0.76214],"hit_lines":11,"nonhit_lines":371,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":3.46776,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":3,"hits_annotated":15,"lineage_tested":33,"tested_annotated":541,"enrichment":3.27879,"p_one_sided_uncorrected":0.05691}},{"compound":"BRD-A93093700","name":"temazepam","moa":"benzodiazepine receptor agonist","target":"GABRA1, GABRA2, GABRA3, GABRA4, GABRA5, GABRA6, GABRB1, GABRB2, GABRB3, GABRD, GABRE, GABRG1, GABRG2, GABRG3, GABRP, GABRQ, GABRR1, GABRR2, GABRR3, TSPO","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":22,"killed_fraction":0.03901,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63901,"interval":[0.49997,0.77826],"hit_lines":16,"nonhit_lines":406,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":0.00058,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":2,"hits_annotated":22,"lineage_tested":9,"tested_annotated":564,"enrichment":5.69697,"p_one_sided_uncorrected":0.04432}},{"compound":"BRD-K00494077","name":"trovafloxacin","moa":"bacterial DNA gyrase inhibitor","target":"TOP2A","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":32,"killed_fraction":0.05915,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.59277,"interval":[0.50196,0.68429],"hit_lines":28,"nonhit_lines":390,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":2.83912,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":3,"hits_annotated":32,"lineage_tested":12,"tested_annotated":541,"enrichment":4.22656,"p_one_sided_uncorrected":0.02874}},{"compound":"BRD-K88568253","name":"iproniazid","moa":"monoamine oxidase inhibitor","target":"MAOA, MAOB","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":36,"killed_fraction":0.06569,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56573,"interval":[0.45863,0.67651],"hit_lines":24,"nonhit_lines":355,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":2,"hits_annotated":36,"lineage_tested":4,"tested_annotated":548,"enrichment":7.61111,"p_one_sided_uncorrected":0.02317}},{"compound":"BRD-K27217864","name":"butamben","moa":"sodium channel blocker","target":"NA","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":557,"lines_killed":10,"killed_fraction":0.01795,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52152,"interval":[0.36954,0.64815],"hit_lines":8,"nonhit_lines":424,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":3.34952,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":21,"tested_annotated":557,"enrichment":5.30476,"p_one_sided_uncorrected":0.05079}},{"compound":"BRD-A06352418","name":"terfenadine","moa":"histamine receptor antagonist","target":"CHRM1, CHRM2, CHRM3, CHRM4, CHRM5, HRH1, KCNH1, KCNH2","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":26,"killed_fraction":0.04806,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50824,"interval":[0.36852,0.63702],"hit_lines":21,"nonhit_lines":370,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":18,"median_ic50_uM":5.50734,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":5,"hits_annotated":26,"lineage_tested":39,"tested_annotated":541,"enrichment":2.66765,"p_one_sided_uncorrected":0.03201}},{"compound":"BRD-K86887724","name":"dofetilide","moa":"potassium channel blocker","target":"KCNH1, KCNH2, KCNJ12, KCNK2","disease_area":"NA","indication":"NA","phase":"Withdrawn","phase_group":"withdrawn","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.59,"lines_tested":541,"lines_killed":18,"killed_fraction":0.03327,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50289,"interval":[0.34998,0.66525],"hit_lines":13,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":4.98237,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":36,"tested_annotated":541,"enrichment":2.50463,"p_one_sided_uncorrected":0.11064}},{"compound":"BRD-K03294269","name":"NU6027","moa":"CDK inhibitor","target":"CCNA2, CDK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":7,"killed_fraction":0.01241,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.8,"interval":[0.46721,0.98599],"hit_lines":5,"nonhit_lines":435,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.66233,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":21,"tested_annotated":564,"enrichment":7.67347,"p_one_sided_uncorrected":0.02479}},{"compound":"BRD-K13169950","name":"NSC-3852","moa":"HDAC inhibitor","target":"HDAC1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":237,"killed_fraction":0.42626,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74958,"interval":[0.69924,0.79282],"hit_lines":191,"nonhit_lines":247,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":186,"median_ic50_uM":1.80243,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":19,"hits_annotated":237,"lineage_tested":23,"tested_annotated":556,"enrichment":1.93799,"p_one_sided_uncorrected":8e-05}},{"compound":"BRD-K50000283","name":"PHA-767491","moa":"CDC inhibitor","target":"CDK1, RPS6KB1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":139,"killed_fraction":0.24645,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74665,"interval":[0.69938,0.79572],"hit_lines":107,"nonhit_lines":351,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":106,"median_ic50_uM":2.50873,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":6,"hits_annotated":139,"lineage_tested":12,"tested_annotated":564,"enrichment":2.02878,"p_one_sided_uncorrected":0.04918}},{"compound":"BRD-K72703948","name":"ZM-447439","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":197,"killed_fraction":0.35432,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74405,"interval":[0.6972,0.78944],"hit_lines":170,"nonhit_lines":295,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":155,"median_ic50_uM":1.48051,"hit_lines_ic50_at_most_1uM":27}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":21,"hits_annotated":197,"lineage_tested":40,"tested_annotated":556,"enrichment":1.48173,"p_one_sided_uncorrected":0.01638}},{"compound":"BRD-K77677632","name":"SB-200646","moa":"serotonin receptor antagonist","target":"HTR2B, HTR2C","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":6,"killed_fraction":0.01083,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.74198,"interval":[0.66443,0.8162],"hit_lines":3,"nonhit_lines":447,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":1.89578,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":3,"hits_annotated":6,"lineage_tested":99,"tested_annotated":554,"enrichment":2.79798,"p_one_sided_uncorrected":0.07341}},{"compound":"BRD-K62814476","name":"BMS-265246","moa":"CDK inhibitor","target":"CDK1, CDK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":159,"killed_fraction":0.28597,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7409,"interval":[0.69735,0.78082],"hit_lines":137,"nonhit_lines":328,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":137,"median_ic50_uM":0.62909,"hit_lines_ic50_at_most_1uM":122}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":15,"hits_annotated":159,"lineage_tested":34,"tested_annotated":556,"enrichment":1.54273,"p_one_sided_uncorrected":0.03397}},{"compound":"BRD-K28360340","name":"TW-37","moa":"BCL inhibitor","target":"BCL2, BCL2L1, MCL1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.31,"lines_tested":530,"lines_killed":166,"killed_fraction":0.31321,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73915,"interval":[0.68862,0.78258],"hit_lines":144,"nonhit_lines":288,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":144,"median_ic50_uM":0.36811,"hit_lines_ic50_at_most_1uM":140}},"independent":{"status":"not_replicated","separation":0.59823,"interval":[0.53394,0.65076],"hit_lines":140,"nonhit_lines":302},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":12,"hits_annotated":166,"lineage_tested":22,"tested_annotated":530,"enrichment":1.74151,"p_one_sided_uncorrected":0.01785}},{"compound":"BRD-K31086665","name":"NH125","moa":"eukaryotic translation elongation factor 2 inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":225,"killed_fraction":0.40107,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73683,"interval":[0.68645,0.78239],"hit_lines":194,"nonhit_lines":274,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":191,"median_ic50_uM":1.7598,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":31,"hits_annotated":225,"lineage_tested":43,"tested_annotated":561,"enrichment":1.79752,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K40255344","name":"tyrphostin-A9","moa":"protein tyrosine kinase inhibitor, tyrosine kinase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":75,"killed_fraction":0.13298,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73676,"interval":[0.68026,0.78758],"hit_lines":62,"nonhit_lines":402,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":62,"median_ic50_uM":1.14978,"hit_lines_ic50_at_most_1uM":24}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":7,"hits_annotated":75,"lineage_tested":23,"tested_annotated":564,"enrichment":2.2887,"p_one_sided_uncorrected":0.0232}},{"compound":"BRD-K19333160","name":"RKI-1447","moa":"rho associated kinase inhibitor","target":"CDC42BPA, DMPK, LIMK1, MYLK, PAK1, PKN1, ROCK1, ROCK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":6,"killed_fraction":0.01071,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73363,"interval":[0.63878,0.82228],"hit_lines":5,"nonhit_lines":446,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":3.03777,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":6,"lineage_tested":41,"tested_annotated":560,"enrichment":4.55285,"p_one_sided_uncorrected":0.06502}},{"compound":"BRD-K02764365","name":"methiazole","moa":"anthelmintic agent","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":146,"killed_fraction":0.25887,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.73327,"interval":[0.68329,0.77766],"hit_lines":123,"nonhit_lines":338,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":118,"median_ic50_uM":1.25437,"hit_lines_ic50_at_most_1uM":40}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":11,"hits_annotated":146,"lineage_tested":23,"tested_annotated":564,"enrichment":1.84753,"p_one_sided_uncorrected":0.0172}},{"compound":"BRD-A06352508","name":"SB-218078","moa":"CHK inhibitor","target":"CHEK1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":46,"killed_fraction":0.08214,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.7299,"interval":[0.63445,0.81306],"hit_lines":36,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":29,"median_ic50_uM":0.628,"hit_lines_ic50_at_most_1uM":24}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":8,"hits_annotated":46,"lineage_tested":34,"tested_annotated":560,"enrichment":2.86445,"p_one_sided_uncorrected":0.00396}},{"compound":"BRD-K82091397","name":"SB-239063","moa":"p38 MAPK inhibitor","target":"MAPK11, MAPK14, PTGS2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72833,"interval":[0.58889,0.89836],"hit_lines":4,"nonhit_lines":450,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":2.03699,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":27,"tested_annotated":556,"enrichment":8.23704,"p_one_sided_uncorrected":0.02076}},{"compound":"BRD-K21025364","name":"NVP-TAE226","moa":"protein tyrosine kinase inhibitor","target":"PTK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":257,"killed_fraction":0.47505,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72701,"interval":[0.67854,0.77043],"hit_lines":221,"nonhit_lines":218,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":221,"median_ic50_uM":0.26094,"hit_lines_ic50_at_most_1uM":212}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":18,"hits_annotated":257,"lineage_tested":26,"tested_annotated":541,"enrichment":1.45735,"p_one_sided_uncorrected":0.01865}},{"compound":"BRD-K39381259","name":"DMH1","moa":"ALK tyrosine kinase receptor inhibitor","target":"ACVR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":11,"killed_fraction":0.01964,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72569,"interval":[0.53523,0.8898],"hit_lines":8,"nonhit_lines":432,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":7.60929,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":34,"tested_annotated":560,"enrichment":4.49198,"p_one_sided_uncorrected":0.02416}},{"compound":"BRD-K22385716","name":"LY303511","moa":"casein kinase inhibitor, mTOR inhibitor, PI3K inhibitor","target":"BRD2, BRD3, BRD4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":11,"killed_fraction":0.01978,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72196,"interval":[0.50837,0.91962],"hit_lines":9,"nonhit_lines":416,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.87558,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":4,"hits_annotated":11,"lineage_tested":43,"tested_annotated":556,"enrichment":4.7019,"p_one_sided_uncorrected":0.00689}},{"compound":"BRD-K00535541","name":"9-aminoacridine","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":54,"killed_fraction":0.09982,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72177,"interval":[0.64513,0.79092],"hit_lines":49,"nonhit_lines":390,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":49,"median_ic50_uM":1.60027,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":7,"hits_annotated":54,"lineage_tested":33,"tested_annotated":541,"enrichment":2.12514,"p_one_sided_uncorrected":0.0363}},{"compound":"BRD-K61688984","name":"RGFP966","moa":"HDAC inhibitor","target":"HDAC3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":7,"killed_fraction":0.0125,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.72126,"interval":[0.40232,0.9769],"hit_lines":5,"nonhit_lines":381,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":0.44261,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":7,"lineage_tested":5,"tested_annotated":560,"enrichment":16.0,"p_one_sided_uncorrected":0.06117}},{"compound":"BRD-K98203492","name":"GSK-J4","moa":"histone lysine demethylase inhibitor","target":"KDM6A, KDM6B","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":536,"lines_killed":12,"killed_fraction":0.02239,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71577,"interval":[0.53947,0.84475],"hit_lines":9,"nonhit_lines":448,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":1.29999,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"insufficient","separation":null,"interval":null,"hit_lines":1,"nonhit_lines":45},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":3,"hits_annotated":12,"lineage_tested":36,"tested_annotated":536,"enrichment":3.72222,"p_one_sided_uncorrected":0.04025}},{"compound":"BRD-K34851558","name":"parthenolide-(-)","moa":"NFkB pathway inhibitor","target":"HDAC1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":11,"killed_fraction":0.01978,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71512,"interval":[0.5442,0.86879],"hit_lines":10,"nonhit_lines":443,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":3.76511,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":24,"tested_annotated":556,"enrichment":4.21212,"p_one_sided_uncorrected":0.07744}},{"compound":"BRD-A68631409","name":"evodiamine","moa":"ATPase inhibitor, TRPV agonist","target":"TRPV1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":264,"killed_fraction":0.47482,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71474,"interval":[0.66764,0.76082],"hit_lines":232,"nonhit_lines":232,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":224,"median_ic50_uM":1.41636,"hit_lines_ic50_at_most_1uM":42}},"independent":{"status":"not_replicated","separation":0.61708,"interval":[0.56788,0.66673],"hit_lines":231,"nonhit_lines":247},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":15,"hits_annotated":264,"lineage_tested":24,"tested_annotated":556,"enrichment":1.31629,"p_one_sided_uncorrected":0.0972}},{"compound":"BRD-K87112191","name":"PP242","moa":"mTOR inhibitor","target":"MTOR, PASK","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":189,"killed_fraction":0.3363,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71459,"interval":[0.65907,0.7577],"hit_lines":159,"nonhit_lines":303,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":157,"median_ic50_uM":0.7479,"hit_lines_ic50_at_most_1uM":111}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":20,"hits_annotated":189,"lineage_tested":37,"tested_annotated":562,"enrichment":1.60732,"p_one_sided_uncorrected":0.00657}},{"compound":"BRD-K42973005","name":"CHIR-98014","moa":"glycogen synthase kinase inhibitor","target":"GSK3A, GSK3B","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":11,"killed_fraction":0.01957,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.71053,"interval":[0.55569,0.85252],"hit_lines":10,"nonhit_lines":418,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":7.52508,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"fibroblast","hits_in_lineage":1,"hits_annotated":11,"lineage_tested":1,"tested_annotated":562,"enrichment":51.09091,"p_one_sided_uncorrected":0.01957}},{"compound":"BRD-K35329391","name":"GZD824","moa":"Bcr-Abl kinase inhibitor","target":"ABL1, BCR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":31,"killed_fraction":0.05536,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70943,"interval":[0.61192,0.80199],"hit_lines":27,"nonhit_lines":427,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":27,"median_ic50_uM":0.08086,"hit_lines_ic50_at_most_1uM":25}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":3,"hits_annotated":31,"lineage_tested":11,"tested_annotated":560,"enrichment":4.92669,"p_one_sided_uncorrected":0.01876}},{"compound":"BRD-K76973696","name":"tryptanthrin","moa":"cyclooxygenase inhibitor","target":"IDO1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.01,"lines_tested":556,"lines_killed":14,"killed_fraction":0.02518,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.70361,"interval":[0.57788,0.81419],"hit_lines":13,"nonhit_lines":456,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":13,"median_ic50_uM":0.85382,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":14,"lineage_tested":24,"tested_annotated":556,"enrichment":4.96429,"p_one_sided_uncorrected":0.01883}},{"compound":"BRD-K85920262","name":"WAY-600","moa":"mTOR inhibitor","target":"MTOR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":126,"killed_fraction":0.225,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69633,"interval":[0.64233,0.74929],"hit_lines":106,"nonhit_lines":365,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":105,"median_ic50_uM":1.05438,"hit_lines_ic50_at_most_1uM":51}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":10,"hits_annotated":126,"lineage_tested":20,"tested_annotated":560,"enrichment":2.22222,"p_one_sided_uncorrected":0.00553}},{"compound":"BRD-K47598052","name":"PP-1","moa":"src inhibitor","target":"HCK, RET","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":551,"lines_killed":30,"killed_fraction":0.05445,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69591,"interval":[0.57595,0.80675],"hit_lines":24,"nonhit_lines":426,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":16,"median_ic50_uM":1.68988,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":3,"hits_annotated":30,"lineage_tested":9,"tested_annotated":551,"enrichment":6.12222,"p_one_sided_uncorrected":0.00982}},{"compound":"BRD-K06543683","name":"bisindolylmaleimide-ix","moa":"PKC inhibitor","target":"AKT1, GSK3B, LCK, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, ROCK1, RPS6KB1, SIRT1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":64,"killed_fraction":0.11408,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69381,"interval":[0.62254,0.76055],"hit_lines":55,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":55,"median_ic50_uM":1.4745,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":6,"hits_annotated":64,"lineage_tested":23,"tested_annotated":561,"enrichment":2.28668,"p_one_sided_uncorrected":0.0368}},{"compound":"BRD-K03109492","name":"NSC-663284","moa":"CDC inhibitor","target":"CDC25A, CDC25B, CDC25C","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":274,"killed_fraction":0.49281,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69327,"interval":[0.64448,0.74225],"hit_lines":227,"nonhit_lines":232,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":224,"median_ic50_uM":1.95409,"hit_lines_ic50_at_most_1uM":25}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":34,"hits_annotated":274,"lineage_tested":43,"tested_annotated":556,"enrichment":1.60448,"p_one_sided_uncorrected":3e-05}},{"compound":"BRD-K39841531","name":"TG-101209","moa":"JAK inhibitor","target":"JAK2, JAK3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":156,"killed_fraction":0.27857,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.69264,"interval":[0.64009,0.74542],"hit_lines":134,"nonhit_lines":333,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":131,"median_ic50_uM":2.05839,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":14,"hits_annotated":156,"lineage_tested":23,"tested_annotated":560,"enrichment":2.18506,"p_one_sided_uncorrected":0.00073}},{"compound":"BRD-K64888243","name":"AZ960","moa":"JAK inhibitor","target":"JAK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":562,"lines_killed":103,"killed_fraction":0.18327,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68984,"interval":[0.62673,0.74357],"hit_lines":85,"nonhit_lines":371,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":82,"median_ic50_uM":0.67933,"hit_lines_ic50_at_most_1uM":63}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":10,"hits_annotated":103,"lineage_tested":23,"tested_annotated":562,"enrichment":2.37231,"p_one_sided_uncorrected":0.00389}},{"compound":"BRD-A54927599","name":"KF-38789","moa":"P selectin inhibitor","target":"SELP","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":254,"killed_fraction":0.45848,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68776,"interval":[0.63991,0.73768],"hit_lines":212,"nonhit_lines":256,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":209,"median_ic50_uM":1.17983,"hit_lines_ic50_at_most_1uM":77}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":18,"hits_annotated":254,"lineage_tested":22,"tested_annotated":554,"enrichment":1.78454,"p_one_sided_uncorrected":0.00048}},{"compound":"BRD-K32730239","name":"SU3327","moa":"JNK inhibitor","target":"MAPK8","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":217,"killed_fraction":0.38681,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6826,"interval":[0.62773,0.73514],"hit_lines":179,"nonhit_lines":286,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":175,"median_ic50_uM":2.4168,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":19,"hits_annotated":217,"lineage_tested":23,"tested_annotated":561,"enrichment":2.13564,"p_one_sided_uncorrected":1e-05}},{"compound":"BRD-K11636097","name":"JNJ-7706621","moa":"CDK inhibitor","target":"AURKA, AURKB, CDK1, CDK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":159,"killed_fraction":0.28597,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.68095,"interval":[0.62993,0.73574],"hit_lines":129,"nonhit_lines":305,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":126,"median_ic50_uM":1.78759,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":12,"hits_annotated":159,"lineage_tested":27,"tested_annotated":556,"enrichment":1.55416,"p_one_sided_uncorrected":0.05324}},{"compound":"BRD-A08840375","name":"CID-5458317","moa":"MAP kinase phosphatase inhibitor","target":"MAPK3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":259,"killed_fraction":0.47263,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67903,"interval":[0.63186,0.72416],"hit_lines":225,"nonhit_lines":244,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":222,"median_ic50_uM":2.16906,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":17,"hits_annotated":259,"lineage_tested":23,"tested_annotated":548,"enrichment":1.56387,"p_one_sided_uncorrected":0.00766}},{"compound":"BRD-K61314889","name":"endo-IWR-1","moa":"PARP inhibitor","target":"TNKS, TNKS2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":12,"killed_fraction":0.02128,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67809,"interval":[0.42109,0.88847],"hit_lines":10,"nonhit_lines":461,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":1.14542,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":12,"lineage_tested":42,"tested_annotated":564,"enrichment":3.35714,"p_one_sided_uncorrected":0.0527}},{"compound":"BRD-K38548312","name":"VER-49009","moa":"HSP inhibitor","target":"HSP90AA1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":268,"killed_fraction":0.47772,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67695,"interval":[0.62384,0.72049],"hit_lines":227,"nonhit_lines":225,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":221,"median_ic50_uM":1.4374,"hit_lines_ic50_at_most_1uM":40}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":59,"hits_annotated":268,"lineage_tested":101,"tested_annotated":561,"enrichment":1.22281,"p_one_sided_uncorrected":0.01204}},{"compound":"BRD-K46392623","name":"TG-100713","moa":"PI3K inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":16,"killed_fraction":0.02837,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6758,"interval":[0.5464,0.79596],"hit_lines":13,"nonhit_lines":438,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":2.20763,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":3,"hits_annotated":16,"lineage_tested":43,"tested_annotated":564,"enrichment":2.4593,"p_one_sided_uncorrected":0.11505}},{"compound":"BRD-K54095730","name":"CMPD-1","moa":"p38 MAPK inhibitor","target":"GNRHR, MAPK14","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":129,"killed_fraction":0.23077,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.67325,"interval":[0.6322,0.72296],"hit_lines":115,"nonhit_lines":354,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":112,"median_ic50_uM":1.68759,"hit_lines_ic50_at_most_1uM":14}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":11,"hits_annotated":129,"lineage_tested":24,"tested_annotated":559,"enrichment":1.98611,"p_one_sided_uncorrected":0.01015}},{"compound":"BRD-K30867024","name":"SB-216641","moa":"serotonin receptor antagonist","target":"HTR1A, HTR1B, HTR1D, HTR2A, HTR2B, HTR2C","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":5,"killed_fraction":0.00903,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66593,"interval":[0.52924,0.86444],"hit_lines":3,"nonhit_lines":450,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":4.18352,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":3,"tested_annotated":554,"enrichment":36.93333,"p_one_sided_uncorrected":0.02688}},{"compound":"BRD-K70402238","name":"nexturastat-a","moa":"HDAC inhibitor","target":"HDAC1, HDAC6","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":5,"killed_fraction":0.00891,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.66302,"interval":[0.42506,0.90085],"hit_lines":4,"nonhit_lines":411,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":4.38662,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"liver","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":21,"tested_annotated":561,"enrichment":5.34286,"p_one_sided_uncorrected":0.17424}},{"compound":"BRD-K65814004","name":"diphenyleneiodonium","moa":"nitric oxide synthase inhibitor","target":"NOS2, NOS3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":263,"killed_fraction":0.47302,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65727,"interval":[0.60319,0.70368],"hit_lines":217,"nonhit_lines":226,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":217,"median_ic50_uM":0.07681,"hit_lines_ic50_at_most_1uM":214}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"thyroid","hits_in_lineage":9,"hits_annotated":263,"lineage_tested":11,"tested_annotated":556,"enrichment":1.72969,"p_one_sided_uncorrected":0.02062}},{"compound":"BRD-K42205652","name":"MNS-(3,4-Methylenedioxy-nitrostyrene)","moa":"src inhibitor, syk inhibitor","target":"SRC, SYK","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":37,"killed_fraction":0.0656,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65441,"interval":[0.53367,0.78065],"hit_lines":26,"nonhit_lines":411,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":24,"median_ic50_uM":3.4964,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":5,"hits_annotated":37,"lineage_tested":23,"tested_annotated":564,"enrichment":3.31375,"p_one_sided_uncorrected":0.01303}},{"compound":"BRD-K26253904","name":"NMS-873","moa":"ATPase inhibitor","target":"VCP","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":87,"killed_fraction":0.15536,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65425,"interval":[0.5886,0.72246],"hit_lines":74,"nonhit_lines":386,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":74,"median_ic50_uM":0.24776,"hit_lines_ic50_at_most_1uM":72}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":8,"hits_annotated":87,"lineage_tested":23,"tested_annotated":560,"enrichment":2.23888,"p_one_sided_uncorrected":0.01643}},{"compound":"BRD-K53561341","name":"aurora-a-inhibitor-i","moa":"Aurora kinase inhibitor","target":"AURKA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":191,"killed_fraction":0.34107,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.65357,"interval":[0.598,0.70393],"hit_lines":155,"nonhit_lines":300,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":149,"median_ic50_uM":2.48469,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":13,"hits_annotated":191,"lineage_tested":23,"tested_annotated":560,"enrichment":1.65718,"p_one_sided_uncorrected":0.02045}},{"compound":"BRD-K66030860","name":"salidroside","moa":"beta amyloid protein neurotoxicity inhibitor","target":"APP","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":5,"killed_fraction":0.00899,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.64618,"interval":[0.39169,0.89567],"hit_lines":4,"nonhit_lines":419,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":27,"tested_annotated":556,"enrichment":8.23704,"p_one_sided_uncorrected":0.02076}},{"compound":"BRD-K27799744","name":"cyclovirobuxin-d","moa":"calcium channel modulator","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.52,"lines_tested":530,"lines_killed":8,"killed_fraction":0.01509,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6416,"interval":[0.44932,0.85656],"hit_lines":5,"nonhit_lines":375,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":12.66404,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":12,"tested_annotated":530,"enrichment":11.04167,"p_one_sided_uncorrected":0.01222}},{"compound":"BRD-K67868012","name":"PI-103","moa":"mTOR inhibitor, PI3K inhibitor","target":"MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":165,"killed_fraction":0.29255,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63951,"interval":[0.5889,0.69419],"hit_lines":146,"nonhit_lines":310,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":135,"median_ic50_uM":2.9342,"hit_lines_ic50_at_most_1uM":7}},"independent":{"status":"not_replicated","separation":0.54661,"interval":[0.48489,0.60463],"hit_lines":142,"nonhit_lines":339},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":10,"hits_annotated":165,"lineage_tested":20,"tested_annotated":564,"enrichment":1.70909,"p_one_sided_uncorrected":0.03797}},{"compound":"BRD-K01653460","name":"chlorindanol","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63923,"interval":[0.42249,0.81904],"hit_lines":4,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":2.3985,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":26,"tested_annotated":541,"enrichment":5.94505,"p_one_sided_uncorrected":0.04022}},{"compound":"BRD-K24556407","name":"ETP-46464","moa":"ATR kinase inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":10,"killed_fraction":0.01783,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63626,"interval":[0.41971,0.8386],"hit_lines":8,"nonhit_lines":455,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":8,"median_ic50_uM":1.02127,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_replicated","separation":0.68818,"interval":[0.57901,0.80051],"hit_lines":9,"nonhit_lines":328},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":1,"hits_annotated":10,"lineage_tested":3,"tested_annotated":561,"enrichment":18.7,"p_one_sided_uncorrected":0.05262}},{"compound":"BRD-K41312087","name":"GW-441756","moa":"growth factor receptor inhibitor","target":"NTRK1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":58,"killed_fraction":0.10376,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63484,"interval":[0.54752,0.72155],"hit_lines":50,"nonhit_lines":376,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":0.81139,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":7,"hits_annotated":58,"lineage_tested":26,"tested_annotated":559,"enrichment":2.59483,"p_one_sided_uncorrected":0.01223}},{"compound":"BRD-K73982490","name":"BI-78D3","moa":"JNK inhibitor","target":"MAPK8","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":255,"killed_fraction":0.46029,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63381,"interval":[0.58083,0.68609],"hit_lines":210,"nonhit_lines":232,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":206,"median_ic50_uM":2.27328,"hit_lines_ic50_at_most_1uM":16}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":29,"hits_annotated":255,"lineage_tested":43,"tested_annotated":554,"enrichment":1.46521,"p_one_sided_uncorrected":0.00271}},{"compound":"BRD-K40109029","name":"SB-505124","moa":"ALK tyrosine kinase receptor inhibitor","target":"TGFBR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":42,"killed_fraction":0.07447,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.63213,"interval":[0.53966,0.72306],"hit_lines":35,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":28,"median_ic50_uM":5.51814,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":13,"hits_annotated":42,"lineage_tested":43,"tested_annotated":564,"enrichment":4.0598,"p_one_sided_uncorrected":0.0}},{"compound":"BRD-K41337261","name":"ZM-306416","moa":"Abl kinase inhibitor, src inhibitor, VEGFR inhibitor","target":"EGFR, FLT1, FLT4, KDR","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":271,"killed_fraction":0.4805,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62942,"interval":[0.57763,0.67946],"hit_lines":223,"nonhit_lines":227,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":110,"median_ic50_uM":2.05221,"hit_lines_ic50_at_most_1uM":22}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"upper_aerodigestive","hits_in_lineage":21,"hits_annotated":271,"lineage_tested":27,"tested_annotated":564,"enrichment":1.6187,"p_one_sided_uncorrected":0.00125}},{"compound":"BRD-K18787491","name":"U-0126","moa":"MEK inhibitor","target":"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAP2K2, MAP2K7, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":14,"killed_fraction":0.02518,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.6293,"interval":[0.45976,0.7951],"hit_lines":10,"nonhit_lines":454,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":3.0553,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":3,"hits_annotated":14,"lineage_tested":34,"tested_annotated":556,"enrichment":3.5042,"p_one_sided_uncorrected":0.04785}},{"compound":"BRD-K78318619","name":"PF-4981517","moa":"cytochrome P450 inhibitor","target":"CYP3A4","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":31,"killed_fraction":0.05496,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62687,"interval":[0.49648,0.74985],"hit_lines":29,"nonhit_lines":413,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":1.72136,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":2,"hits_annotated":31,"lineage_tested":5,"tested_annotated":564,"enrichment":7.27742,"p_one_sided_uncorrected":0.02638}},{"compound":"BRD-A67748489","name":"K-858","moa":"kinesin-like spindle protein inhibitor","target":"KIF11","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":251,"killed_fraction":0.45144,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62605,"interval":[0.57849,0.67975],"hit_lines":204,"nonhit_lines":241,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":199,"median_ic50_uM":0.57175,"hit_lines_ic50_at_most_1uM":174}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":15,"hits_annotated":251,"lineage_tested":23,"tested_annotated":556,"enrichment":1.44466,"p_one_sided_uncorrected":0.03915}},{"compound":"BRD-K08078237","name":"tetrandrine","moa":"calcium channel blocker","target":"SLC6A3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":181,"killed_fraction":0.34151,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.62288,"interval":[0.57342,0.67767],"hit_lines":151,"nonhit_lines":274,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":145,"median_ic50_uM":2.91943,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":27,"hits_annotated":181,"lineage_tested":41,"tested_annotated":530,"enrichment":1.92831,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K57136142","name":"CCT129202","moa":"Aurora kinase inhibitor","target":"AURKA, AURKB, AURKC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":180,"killed_fraction":0.322,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61361,"interval":[0.55911,0.667],"hit_lines":151,"nonhit_lines":308,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":124,"median_ic50_uM":2.52207,"hit_lines_ic50_at_most_1uM":8}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":16,"hits_annotated":180,"lineage_tested":23,"tested_annotated":559,"enrichment":2.16039,"p_one_sided_uncorrected":0.0002}},{"compound":"BRD-K06753942","name":"nobiletin","moa":"MEK inhibitor","target":"MAP2K1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":45,"killed_fraction":0.08094,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61278,"interval":[0.50263,0.70736],"hit_lines":34,"nonhit_lines":417,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":18,"median_ic50_uM":2.48511,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":5,"hits_annotated":45,"lineage_tested":34,"tested_annotated":556,"enrichment":1.81699,"p_one_sided_uncorrected":0.13017}},{"compound":"BRD-K81801188","name":"PP-121","moa":"protein tyrosine kinase inhibitor","target":"ABL1, EGFR, HCK, KDR, MTOR, PDGFRA, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PRKDC, SRC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":273,"killed_fraction":0.4875,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.61035,"interval":[0.55832,0.66138],"hit_lines":235,"nonhit_lines":231,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":235,"median_ic50_uM":0.15073,"hit_lines_ic50_at_most_1uM":233}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":9,"hits_annotated":273,"lineage_tested":12,"tested_annotated":560,"enrichment":1.53846,"p_one_sided_uncorrected":0.05964}},{"compound":"BRD-K77245796","name":"gamma-aminobutyric-acid","moa":"benzodiazepine receptor agonist","target":"GABBR1, GABBR2, GABRA1, GABRA2, GABRA3, GABRA5, GABRB2, GABRG2, GATM, KCTD12, KCTD16, KCTD8, SLC6A1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":5,"killed_fraction":0.00912,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.60622,"interval":[0.25518,0.94982],"hit_lines":4,"nonhit_lines":386,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":2.38984,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"mesothelioma","hits_in_lineage":1,"hits_annotated":5,"lineage_tested":9,"tested_annotated":548,"enrichment":12.17778,"p_one_sided_uncorrected":0.07975}},{"compound":"BRD-K54395039","name":"PR-619","moa":"DUB inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":38,"killed_fraction":0.06738,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.60432,"interval":[0.49149,0.71767],"hit_lines":26,"nonhit_lines":417,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":25,"median_ic50_uM":1.90667,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":8,"hits_annotated":38,"lineage_tested":43,"tested_annotated":564,"enrichment":2.76132,"p_one_sided_uncorrected":0.00511}},{"compound":"BRD-K19669037","name":"GGTI-298","moa":"GGTase inhibitor","target":"CDKN1A","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":547,"lines_killed":6,"killed_fraction":0.01097,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.59992,"interval":[0.3899,0.79216],"hit_lines":6,"nonhit_lines":437,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":2.46651,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":3,"hits_annotated":6,"lineage_tested":43,"tested_annotated":547,"enrichment":6.36047,"p_one_sided_uncorrected":0.00768}},{"compound":"BRD-K06234293","name":"LY364947","moa":"TGF beta receptor inhibitor, p38 MAPK inhibitor","target":"TGFBR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":214,"killed_fraction":0.38628,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5949,"interval":[0.53806,0.65148],"hit_lines":167,"nonhit_lines":230,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":11,"median_ic50_uM":8.17774,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":24,"hits_annotated":214,"lineage_tested":41,"tested_annotated":554,"enrichment":1.51539,"p_one_sided_uncorrected":0.00586}},{"compound":"BRD-K47557313","name":"LY2109761","moa":"TGF beta receptor inhibitor","target":"TGFBR1, TGFBR2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":10,"killed_fraction":0.01786,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58726,"interval":[0.37726,0.83653],"hit_lines":7,"nonhit_lines":415,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":2,"hits_annotated":10,"lineage_tested":20,"tested_annotated":560,"enrichment":5.6,"p_one_sided_uncorrected":0.04595}},{"compound":"BRD-K78496197","name":"SCS","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":8,"killed_fraction":0.01431,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58679,"interval":[0.28077,0.84665],"hit_lines":6,"nonhit_lines":338,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":2,"median_ic50_uM":1.22645,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":26,"tested_annotated":559,"enrichment":5.375,"p_one_sided_uncorrected":0.04904}},{"compound":"BRD-K36198571","name":"WAY-170523","moa":"metalloproteinase inhibitor","target":"MMP13","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":532,"lines_killed":8,"killed_fraction":0.01504,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58667,"interval":[0.22831,0.90769],"hit_lines":6,"nonhit_lines":450,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.97049,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":10,"tested_annotated":532,"enrichment":6.65,"p_one_sided_uncorrected":0.14172}},{"compound":"BRD-K80480517","name":"repsox","moa":"TGF beta receptor inhibitor","target":"TGFBR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":64,"killed_fraction":0.11429,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58477,"interval":[0.506,0.66473],"hit_lines":54,"nonhit_lines":407,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":39,"median_ic50_uM":1.6423,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":18,"hits_annotated":64,"lineage_tested":99,"tested_annotated":560,"enrichment":1.59091,"p_one_sided_uncorrected":0.01914}},{"compound":"BRD-K98157055","name":"SIB-1757","moa":"glutamate receptor antagonist","target":"GRM5","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":128,"killed_fraction":0.22898,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.58001,"interval":[0.50674,0.64406],"hit_lines":79,"nonhit_lines":290,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":0.265,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":14,"hits_annotated":128,"lineage_tested":43,"tested_annotated":559,"enrichment":1.42188,"p_one_sided_uncorrected":0.08694}},{"compound":"BRD-A55484088","name":"BNTX","moa":"opioid receptor antagonist","target":"OPRD1, OPRK1, OPRM1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":245,"killed_fraction":0.43672,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.57897,"interval":[0.53085,0.62883],"hit_lines":219,"nonhit_lines":234,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":214,"median_ic50_uM":2.07775,"hit_lines_ic50_at_most_1uM":35}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":16,"hits_annotated":245,"lineage_tested":24,"tested_annotated":561,"enrichment":1.52653,"p_one_sided_uncorrected":0.01759}},{"compound":"BRD-K15025317","name":"BAY-11-7082","moa":"NFkB pathway inhibitor","target":"RELA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":186,"killed_fraction":0.33453,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.57517,"interval":[0.52417,0.63279],"hit_lines":159,"nonhit_lines":281,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":156,"median_ic50_uM":3.75729,"hit_lines_ic50_at_most_1uM":4}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":13,"hits_annotated":186,"lineage_tested":23,"tested_annotated":556,"enrichment":1.68957,"p_one_sided_uncorrected":0.01717}},{"compound":"BRD-K29542628","name":"1-naphthyl-PP1","moa":"src inhibitor","target":"SRC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":62,"killed_fraction":0.11191,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.57417,"interval":[0.49751,0.64776],"hit_lines":53,"nonhit_lines":385,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":48,"median_ic50_uM":1.75407,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":6,"hits_annotated":62,"lineage_tested":23,"tested_annotated":554,"enrichment":2.331,"p_one_sided_uncorrected":0.03373}},{"compound":"BRD-K44067360","name":"flufenamic-acid","moa":"chloride channel blocker","target":"AKR1C3, ANO1, AR, GJA1, GJA10, GJA3, GJA4, GJA5, GJA8, GJA9, GJB1, GJB2, GJB3, GJB4, GJB5, GJB6, GJB7, GJC1, GJC2, GJC3, GJD2, GJD3, GJD4, GJE1, PANX1, PANX2, PANX3, PKD2L1, PTGS1, PTGS2, TRPC5, TRPM2, TRPM5","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":58,"killed_fraction":0.10721,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.57157,"interval":[0.48552,0.65],"hit_lines":47,"nonhit_lines":338,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"esophagus","hits_in_lineage":6,"hits_annotated":58,"lineage_tested":24,"tested_annotated":541,"enrichment":2.3319,"p_one_sided_uncorrected":0.03386}},{"compound":"BRD-K92000912","name":"AM-251","moa":"cannabinoid receptor antagonist","target":"CNR1, GPR18, GPR55","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":40,"killed_fraction":0.07156,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56799,"interval":[0.47806,0.65616],"hit_lines":30,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":19,"median_ic50_uM":4.12653,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":5,"hits_annotated":40,"lineage_tested":21,"tested_annotated":559,"enrichment":3.32738,"p_one_sided_uncorrected":0.01263}},{"compound":"BRD-K04552268","name":"4-pyrimidinecarbonitrile","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":5.0,"lines_tested":541,"lines_killed":103,"killed_fraction":0.19039,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5654,"interval":[0.49939,0.63156],"hit_lines":93,"nonhit_lines":340,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":18,"median_ic50_uM":4.02283,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":13,"hits_annotated":103,"lineage_tested":22,"tested_annotated":541,"enrichment":3.10371,"p_one_sided_uncorrected":2e-05}},{"compound":"BRD-K76064317","name":"tyrphostin-AG-1296","moa":"FLT3 inhibitor","target":"FLT3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":8,"killed_fraction":0.01426,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.56339,"interval":[0.26619,0.8425],"hit_lines":5,"nonhit_lines":448,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":3,"median_ic50_uM":1.36433,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":41,"tested_annotated":561,"enrichment":3.42073,"p_one_sided_uncorrected":0.11023}},{"compound":"BRD-A11551002","name":"dehydrocholate-acid","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":541,"lines_killed":7,"killed_fraction":0.01294,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55628,"interval":[0.28066,0.84166],"hit_lines":4,"nonhit_lines":382,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"breast","hits_in_lineage":2,"hits_annotated":7,"lineage_tested":26,"tested_annotated":541,"enrichment":5.94505,"p_one_sided_uncorrected":0.04022}},{"compound":"BRD-K16338837","name":"CCMI","moa":"acetylcholine receptor allosteric modulator","target":"CHRNA7","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":23,"killed_fraction":0.04137,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.55575,"interval":[0.39782,0.72767],"hit_lines":13,"nonhit_lines":436,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":3.77887,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"colorectal","hits_in_lineage":4,"hits_annotated":23,"lineage_tested":34,"tested_annotated":556,"enrichment":2.84399,"p_one_sided_uncorrected":0.045}},{"compound":"BRD-A27883417","name":"alexidine","moa":"phosphatidylglycerophosphatase inhibitor","target":"PTPMT1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":548,"lines_killed":157,"killed_fraction":0.2865,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54714,"interval":[0.4881,0.60157],"hit_lines":137,"nonhit_lines":321,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":137,"median_ic50_uM":3.16469,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":16,"hits_annotated":157,"lineage_tested":39,"tested_annotated":548,"enrichment":1.43198,"p_one_sided_uncorrected":0.05899}},{"compound":"BRD-K18424115","name":"TG-100572","moa":"src inhibitor, VEGFR inhibitor","target":"KDR, SRC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":22,"killed_fraction":0.03957,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.54415,"interval":[0.40981,0.66844],"hit_lines":17,"nonhit_lines":443,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":17,"median_ic50_uM":2.07393,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":2,"hits_annotated":22,"lineage_tested":9,"tested_annotated":556,"enrichment":5.61616,"p_one_sided_uncorrected":0.04549}},{"compound":"BRD-K08893438","name":"CCG-50014","moa":"G protein signaling inhibitor","target":"RGS4, RGS8","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.52,"lines_tested":520,"lines_killed":8,"killed_fraction":0.01538,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53999,"interval":[0.30866,0.78048],"hit_lines":7,"nonhit_lines":409,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":1.42908,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"soft_tissue","hits_in_lineage":1,"hits_annotated":8,"lineage_tested":5,"tested_annotated":520,"enrichment":13.0,"p_one_sided_uncorrected":0.07487}},{"compound":"BRD-A72703248","name":"SKF-96365","moa":"calcium channel blocker","target":"CYP3A4, PKD2, TRPC1, TRPC3, TRPC4, TRPC5, TRPV2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":18,"killed_fraction":0.0322,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53455,"interval":[0.37446,0.68596],"hit_lines":15,"nonhit_lines":384,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":15,"median_ic50_uM":1.53762,"hit_lines_ic50_at_most_1uM":3}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":3,"hits_annotated":18,"lineage_tested":23,"tested_annotated":559,"enrichment":4.05072,"p_one_sided_uncorrected":0.03316}},{"compound":"BRD-K81645907","name":"captamine","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":530,"lines_killed":19,"killed_fraction":0.03585,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.5344,"interval":[0.39473,0.67585],"hit_lines":16,"nonhit_lines":407,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":2.16482,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":19,"lineage_tested":40,"tested_annotated":530,"enrichment":2.09211,"p_one_sided_uncorrected":0.16609}},{"compound":"BRD-A53134341","name":"Ro-106-9920","moa":"NFkB pathway inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":536,"lines_killed":37,"killed_fraction":0.06903,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53395,"interval":[0.443,0.63387],"hit_lines":32,"nonhit_lines":428,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":32,"median_ic50_uM":1.10122,"hit_lines_ic50_at_most_1uM":15}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdomyosarcoma","hits_in_lineage":2,"hits_annotated":37,"lineage_tested":3,"tested_annotated":536,"enrichment":9.65766,"p_one_sided_uncorrected":0.01333}},{"compound":"BRD-A25569250","name":"KI-16425","moa":"lysophosphatidic acid receptor antagonist","target":"LPAR1, LPAR3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":31,"killed_fraction":0.05576,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.53254,"interval":[0.41699,0.64932],"hit_lines":25,"nonhit_lines":421,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":12,"median_ic50_uM":5.33487,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":5,"hits_annotated":31,"lineage_tested":41,"tested_annotated":556,"enrichment":2.18725,"p_one_sided_uncorrected":0.06875}},{"compound":"BRD-K18375018","name":"spermine","moa":"NA","target":"CA14, CA4, CA6, CA9, CASR, GRIN1, GRIN2A, KCNJ4, ODC1, SMOX, SMS, TRPM4, TRPM5","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":11,"killed_fraction":0.01968,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.52931,"interval":[0.38349,0.69269],"hit_lines":9,"nonhit_lines":436,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":7,"median_ic50_uM":5.35652,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"skin","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":43,"tested_annotated":559,"enrichment":3.54545,"p_one_sided_uncorrected":0.0453}},{"compound":"BRD-K61536336","name":"SB-366791","moa":"TRPV antagonist","target":"TRPV1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":61,"killed_fraction":0.10873,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51227,"interval":[0.4267,0.60325],"hit_lines":47,"nonhit_lines":390,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":23,"median_ic50_uM":2.68166,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":61,"lineage_tested":12,"tested_annotated":561,"enrichment":3.06557,"p_one_sided_uncorrected":0.03214}},{"compound":"BRD-A93477898","name":"PETCM","moa":"caspase activator","target":"CASP3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":13,"killed_fraction":0.02338,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51206,"interval":[0.4065,0.60929],"hit_lines":10,"nonhit_lines":431,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":10,"median_ic50_uM":6.09388,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":13,"lineage_tested":24,"tested_annotated":556,"enrichment":5.34615,"p_one_sided_uncorrected":0.01523}},{"compound":"BRD-K13566078","name":"BMS-345541","moa":"IKK inhibitor","target":"CHUK, IKBKB","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":35,"killed_fraction":0.06239,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.51149,"interval":[0.3885,0.63988],"hit_lines":26,"nonhit_lines":425,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":21,"median_ic50_uM":1.90095,"hit_lines_ic50_at_most_1uM":6}},"independent":{"status":"not_replicated","separation":0.59833,"interval":[0.49028,0.7115],"hit_lines":31,"nonhit_lines":436},"lineage":{"status":"estimable","lineage":"gastric","hits_in_lineage":5,"hits_annotated":35,"lineage_tested":20,"tested_annotated":561,"enrichment":4.00714,"p_one_sided_uncorrected":0.00555}},{"compound":"BRD-K48443249","name":"CNX-774","moa":"Bruton's tyrosine kinase (BTK) inhibitor","target":"BTK","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":40,"killed_fraction":0.0713,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50251,"interval":[0.38503,0.61272],"hit_lines":34,"nonhit_lines":410,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":24,"median_ic50_uM":2.96523,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"fibroblast","hits_in_lineage":1,"hits_annotated":40,"lineage_tested":1,"tested_annotated":561,"enrichment":14.025,"p_one_sided_uncorrected":0.0713}},{"compound":"BRD-K87696786","name":"LY456236","moa":"glutamate receptor antagonist","target":"GRM1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":50,"killed_fraction":0.08993,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.50022,"interval":[0.39573,0.59548],"hit_lines":43,"nonhit_lines":414,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":35,"median_ic50_uM":1.66153,"hit_lines_ic50_at_most_1uM":5}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":7,"hits_annotated":50,"lineage_tested":40,"tested_annotated":556,"enrichment":1.946,"p_one_sided_uncorrected":0.05659}},{"compound":"BRD-K44084986","name":"Y-27632","moa":"rho associated kinase inhibitor","target":"PKIA, PKN2, PRKACA, PRKCE, ROCK1, ROCK2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":86,"killed_fraction":0.15468,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4929,"interval":[0.41042,0.56446],"hit_lines":66,"nonhit_lines":333,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":52,"median_ic50_uM":2.1848,"hit_lines_ic50_at_most_1uM":12}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"rhabdoid","hits_in_lineage":4,"hits_annotated":86,"lineage_tested":12,"tested_annotated":556,"enrichment":2.15504,"p_one_sided_uncorrected":0.09867}},{"compound":"BRD-K67298865","name":"SB-431542","moa":"TGF beta receptor inhibitor","target":"ACVR1C, TGFBR1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":5,"killed_fraction":0.00891,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4894,"interval":[0.21094,0.65848],"hit_lines":4,"nonhit_lines":448,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":4,"median_ic50_uM":1.3847,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"replicated","separation":0.7121,"interval":[0.5233,0.91152],"hit_lines":5,"nonhit_lines":471},"lineage":{"status":"estimable","lineage":"ovary","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":36,"tested_annotated":561,"enrichment":6.23333,"p_one_sided_uncorrected":0.03544}},{"compound":"BRD-K57284066","name":"Ro-9187","moa":"HCV inhibitor","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":8,"killed_fraction":0.01418,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.48582,"interval":[0.25772,0.73295],"hit_lines":6,"nonhit_lines":435,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":4.25041,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"uterus","hits_in_lineage":2,"hits_annotated":8,"lineage_tested":23,"tested_annotated":564,"enrichment":6.13043,"p_one_sided_uncorrected":0.03838}},{"compound":"BRD-K95785537","name":"PP-2","moa":"src inhibitor","target":"ABL1, LCK, LYN, RIPK2, SRC","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":551,"lines_killed":17,"killed_fraction":0.03085,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.47556,"interval":[0.28563,0.66534],"hit_lines":13,"nonhit_lines":395,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":9,"median_ic50_uM":2.92662,"hit_lines_ic50_at_most_1uM":2}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"urinary_tract","hits_in_lineage":3,"hits_annotated":17,"lineage_tested":24,"tested_annotated":551,"enrichment":4.05147,"p_one_sided_uncorrected":0.03305}},{"compound":"BRD-K61097567","name":"SB-218795","moa":"tachykinin antagonist","target":"TACR3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":554,"lines_killed":11,"killed_fraction":0.01986,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.45124,"interval":[0.2628,0.65741],"hit_lines":8,"nonhit_lines":423,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":6,"median_ic50_uM":3.18198,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"central_nervous_system","hits_in_lineage":3,"hits_annotated":11,"lineage_tested":41,"tested_annotated":554,"enrichment":3.68514,"p_one_sided_uncorrected":0.04095}},{"compound":"BRD-K45662124","name":"3'-fluorobenzylspiperone","moa":"dopamine receptor ligand","target":"DRD2","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":561,"lines_killed":10,"killed_fraction":0.01783,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.43308,"interval":[0.14711,0.70568],"hit_lines":7,"nonhit_lines":380,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":6.79332,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"lung","hits_in_lineage":5,"hits_annotated":10,"lineage_tested":101,"tested_annotated":561,"enrichment":2.77723,"p_one_sided_uncorrected":0.0203}},{"compound":"BRD-K18613660","name":"mexeneone","moa":"NA","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":557,"lines_killed":5,"killed_fraction":0.00898,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.42294,"interval":[0.13938,0.79885],"hit_lines":4,"nonhit_lines":425,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"peripheral_nervous_system","hits_in_lineage":2,"hits_annotated":5,"lineage_tested":10,"tested_annotated":557,"enrichment":22.28,"p_one_sided_uncorrected":0.00282}},{"compound":"BRD-K95926480","name":"SRT1720","moa":"SIRT activator","target":"SIRT1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":556,"lines_killed":11,"killed_fraction":0.01978,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.4061,"interval":[0.24435,0.56081],"hit_lines":5,"nonhit_lines":426,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":5,"median_ic50_uM":5.88943,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"kidney","hits_in_lineage":2,"hits_annotated":11,"lineage_tested":19,"tested_annotated":556,"enrichment":5.32057,"p_one_sided_uncorrected":0.05066}},{"compound":"BRD-K62810658","name":"PD-98059","moa":"MEK inhibitor","target":"AKT1, CHEK1, GSK3B, LCK, MAP2K1, MAPK1, MAPK11, MAPK12, MAPK14, MAPK8, PRKCA, RAF1, ROCK1, RPS6KB1, SGK1","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":559,"lines_killed":13,"killed_fraction":0.02326,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.35588,"interval":[0.14158,0.63758],"hit_lines":7,"nonhit_lines":283,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"prostate","hits_in_lineage":1,"hits_annotated":13,"lineage_tested":4,"tested_annotated":559,"enrichment":10.75,"p_one_sided_uncorrected":0.09006}},{"compound":"BRD-K61250484","name":"FPH1-(BRD-6125)","moa":"hepatocyte function enhancer","target":"NA","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":560,"lines_killed":27,"killed_fraction":0.04821,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.34827,"interval":[0.24698,0.4709],"hit_lines":19,"nonhit_lines":363,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":1,"median_ic50_uM":0.3734,"hit_lines_ic50_at_most_1uM":1}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"bone","hits_in_lineage":4,"hits_annotated":27,"lineage_tested":23,"tested_annotated":560,"enrichment":3.60709,"p_one_sided_uncorrected":0.02023}},{"compound":"BRD-K11853856","name":"PJ-34","moa":"PARP inhibitor","target":"EEF2, PARP1, PARP15, PARP3","disease_area":"NA","indication":"NA","phase":"Preclinical","phase_group":"preclinical_or_unknown","oncology":false,"tier":"not_confirmed","primary":{"dose_uM":2.5,"lines_tested":564,"lines_killed":7,"killed_fraction":0.01241,"class":"selective"},"secondary":{"status":"not_confirmed","separation":0.24711,"interval":[0.09931,0.43089],"hit_lines":6,"nonhit_lines":433,"screen_id":"HTS002","potency":{"hit_lines_with_ic50":0,"median_ic50_uM":null,"hit_lines_ic50_at_most_1uM":0}},"independent":{"status":"not_available"},"lineage":{"status":"estimable","lineage":"pancreas","hits_in_lineage":3,"hits_annotated":7,"lineage_tested":37,"tested_annotated":564,"enrichment":6.53282,"p_one_sided_uncorrected":0.00759}}]}